NZ721138A - Bispecific t cell activating antigen binding molecules - Google Patents
Bispecific t cell activating antigen binding molecules Download PDFInfo
- Publication number
- NZ721138A NZ721138A NZ721138A NZ72113812A NZ721138A NZ 721138 A NZ721138 A NZ 721138A NZ 721138 A NZ721138 A NZ 721138A NZ 72113812 A NZ72113812 A NZ 72113812A NZ 721138 A NZ721138 A NZ 721138A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antigen binding
- domain
- cell
- seq
- heavy chain
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Discloses CD3 binding bispecific T cell activating antigen binding molecules comprising a crossover Fab molecule wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged. Either the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain, or (ii) the first antigen binding moiety is fused at the C- terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety and the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain. The T cell activating bispecific antigen binding molecule comprises not more than one antigen binding moiety capable of specific binding to CD3.
Description
Bispecific T cell activating antigen binding molecules
Field of the Invention
The present ion generally relates to bispecific antigen binding molecules for activating T
cells. In addition, the present invention relates to polynucleotides encoding such bispecific
antigen g molecules, and vectors and host cells comprising such polynucleotides. The
invention further relates to methods for producing the bispecific antigen g molecules of the
invention, and to methods of using these bispecific antigen binding molecules in the treatment of
disease.
Background
The selective destruction of an dual cell or a specific cell type is often desirable in a y
of clinical settings. For example, it is a primary goal of cancer therapy to specifically destroy
tumor cells, while leaving healthy cells and tissues intact and undamaged.
An attractive way of achieving this is by inducing an immune response against the tumor, to
make immune effector cells such as natural killer (NK) cells or cytotoxic T lymphocytes (CTLs)
attack and destroy tumor cells. CTLs constitute the most potent effector cells of the immune
, however they cannot be activated by the effector mechanism mediated by the Fc domain
of conventional eutic antibodies.
In this regard, ific dies designed to bind with one “arm” to a surface antigen on
target cells, and with the second “arm” to an activating, invariant component of the T cell
receptor (TCR) x, have become of interest in recent years. The simultaneous binding of
such an antibody to both of its targets will force a temporary interaction between target cell and
T cell, causing activation of any cytotoxic T cell and subsequent lysis of the target cell. Hence,
the immune response is re-directed to the target cells and is independent of peptide antigen
presentation by the target cell or the specificity of the T cell as would be relevant for normal
MHC-restricted tion of CTLs. In this context it is crucial that CTLs are only activated
when a target cell is ting the bispecific antibody to them, i.e. the immunological synapse is
mimicked. Particularly desirable are ific antibodies that do not require lymphocyte
preconditioning or co-stimulation in order to elicit efficient lysis of target cells.
Several bispecific antibody formats have been developed and their suitability for T cell mediated
immunotherapy igated. Out of these, the so-called BiTE (bispecific T cell engager)
molecules have been very well characterized and already shown some promise in the clinic
(reviewed in Nagorsen and Bäuerle, Exp Cell Res 317, 1255-1260 (2011)). BiTEs are tandem
scFv molecules n two scFv molecules are fused by a le linker. Further bispecific
formats being evaluated for T cell engagement include diabodies (Holliger et al., Prot Eng 9,
299-305 (1996)) and derivatives f, such as tandem diabodies (Kipriyanov et al., J Mol Biol
293, 41-66 (1999)). A more recent development are the so-called DART (dual affinity
retargeting) molecules, which are based on the y format but feature a C-terminal disulfide
bridge for additional stabilization (Moore et al., Blood 117, 4542-51 (2011)). The so-called
triomabs, which are whole hybrid mouse/rat IgG molecules and also currently being evaluated in
clinical , represent a larger sized format (reviewed in z et al., Cancer Treat Rev 36,
458-467 (2010)).
The variety of formats that are being developed shows the great ial attributed to T cell re-
direction and activation in immunotherapy. The task of generating bispecific antibodies suitable
therefor is, r, by no means trivial, but involves a number of challenges that have to be
met d to cy, ty, applicability and produceability of the antibodies.
Small constructs such as, for example, BiTE molecules – while being able to efficiently crosslink
effector and target cells – have a very short serum half life requiring them to be administered to
patients by continuous infusion. IgG-like formats on the other hand – while having the great
t of a long half life – suffer from toxicity associated with the native effector functions
inherent to IgG molecules. Their immunogenic potential constitutes another rable feature
of IgG-like bispecific antibodies, especially non-human formats, for sful therapeutic
development. Finally, a major challenge in the general development of bispecific antibodies has
been the production of bispecific antibody constructs at a clinically sufficient quantity and
purity, due to the mispairing of antibody heavy and light chains of different specificities upon
co-expression, which decreases the yield of the correctly assembled construct and results in a
number of non-functional side ts from which the desired bispecific antibody may be
difficult to separate.
Given the difficulties and disadvantages associated with currently available bispecific antibodies
for T cell mediated immunotherapy, there remains a need for novel, improved formats of such
molecules. The present invention provides bispecific antigen binding molecules designed for T
cell tion and re-direction that combine good efficacy and eability with low toxicity
and favorable pharmacokinetic properties; and/or which at least provides the public with a useful
choice.
In this specification where reference has been made to patent specifications, other external
nts, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such al documents is not to be construed as an admission that such documents,
or such sources of information, in any iction, are prior art, or form part of the common
general knowledge in the art.
In the description in this specification reference may be made to subject matter that is not within
the scope of the claims of the current application. That subject matter should be readily
identifiable by a person skilled in the art and may assist in putting into ce the invention as
defined in the claims of this application.
Summary of the Invention
In a first aspect, the invention provides a T cell activating ific antigen binding molecule
sing a first and a second antigen binding moiety, one of which is a Fab molecule capable
of specific binding to CD3 and the other one of which is a Fab molecule capable of specific
binding to a target cell antigen, and an Fc domain composed of a first and a second t
e of stable association;
wherein the first n binding moiety is
a crossover Fab le wherein either the variable or the constant regions of the Fab light
chain and the Fab heavy chain are exchanged;
wherein (i) the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain
to the N-terminus of the Fab heavy chain of the first antigen binding moiety and the first antigen
binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or
second subunit of the Fc domain, or (ii) the first antigen binding moiety is fused at the C-
terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen
binding moiety and the second antigen binding moiety is fused at the C-terminus of the Fab
heavy chain to the N-terminus of the first or the second subunit of the Fc domain; and
wherein the T cell activating bispecific antigen binding molecule comprises not more than one
n binding moiety capable of specific binding to CD3.
In a second aspect, the invention provides an isolated polynucleotide encoding the T cell
activating bispecific antigen binding molecule of the first aspect.
In a third aspect, the invention provides a vector, comprising the isolated polynucleotide of
thesecond aspect.
In a fourth aspect, the invention provides a host cell comprising the ed polynucleotide of
the second aspect or the vector of the third aspect, wherein the host cell is not a human cell
within a human.
In a fifth aspect, the invention provides a method of producing the T cell activating bispecific
antigen binding molecule of the first aspect, comprising the steps of a) culturing the host cell of
the fourth aspect under conditions suitable for the expression of the T cell activating bispecific
antigen binding molecule and b) recovering the T cell activating bispecific antigen g
In a sixth aspect, the invention provides a pharmaceutical composition comprising the T cell
activating bispecific antigen binding le of the first aspect and a pharmaceutically
acceptable carrier.
In a seventh aspect, the invention provides use of the T cell activating bispecific antigen binding
molecule of the first , for the manufacture of a medicament for the treatment of a disease
in an individual in need thereof.
In an eighth aspect, the invention provides an in vitro method for inducing lysis of a target cell,
comprising contacting a target cell with the T cell activating bispecific antigen binding molecule
of the first aspect, in the ce of a T cell.
Brief Decription
Broadly described is a T cell activating bispecific antigen binding le comprising a first
and a second antigen binding , one of which is a Fab molecule capable of ic binding
to an activating T cell n and the other one of which is a Fab le capable of specific
binding to a target cell antigen, and an Fc domain ed of a first and a second subunit
capable of stable association; wherein the first antigen binding moiety is (a) a single chain Fab
molecule wherein the Fab light chain and the Fab heavy chain are connected by a peptide linker,
or (b) a crossover Fab molecule wherein either the variable or the nt regions of the Fab
light chain and the Fab heavy chain are exchanged.
In a particular embodiment, not more than one antigen binding moiety capable of specific
binding to an activating T cell antigen is present in the T cell activating bispecific antigen
g molecule (i.e. the T cell activating bispecific antigen binding molecule provides
monovalent binding to the activating T cell n). In ular embodiments, the first antigen
binding moiety is a ver Fab molecule. In even more particular ments, the first
antigen binding moiety is a crossover Fab le wherein the constant regions of the Fab light
chain and the Fab heavy chain are exchanged.
In some embodiments, the first and the second antigen binding moiety of the T cell activating
bispecific antigen g molecule are fused to each other, optionally via a peptide linker. In
one such embodiment, the second antigen binding moiety is fused at the C-terminus of the Fab
heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety. In
another such embodiment, the first n binding moiety is fused at the C-terminus of the Fab
heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety. In
yet another such embodiment, the second antigen binding moiety is fused at the inus of
the Fab light chain to the N-terminus of the Fab light chain of the first antigen binding . In
embodiments wherein the first antigen binding moiety is a crossover Fab molecule and wherein
either (i) the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to
the N-terminus of the Fab heavy chain of the first antigen binding moiety or (ii) the first antigen
g moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second antigen binding moiety, additionally the Fab light chain of the first
antigen binding moiety and the Fab light chain of the second antigen binding moiety may be
fused to each other, optionally via a peptide linker.
In one embodiment, the second antigen binding moiety of the T cell activating bispecific antigen
binding le is fused at the C-terminus of the Fab heavy chain to the inus of the first
or the second subunit of the Fc domain. In another embodiment, the first antigen binding moiety
is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit
of the Fc domain.
In one embodiment, the first and the second antigen binding moiety of the T cell ting
bispecific antigen binding molecule are each fused at the C-terminus of the Fab heavy chain to
the N-terminus of one of the subunits of the Fc domain.
In certain embodiments, the T cell activating bispecific antigen binding molecule comprises a
third antigen binding moiety which is a Fab molecule capable of ic binding to a target cell
antigen. In one such embodiment, the third antigen g moiety is fused at the C-terminus of
the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In a
particular embodiment, the second and the third antigen binding moiety of the T cell activating
antigen g molecule are each fused at the C-terminus of the Fab heavy chain to the N-
terminus of one of the subunits of the Fc domain, and the first antigen binding moiety is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second
antigen binding moiety. In another particular embodiment, the first and the third antigen binding
moiety of the T cell ting antigen binding molecule are each fused at the C-terminus of the
Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the second
antigen binding moiety is fused at the inus of the Fab heavy chain to the N-terminus of
the Fab heavy chain of the first antigen binding moiety. The components of the T cell activating
bispecific antigen binding molecule may be fused directly or through suitable peptide linkers. In
one embodiment the second and the third n binding moiety and the Fc domain are part of
an immunoglobulin molecule. In a particular embodiment the immunoglobulin molecule is an
IgG class immunoglobulin. In an even more ular embodiment the immunoglobulin is an
IgG1 ss immunoglobulin. In another ment, the immunoglobulin is an IgG4 subclass
immunoglobulin.
In a particular embodiment, the Fc domain is an IgG Fc domain. In a specific embodiment, the
Fc domain is an IgG1 Fc domain. In r specific embodiment, the Fc domain is an IgG4 Fc
domain. In an even more specific embodiment, the Fc domain is an IgG4 Fc domain comprising
the amino acid substitution S228P (EU ing). In particular embodiments the Fc domain is
a human Fc domain.
In particular embodiments the Fc domain ses a cation promoting the association of
the first and the second Fc domain subunit. In a specific such ment, an amino acid residue
in the CH3 domain of the first subunit of the Fc domain is replaced with an amino acid residue
having a larger side chain volume, thereby generating a protuberance within the CH3 domain of
the first subunit which is positionable in a cavity within the CH3 domain of the second subunit,
and an amino acid residue in the CH3 domain of the second subunit of the Fc domain is replaced
with an amino acid residue having a smaller side chain volume, thereby generating a cavity
within the CH3 domain of the second subunit within which the erance within the CH3
domain of the first subunit is positionable.
In a particular embodiment the Fc domain exhibits reduced binding affinity to an Fc receptor
and/or reduced effector function, as compared to a native IgG1 Fc domain. In certain
embodiments the Fc domain is engineered to have reduced binding affinity to an Fc receptor
and/or reduced effector function, as compared to a non-engineered Fc domain. In one
embodiment, the Fc domain comprises one or more amino acid substitution that s binding
to an Fc receptor and/or or function. In one embodiment, the one or more amino acid
substitution in the Fc domain that reduces binding to an Fc receptor and/or effector function is at
one or more position selected from the group of L234, L235, and P329 (EU numbering). In
ular embodiments, each subunit of the Fc domain comprises three amino acid substitutions
that reduce binding to an Fc receptor and/or effector function wherein said amino acid
substitutions are L234A, L235A and P329G. In one such embodiment, the Fc domain is an IgG1
Fc , particularly a human IgG1 Fc domain. In other embodiments, each subunit of the Fc
domain comprises two amino acid substitutions that reduce binding to an Fc receptor and/or
effector function n said amino acid substitutions are L235E and P329G. In one such
embodiment, the Fc domain is an IgG4 Fc domain, particularly a human IgG4 Fc domain.
In one embodiment the Fc receptor is an Fcγ receptor. In one embodiment the Fc receptor is a
human Fc receptor. In one embodiment, the Fc receptor is an ting Fc receptor. In a specific
embodiment, the Fc receptor is human FcγRIIa, FcγRI, and/or FcγRIIIa. In one embodiment, the
effector function is antibody-dependent cell-mediated xicity (ADCC).
In a particular embodiment, the activating T cell antigen that the bispecific antigen binding
molecule is capable of binding is CD3. In other embodiments, the target cell antigen that the
bispecific antigen binding molecule is capable of binding is a tumor cell antigen. In one
embodiment, the target cell n is selected from the group consisting of: maassociated
Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor
, Carcinoembryonic Antigen (CEA), Fibroblast Activation Protein (FAP), CD19, CD20
and CD33.
Also described is an ed polynucleotide encoding a T cell activating bispecific antigen
binding molecule described or a nt thereof. Also described are polypeptides encoded by
the polynucleotidesdescribed. r bed is an expression vector comprising the isolated
polynucleotide i described, and a host cell comprising the isolated polynucleotide or the
sion vector described. In some embodiments the host cell is a eukaryotic cell, particularly
a mammalian cell.
Also described is a method of producing the T cell activating bispecific antigen binding
molecule described, comprising the steps of a) culturing the host cell described under conditions
suitable for the expression of the T cell ting bispecific antigen binding molecule and b)
recovering the T cell activating bispecific antigen binding molecule. Also described is a T cell
activating bispecific antigen binding molecule produced by the method described.
Also described is a pharmaceutical composition comprising the T cell activating bispecific
antigen binding molecule described and a pharmaceutically acceptable carrier.
Also described are methods of using the T cell activating bispecific antigen binding molecule
and pharmaceutical composition described. bed is a T cell activating bispecific antigen
binding molecule or a pharmaceutical composition described for use as a medicament. Described
is a T cell activating bispecific antigen binding molecule or a pharmaceutical composition
described for use in the treatment of a disease in an individual in need thereof. In a specific
embodiment the e is cancer.
Also described is the use of a T cell activating bispecific antigen binding molecule described for
the cture of a medicament for the treatment of a disease in an individual in need thereof;
as well as a method of treating a disease in an individual, comprising stering to said
individual a therapeutically effective amount of a composition comprising the T cell activating
ific antigen binding molecule bed in a pharmaceutically acceptable form. In a
specific embodiment the disease is cancer. In any of the above embodiments the individual
preferably is a mammal, ularly a human.
Also described is a method for inducing lysis of a target cell, particularly a tumor cell,
comprising contacting a target cell with a T cell activating bispecific antigen g molecule
described in the presence of a T cell, particularly a cytotoxic T cell.
Brief Description of the gs
FIGURE 1. ary configurations of the T cell activating bispecific antigen binding
molecules described. Illustration of (A) the “1+1 IgG scFab, one armed”, and (B) the “1+1 IgG
scFab, one armed inverted” molecule. In the “1+1 IgG scFab, one armed” molecule the light
chain of the T cell targeting Fab is fused to the heavy chain by a linker, while the “1+1 IgG
scFab, one armed inverted” molecule has the linker in the tumor targeting Fab. (C) Illustration of
the “2+1 IgG scFab” molecule. (D) Illustration of the “1+1 IgG scFab” molecule. (E) Illustration
of the “1+1 IgG ab” molecule. (F) ration of the “2+1 IgG Crossfab” molecule. (G)
Illustration of the “2+1 IgG Crossfab” le with ative order of Crossfab and Fab
components rted”). (H) Illustration of the “1+1 IgG Crossfab light chain (LC) fusion”
molecule. (I) Illustration of the “1+1 CrossMab” molecule. (J) Illustration of the “2+1 IgG
Crossfab, linked light chain” molecule. (K) Illustration of the “1+1 IgG ab, linked light
chain” molecule. (L) Illustration of the “2+1 IgG Crossfab, inverted, linked light chain”
molecule. (M) Illustration of the “1+1 IgG Crossfab, inverted, linked light chain” molecule.
Black dot: optional modification in the Fc domain promoting heterodimerization.
FIGURE 2. SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, Coomassie-stained) of “1+1 IgG
scFab, one armed” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 1, 3, 5), non reduced (A) and
reduced (B), and of “1+1 IgG scFab, one armed inverted” MCSP/anti-huCD3) (see SEQ ID
NOs 7, 9, 11), non reduced (C) and reduced (D).
FIGURE 3. Analytical size exclusion chromatography (Superdex 200 10/300 GL GE Healthcare;
2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg sample injected) of “1+1 IgG
scFab, one armed” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 1, 3, 5) (A) and “1+1 IgG scFab,
one armed inverted” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 7, 9, 11) (B).
FIGURE 4. SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, Coomassie-stained) of “1+1 IgG
scFab, one armed” (anti-EGFR/anti-huCD3) (see SEQ ID NOs 43, 45, 57), non reduced (A) and
reduced (B), and of “1+1 IgG scFab, one armed inverted” (anti-EGFR/anti-huCD3) (see SEQ ID
NOs 11, 49, 51), non reduced (C) and reduced (D).
FIGURE 5. Analytical size exclusion chromatography (Superdex 200 10/300 GL GE Healthcare;
2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg sample injected) of “1+1 IgG
scFab, one armed” (anti-EGFR/anti-huCD3) (see SEQ ID NOs 43, 45, 47) (A) and “1+1 IgG
scFab, one armed inverted” EGFR/anti-huCD3) (see SEQ ID NOs 11, 49, 51) (B).
FIGURE 6. (A, B) SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, sie-stained) of “1+1
IgG scFab, one armed inverted” (anti-FAP/anti-huCD3) (see SEQ ID NOs 11, 51, 55), non
reduced (A) and reduced (B). (C) Analytical size exclusion chromatography (Superdex 200
10/300 GL GE Healthcare; 2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg
sample injected) of “1+1 IgG scFab, one armed inverted” (anti-FAP/anti-huCD3).
FIGURE 7. SDS PAGE (4-12% is, NuPage Invitrogen, Coomassie-stained) of (A) “2+1
IgG scFab, P329G LALA” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 5, 21, 23), non reduced
(lane 2) and d (lane 3); of (B) “2+1 IgG scFab, LALA” (anti-MCSP/anti-huCD3) (see
SEQ ID NOs 5, 17, 19), non reduced (lane 2) and reduced (lane 3); of (C) “2+1 IgG scFab, wt”
(anti-MCSP/anti-huCD3) (see SEQ ID NOs 5, 13, 15), non reduced (lane 2) and reduced (lane 3);
and of (D) “2+1 IgG scFab, P329G LALA N297D” (anti-MCSP/anti-huCD3) (see SEQ ID NOs
, 25, 27), non reduced (lane 2) and reduced (lane 3).
FIGURE 8. Analytical size exclusion chromatography dex 200 10/300 GL GE Healthcare;
2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg sample injected) of (A) “2+1 IgG
scFab, P329G LALA” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 5, 21, 23); of (B) “2+1 IgG
scFab, LALA” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 5, 17, 19); of (C) “2+1 IgG scFab,
wt” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 5, 13, 15); and of (D) “2+1 IgG scFab, P329G
LALA N297D” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 5, 25, 27).
FIGURE 9. (A, B) SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, Coomassie-stained) of “2+1
IgG scFab, P329G LALA” (anti-EGFR/anti-huCD3) (see SEQ ID NOs 45, 47, 53), non reduced
(A) and reduced (B). (C) Analytical size exclusion chromatography (Superdex 200 10/300 GL
GE Healthcare; 2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg sample ed)
of “2+1 IgG scFab, P329G LALA” EGFR/anti-huCD3).
FIGURE 10. (A, B) SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, sie-stained) of
“2+1 IgG scFab, P329G LALA” (anti-FAP/anti-huCD3) (see SEQ ID NOs 57, 59, 61), non
d (A) and reduced (B). (C) Analytical size exclusion chromatography (Superdex 200
/300 GL GE Healthcare; 2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg
sample injected) of “2+1 IgG scFab, P329G LALA” FAP/anti-huCD3).
FIGURE 11. (A, B) SDS PAGE (4-12% Tris-Acetate (A) or 4-12% Bis/Tris (B), NuPage
Invitrogen, Coomassie-stained) of “1+1 IgG Crossfab, Fc(hole) P329G LALA / Fc(knob) wt”
(anti-MCSP/anti-huCD3) (see SEQ ID NOs 5, 29, 31, 33), non reduced (A) and reduced (B). (C)
Analytical size exclusion chromatography (Superdex 200 10/300 GL GE Healthcare; 2 mM
MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg sample injected) of “1+1 IgG Crossfab,
Fc(hole) P329G LALA / Fc(knob) wt” (anti-MCSP/anti-huCD3).
FIGURE 12. (A, B) SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, Coomassie-stained) of
“2+1 IgG Crossfab” (anti-MCSP/anti-huCD3) (see SEQ ID NOs 3, 5, 29, 33), non reduced (A)
and reduced (B). (C) Analytical size exclusion tography (Superdex 200 10/300 GL GE
Healthcare; 2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg sample injected) of
“2+1 IgG Crossfab” (anti-MCSP/anti-huCD3).
FIGURE 13. (A, B) SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, Coomassie-stained) of
“2+1 IgG ab” (anti-MCSP/anti-cyCD3) (see SEQ ID NOs 3, 5, 35, 37), non reduced (A)
and reduced (B). (C) Analytical size exclusion chromatography (Superdex 200 10/300 GL GE
Healthcare; 2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg sample injected) of
“2+1 IgG Crossfab” (anti-MCSP/anti-cyCD3).
FIGURE 14. (A, B) SDS PAGE (4-12% Bis/Tris, NuPage Invitrogen, Coomassie-stained) of
“2+1 IgG Crossfab, inverted” (anti-CEA/anti-huCD3) (see SEQ ID NOs 33, 63, 65, 67), non
reduced (A) and reduced (B). (C) Analytical size exclusion tography (Superdex 200
10/300 GL GE Healthcare; 2 mM MOPS pH 7.3, 150 mM NaCl, 0.02% (w/v) NaCl; 50 μg
sample injected) of “2+1 IgG Crossfab, inverted” (anti-CEA/anti-huCD3).
FIGURE 15. (A) Thermal stability of )2-Fc” and “(dsscFv)2-Fc” (anti-MCSP
(LC007)/anti-huCD3 (V9)). Dynamic Light Scattering, measured in a temperature ramp from 25-
75°C at 0.05°C/min. Black curve: )2-Fc”; grey curve: “(dsscFv)2-Fc”. (B) Thermal
stability of “2+1 IgG scFab” (see SEQ ID NOs 5, 21, 23) and “2+1 IgG Crossfab” (anti-
nti-huCD3) (see SEQ ID NOs 3, 5, 29, 33). Dynamic Light Scattering, measured in a
temperature ramp from 25-75°C at 0.05°C/min. Black curve: “2+1 IgG scFab”; grey curve: “2+1
IgG Crossfab”.
FIGURE 16. Biacore assay setup for (A) determination of ction of various Fc-mutants with
human FcγRIIIa, and for (B) simultaneous binding of T cell bespecific constructs with tumor
target and human CD3γ(G4S)5CD3ε–AcTev–Fc(knob)–Avi/Fc(hole).
FIGURE 17. aneous binding of T-cell bispecific constructs to the D3 domain of human
MCSP and human CD3γ(G4S)5CD3ε–AcTev–Fc(knob)–Avi/Fc(hole). (A) “2+1 IgG Crossfab”
(see SEQ ID NOs 3, 5, 29, 33), (B) “2+1 IgG scFab” (see SEQ ID NOs 5, 21, 23).
FIGURE 18. Simultaneous binding of T-cell bispecific constructs to human EGFR and human
CD3γ(G4S)5CD3ε–AcTev–Fc(knob)–Avi/Fc(hole). (A) “2+1 IgG scFab” (see SEQ ID NOs 45,
47, 53), (B) “1+1 IgG scFab, one armed” (see SEQ ID NOs 43, 45, 47), (C) “1+1 IgG scFab, one
armed ed” (see SEQ ID NOs 11, 49, 51), and (D) “1+1 IgG scFab” (see SEQ ID NOs 47,
53, 213).
FIGURE 19. Binding of the “(scFv)2” molecule (50 nM) to CD3 expressed on Jurkat cells (A),
or to MCSP on Colo-38 cells (B) measured by FACS. Mean fluorescence intensity compared to
untreated cells and cells stained with the ary antibody only is depicted.
FIGURE 20. Binding of the “2+1 IgG scFab, LALA” (see SEQ ID NOs 5, 17, 19) construct (50
nM) to CD3 expressed on Jurkat cells (A), or to MCSP on Colo-38 cells (B) measured by FACS.
Mean fluorescence intensity compared to cells d with the nce anti-CD3 IgG (as
ted), untreated cells, and cells stained with the secondary antibody only is depicted.
FIGURE 21. Binding of the “1+1 IgG scFab, one armed” (see SEQ ID NOs 1, 3, 5) and “1+1
IgG scFab, one armed inverted” (see SEQ ID NOs 7, 9, 11) constructs (50 nM) to CD3
expressed on Jurkat cells (A), or to MCSP on Colo-38 cells (B) measured by FACS. Mean
fluorescence intensity compared to cells treated with the reference D3 or anti-MCSP IgG
(as indicated), untreated cells, and cells stained with the secondary antibody only is depicted.
FIGURE 22. Dose dependent binding of the “2+1 IgG scFab, LALA” (see SEQ ID NOs 5, 17,
19) bispecific construct and the corresponding anti-MCSP IgG to MCSP on Colo-38 cells as
measured by FACS.
FIGURE 23. Surface expression level of different activation markers on human T cells after
incubation with 1 nM of “2+1 IgG scFab, LALA” (see SEQ ID NOs 5, 17, 19) or “(scFv)2”
CD3-MCSP bispecific constructs in the presence or absence of Colo-38 tumor target cells, as
ted (E:T ratio of PBMCs to tumor cells = 10:1). Depicted is the expression level of the
early activation marker CD69 (A), or the late activation marker CD25 (B) on CD8+ T cells after
15 or 24 hours tion, respectively.
FIGURE 24. Surface expression level of the late activation marker CD25 on human T cells after
tion with 1 nM of “2+1 IgG scFab, LALA” (see SEQ ID NOs 5, 17, 19) or “(scFv)2”
CD3-MCSP bispecific constructs in the presence or absence of Colo-38 tumor target cells, as
indicated (E:T ratio = 5:1). Depicted is the sion level of the late activation marker CD25
on CD8+ T cells (A) or on CD4+ T cells (B) after 5 days incubation.
FIGURE 25. Surface expression level of the late activation marker CD25 on cynomolgus CD8+
T cells from two different animals (cyno Nestor, cyno Nobu) after 43 hours incubation with the
indicated trations of the “2+1 IgG Crossfab” bispecific construct (targeting cynomolgus
CD3 and human MCSP; see SEQ ID NOs 3, 5, 35, 37), in the presence or absence of human
MCSP-expressing MV-3 tumor target cells (E:T ratio = 3:1). As controls, the reference IgGs
(anti-cynomolgus CD3 IgG, anti-human MCSP IgG) or the unphysiologic stimulus PHA-M were
used.
FIGURE 26. IFN-γ levels, secreted by human pan T cells that were activated for 18.5 hours by
the “2+1 IgG scFab, LALA” CD3-MCSP bispecific construct (see SEQ ID NOs 5, 17, 19) in the
ce of U87MG tumor cells (E:T ratio = 5:1). As ls, the corresponding anti-CD3 and
anti-MCSP IgGs were administered.
FIGURE 27. Killing (as measured by LDH release) of MDA-MB-435 tumor cells upon coculture
with human pan T cells (E:T ratio = 5:1) and activation for 20 hours by different
concentrations of the “2+1 IgG scFab” (see SEQ ID NOs 5, 21, 23), “2+1 IgG Crossfab” (see
SEQ ID NOs 3, 5, 29, 33) and )2” bispecific molecules and corresponding IgGs.
FIGURE 28. Killing (as measured by LDH release) of MDA-MB-435 tumor cells upon coculture
with human pan T cells (E:T ratio = 5:1), and activation for 20 hours by different
concentrations of the bispecific ucts and corresponding IgGs. “2+1 IgG scFab” ucts
differing in their Fc-domain (having either a wild-type Fc domain (see SEQ ID NOs 5, 13, 15),
or a Fc-domain mutated to abolish (NK) effector cell function: P329G LALA (see SEQ ID NOs
, 21, 23), P329G LALA N297D (see SEQ ID NOs 5, 25, 27)) and the “2+1 IgG Crossfab” (see
SEQ ID NOs 3, 5, 29, 33) construct were compared.
FIGURE 29. Killing (as measured by LDH release) of Colo-38 tumor cells upon co-culture with
human pan T cells (E:T ratio = 5:1), treated with CD3-MCSP bispecific “2+1 IgG scFab,
LALA” (see SEQ ID NOs 5, 17, 19) construct, “(scFv)2” le or corresponding IgGs for
18.5 hours.
FIGURE 30. Killing (as measured by LDH release) of Colo-38 tumor cells upon co-culture with
human pan T cells (E:T ratio = 5:1), treated with SP bispecific “2+1 IgG scFab,
LALA” (see SEQ ID NOs 5, 17, 19) construct, the “(scFv)2” molecule or corresponding IgGs for
18 hours.
FIGURE 31. Killing (as measured by LDH release) of MDA-MB-435 tumor cells upon coculture
with human pan T cells (E:T ratio = 5:1), and activation for 23.5 hours by different
trations of the CD3-MCSP bispecific “2+1 IgG scFab, LALA” (see SEQ ID NOs 5, 17,
19) construct, “(scFv)2” molecule or corresponding IgGs.
FIGURE 32. Killing (as measured by LDH release) of Colo-38 tumor cells upon co-culture with
human pan T cells (E:T ratio = 5:1) and activation for 19 hours by different concentrations of the
CD3-MCSP bispecific “1+1 IgG scFab, one armed” (see SEQ ID NOs 1, 3, 5), “1+1 IgG scFab,
one armed inverted” (see SEQ ID NOs 7, 9, 11) or “(scFv)2” constructs, or corresponding IgGs.
FIGURE 33. g (as measured by LDH e) of Colo-38 tumor cells upon co-culture with
human pan T cells (E:T ratio = 5:1), d with “1+1 IgG scFab” CD3-MCSP ific
construct (see SEQ ID NOs 5, 21, 213) or “(scFv)2” molecule for 20 hours.
FIGURE 34. Killing (as ed by LDH release) of MDA-MB-435 tumor cells upon coculture
with human pan T cells (E:T ratio = 5:1), and activation for 21 hours by different
trations of the bispecific constructs and corresponding IgGs. The CD3-MCSP bispecific
“2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29, 33) and “1+1 IgG Crossfab” (see SEQ ID NOs 5,
29, 31, 33) constructs, the “(scFv)2” molecule and corresponding IgGs were compared.
FIGURE 35. Killing (as measured by LDH release) of different target cells (MCSP-positive
Colo-38 tumor target cells, mesenchymal stem cells derived from bone marrow or adipose ,
or pericytes from placenta; as ted) induced by the activation of human T cells by 135
ng/ml or 1.35 ng/ml of the “2+1 IgG Crossfab” CD3-MCSP bispecific construct (see SEQ ID
NOs 3, 5, 29, 33) (E:T ratio = 25:1).
FIGURE 36. Killing (as measured by LDH release) of Colo-38 tumor target cells, measured
after an overnight incubation of 21h, upon co-culture with human PBMCs and ent CD3-
MCSP bispecific constructs (“2+1 IgG scFab, LALA” (see SEQ ID NOs 5, 17, 19) and
)2”) or a glycoengineered anti-MCSP IgG (GlycoMab). The effector to target cell ratio
was fixed at 25:1 (A), or varied as depicted (B). PBMCs were isolated from fresh blood (A) or
from a Buffy Coat (B).
FIGURE 37. Time-dependent cytotoxic effect of the “2+1 IgG Crossfab” construct, targeting
cynomolgus CD3 and human MCSP (see SEQ ID NOs 3, 5, 35, 37). Depicted is the LDH release
from human MCSP-expressing MV-3 cells upon co-culture with primary cynomolgus PBMCs
(E:T ratio = 3:1) for 24 h or 43 h. As controls, the reference IgGs (anti-cyno CD3 IgG and antihuman
MCSP IgG) were used at the same molarity. PHA-M served as a control for
(unphysiologic) T cell activation.
FIGURE 38. Killing (as measured by LDH release) of -positive MV-3 melanoma cells
upon co-culture with human PBMCs (E:T ratio = 10:1), treated with different CD3-MCSP
bispecific constructs (“2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29, 33) and “(scFv)2”) for ~26
hours.
FIGURE 39. Killing (as measured by LDH release) of EGFR-positive LS-174T tumor cells upon
co-culture with human pan T cells (E:T ratio = 5:1), treated with different CD3-EGFR bispecific
ucts (“2+1 IgG scFab” (see SEQ ID NOs 45, 47, 53), “1+1 IgG scFab” (see SEQ ID NOs
47, 53, 213) and “(scFv)2”) or reference IgGs for 18 hours.
FIGURE 40. g (as measured by LDH release) of EGFR-positive LS-174T tumor cells upon
co-culture with human pan T cells (E:T ratio = 5:1), treated with ent CD3-EGFR bispecific
constructs (“1+1 IgG scFab, one armed” (see SEQ ID NOs 43, 45, 47), “1+1 IgG scFab, one
armed ed” (see SEQ ID NOs 11, 49, 51), “1+1 IgG scFab” (see SEQ ID NOs 47, 53, 213)
and “(scFv)2”) or nce IgGs for 21 hours.
FIGURE 41. Killing (as measured by LDH release) of EGFR-positive LS-174T tumor cells upon
co-culture with either human pan T cells (A) or human naive T cells (B), treated with ent
CD3-EGFR bispecific constructs (“1+1 IgG scFab, one armed” (see SEQ ID NOs 43, 45, 47),
“1+1 IgG scFab, one armed inverted” (see SEQ ID NOs 11, 49, 51) and “(scFv)2”) or reference
IgGs for 16 hours. The effector to target cell ratio was 5:1.
FIGURE 42. Killing (as measured by LDH release) of FAP-positive GM05389 fibroblasts upon
co-culture with human pan T cells (E:T ratio = 5:1), treated with different P bispecific
constructs (“1+1 IgG scFab, one armed inverted” (see SEQ ID NOs 11, 51, 55), “1+1 IgG
scFab” (see SEQ ID NOs 57, 61, 213), “2+1 IgG scFab” (see SEQ ID NOs 57, 59, 61) and
“(scFv)2”) for ~18 hours.
FIGURE 43. Flow cytrometric analysis of expression levels of CD107a/b, as well as in
levels in CD8+ T cells that have been treated with different CD3-MCSP bispecific constructs
(“2+1 IgG scFab, LALA” (see SEQ ID NOs 5, 17, 19) and “(scFv)2”) or corresponding control
IgGs in the ce (A) or absence (B) of target cells for 6h. Human pan T cells were incubated
with 9.43 nM of the different molecules in the presence or absence of Colo-38 tumor target cells
at an effector to target ratio of 5:1. Monensin was added after the first hour of incubation to
increase intracellular protein levels by preventing protein ort. Gates were set either on all
CD107a/b positive, perforin-positive or double-positive cells, as depicted.
FIGURE 44. Relative proliferation of either CD8+ (A) or CD4+ (B) human T cells upon
incubation with 1 nM of different SP bispecific constructs (“2+1 IgG scFab, LALA”
(see SEQ ID NOs 5, 17, 19) or “(scFv)2”) or corresponding control IgGs in the presence or
absence of Colo-38 tumor target cells at an effector to target cell ratio of 5:1. CFSE-labeled
human pan T cells were characterized by FACS. The relative proliferation level was determined
by setting a gate around the non-proliferating cells and using the cell number of this gate relative
to the overall measured cell number as the reference.
FIGURE 45. Levels of different nes measured in the supernatant of human PBMCs after
treatment with 1 nM of different CD3-MCSP bispecific constructs (“2+1 IgG scFab, LALA”
(see SEQ ID NOs 5, 17, 19) or “(scFv)2”) or corresponding control IgGs in the presence (A) or
absence (B) of Colo-38 tumor cells for 24 hours. The effector to target cell ratio was 10:1.
FIGURE 46. Levels of ent cytokines measured in the supernatant of whole blood after
treatment with 1 nM of different CD3-MCSP bispecific constructs (“2+1 IgG scFab”, “2+1 IgG
Crossfab” (see SEQ ID NOs 3, 5, 29, 33) or “(scFv)2”) or corresponding control IgGs in the
presence (A, B) or absence (C, D) of Colo-38 tumor cells for 24 hours. Among the bispecific
constructs were different “2+1 IgG scFab” constructs having either a wild-type Fc domain (see
SEQ ID NOs 5, 13, 15), or an Fc domain mutated to abolish (NK) effector cell function (LALA
(see SEQ ID NOs 5, 17, 19), P329G LALA (see SEQ ID NOs 5, 2, 23) and P329G LALA
N297D (see SEQ ID NOs 5, 25, 27)).
FIGURE 47. CE-SDS es. Electropherogram shown as SDS PAGE of 2+1 IgG Crossfab,
linked light chain (see SEQ ID NOs 3, 5, 29, 179). (lane 1: reduced, lane 2: non-reduced).
FIGURE 48. Analytical size exclusion chromatography of 2+1 IgG Crossfab, linked light chain
(see SEQ ID NOs 3, 5, 29, 179) (final product). 20 µg sample were injected.
FIGURE 49. Killing (as ed by LDH release) of MCSP-positive MV-3 tumor cells upon
co-culture by human PBMCs (E:T ratio = 10:1), treated with different CD3-MCSP bispecific
constructs for ~ 44 hours (“2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29, 33) and “2+1 IgG
ab, linked LC” (see SEQ ID NOs 3, 5, 29, 179)). Human PBMCs were isolated from fresh
blood of healthy volunteers.
FIGURE 50. Killing (as measured by LDH release) of MCSP-positive Colo-38 tumor cells upon
co-culture by human PBMCs (E:T ratio = 10:1), treated with different CD3-MCSP bispecific
constructs for ~22 hours (“2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29, 33) and “2+1 IgG
ab, linked LC” (see SEQ ID NOs 3, 5, 29, 179)). Human PBMCs were isolated from fresh
blood of healthy eers.
FIGURE 51. Killing (as ed by LDH release) of MCSP-positive Colo-38 tumor cells upon
co-culture by human PBMCs (E:T ratio = 10:1), treated with ent SP ific
constructs for ~22 hours (“2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29, 33) and “2+1 IgG
Crossfab, linked LC” (see SEQ ID NOs 3, 5, 29, 179)). Human PBMCs were isolated from fresh
blood of healthy volunteers.
FIGURE 52. Killing (as measured by LDH release) of MCSP-positive WM266-4 cells upon co-
culture by human PBMCs (E:T ratio = 10:1), treated with different CD3-MCSP bispecific
constructs for ~22 hours (“2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29, 33) and “2+1 IgG
Crossfab, linked LC” (see SEQ ID NOs 3, 5, 29, 179)). Human PBMCs were isolated from fresh
blood of y volunteers.
FIGURE 53. Surface expression level of the early activation marker CD69 (A) and the late
activation marker CD25 (B) on human CD8+ T cells after 22 hours tion with 10 nM, 80
pM or 3 pM of different CD3-MCSP bispecific constructs (“2+1 IgG Crossfab” (see SEQ ID
NOs 3, 5, 29, 33) and “2+1 IgG Crossfab, linked LC” (see SEQ ID NOs 3, 5, 29, 179)) in the
presence or absence of human MCSP-expressing Colo-38 tumor target cells (E:T ratio = 10:1).
FIGURE 54. CE-SDS analyses. (A) opherogram shown as SDS-PAGE of 1+1 IgG
Crossfab; VL/VH exchange (LC007/V9) (see SEQ ID NOs 5, 29, 33, 181): a) non-reduced, b)
reduced. (B) Electropherogram shown as SDS-PAGE of 1+1 CrossMab; CL/CH1 ge
(LC007/V9) (see SEQ ID NOs 5, 23, 183, 185): a) reduced, b) non-reduced. (C)
Electropherogram shown as SDS-PAGE of 2+1 IgG Crossfab, inverted; CL/CH1 exchange
(LC007/V9) (see SEQ ID NOs 5, 23, 183, 187): a) reduced, b) non-reduced. (D)
Electropherogram shown as SDS-PAGE of 2+1 IgG Crossfab; VL/VH exchange (M4-3 ML2/V9)
(see SEQ ID NOs 33, 189, 191, 193): a) reduced, b) non-reduced. (E) Electropherogram shown
as SDS-PAGE of 2+1 IgG Crossfab; CL/CH1 exchange (M4-3 ML2/V9) (see SEQ ID NOs 183,
189, 193, 195): a) reduced, b) duced. (F) Electropherogram shown as SDS-PAGE of 2+1
IgG Crossfab, inverted; CL/CH1 exchange (CH1A1A/V9) (see SEQ ID NOs 65, 67, 183, 197): a)
reduced, b) non-reduced. (G) Electropherogram shown as SDS-PAGE of 2+1 IgG Crossfab;
CL/CH1 ge (M4-3 ML2/H2C) (see SEQ ID NOs 189, 193, 199, 201): a) reduced, b) nonreduced.
(H) Electropherogram shown as SDS-PAGE of 2+1 IgG Crossfab, inverted; CL/CH1
exchange (431/26/V9) (see SEQ ID NOs 183, 203, 205, 207): a) d, b) non-reduced. (I)
Electropherogram shown as SDS-PAGE of “2+1 IgG Crossfab light chain fusion” (CH1A1A/V9)
(see SEQ ID NOs 183, 209, 211, 213): a) reduced, b) non-reduced. (J) SDS PAGE (4-12%
Bis/Tris, NuPage Invitrogen, Coomassie-stained) of “2+1 IgG Crossfab” (anti-MCSP/antihuCD3
) (see SEQ ID NOs 5, 23, 215, 217), non-reduced (left) and reduced (right). (K)
Electropherogram shown as SDS-PAGE of “2+1 IgG Crossfab, inverted” (anti-MCSP/antihuCD3
) (see SEQ ID NOs 5, 23, 215, 219): a) reduced, b) non-reduced. (L) SDS PAGE (4-12%
is, NuPage Invitrogen, Coomassie-stained) of “1+1 IgG Crossfab” CD33/anti-huCD3)
(see SEQ ID NOs 33, 213, 221, 223), reduced (left) and non-reduced (right). (M) SDS PAGE (4-
12% Bis/Tris, NuPage Invitrogen, Coomassie-stained) of “2+1 IgG Crossfab” (anti-CD33/antihuCD3
) (see SEQ ID NOs 33, 221, 223, 225), reduced (left) and non-reduced (right). (N) SDS
PAGE (4-12% Bis/Tris, NuPage ogen, Coomassie-stained) of “2+1 IgG Crossfab” (anti-
CD20/anti-huCD3) (see SEQ ID NOs 33, 227, 229, 231), non-reduced.
FIGURE 55. Binding of bispecific constructs (CEA/CD3 “2+1 IgG Crossfab, inverted (VL/VH)”
(see SEQ ID NOs 33, 63, 65, 67) and “2+1 IgG Crossfab, inverted (CL/CH1)
2 (see SEQ ID NOs 65, 67, 183, 197)) to human CD3, expressed by Jurkat cells (A), or to human
CEA, expressed by LS-174T cells (B) as determined by FACS. As a control, the equivalent
maximum concentration of the reference IgGs and the background staining due to the labeled
2ndary antibody (goat anti-human FITC-conjugated AffiniPure F(ab’)2 Fragment, Fcγ
Fragment-specific, n Immuno Research Lab # 109098) were assessed as well.
FIGURE 56. Binding of ific constructs constructs (MCSP/CD3 “2+1 IgG Crossfab” (see
SEQ ID NOs 3, 5, 29, 33) and “2+1 IgG Crossfab, inverted” (see SEQ ID NOs 5, 23, 183, 187))
to human CD3, expressed by Jurkat cells (A), or to human MCSP, sed by WM266-4
tumor cells (B) as determined by FACS.
FIGURE 57. Binding of the “1+1 IgG Crossfab light chain fusion” (see SEQ ID NOs 183, 209,
211, 213) to human CD3, expressed by Jurkat cells (A), or to human CEA, expressed by LS-
174T cells (B) as determined by FACS.
FIGURE 58. Binding of the “2+1 IgG Crossfab” (see SEQ ID NOs 5, 23, 215, 217) and the “2+1
IgG Crossfab, inverted” (see SEQ ID NOs 5, 23, 215, 219) constructs to human CD3, expressed
by Jurkat cells (A), or human MCSP, expressed by WM266-4 tumor cells (B) as determined by
FACS.
FIGURE 59. Surface expression level of the early activation marker CD69 (A) or the late
activation marker CD25 (B) on human CD4+ or CD8+ T cells after 24 hours incubation with the
indicated concentrations of the CD3/MCSP “1+1 CrossMab” (see SEQ ID NOs 5, 23, 183, 185),
“1+1 IgG Crossfab” (see SEQ ID NOs 5, 29, 33, 181) and “2+1 IgG ab” (see SEQ ID NOs
3, 5, 29, 33) constructs. The assay was med in the presence or e of MV-3 target
cells, as indicated.
FIGURE 60. Surface expression level of the early activation marker CD25 on CD4+ or CD8+ T
cells from two different cynomolgus monkeys (A and B) in the ce or absence of huMCSP-
positive MV-3 tumor cells upon co-culture with cynomolgus PBMCs (E:T ratio = 3:1,
normalized to CD3+ numbers), treated with the “2+1 IgG Crossfab” (see SEQ ID NOs 5, 23, 215,
217) and the “2+1 IgG Crossfab, inverted” (see SEQ ID NOs 5, 23, 215, 219) for ~41 hours.
FIGURE 61. g (as ed by LDH release) of MKN-45 (A) or LS-174T (B) tumor cells
upon co-culture with human PBMCs (E:T ratio = 10:1) and activation for 28 hours by different
concentrations of the “2+1 IgG Crossfab, inverted (VL/VH)” (see SEQ ID NOs 33, 63, 65, 67)
versus the “2+1 IgG Crossfab, inverted (CL/CH1)” (see SEQ ID NOs 65, 67, 183, 197)
construct.
FIGURE 62. g (as measured by LDH release) of WM266-4 tumor cells upon co-culture
with human PBMCs (E:T ratio = 10:1) and activation for 26 hours by different concentrations of
the “2+1 IgG Crossfab (VL/VH)” (see SEQ ID NOs 33, 189, 191, 193) versus the “2+1 IgG
Crossfab (CL/CH1)” (see SEQ ID NOs 183, 189, 193, 195) construct.
FIGURE 63. Killing (as measured by LDH release) of MV-3 tumor cells upon co-culture with
human PBMCs (E:T ratio = 10:1) and activation for 27 hours by different concentrations of the
“2+1 IgG Crossfab (VH/VL)” (see SEQ ID NOs 33, 189, 191, 193) versus the “2+1 IgG
Crossfab (CL/CH1)” (see SEQ ID NOs 183, 189, 193, 195) constructs.
FIGURE 64. Killing (as measured by LDH release) of human MCSP-positive WM266-4 (A) or
MV-3 (B) tumor cells upon co-culture with human PBMCs (E:T ratio = 10:1) and activation for
21 hours by ent concentrations of the “2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29, 33),
the “1+1 CrossMab” (see SEQ ID NOs 5, 23, 183, 185), and the “1+1 IgG ab” (see SEQ
ID NOs 5, 29, 33, 181), as indicated.
FIGURE 65. g (as measured by LDH release) of MKN-45 (A) or LS-174T (B) tumor cells
upon co-culture with human PBMCs (E:T ratio = 10:1) and activation for 28 hours by different
concentrations of the “1+1 IgG Crossfab LC fusion” (see SEQ ID NOs 183, 209, 211, 213).
FIGURE 66. Killing (as measured by LDH release) of MC38-huCEA tumor cells upon coculture
with human PBMCs (E:T ratio = 10:1) and tion for 24 hours by different
concentrations of the “1+1 IgG ab LC fusion” (see SEQ ID NOs 183, 209, 211, 213)
versus an untargeted “2+1 IgG Crossfab” reference.
FIGURE 67. Killing (as measured by LDH release) of human MCSP-positive MV-3 (A) or
WM266-4 (B) tumor cells upon co-culture with human PBMCs (E:T ratio = 10:1), treated with
the “2+1 IgG Crossfab (V9)” (see SEQ ID NOs 3, 5, 29, 33) and the “2+1 IgG Crossfab, inverted
(V9)” (see SEQ ID NOs 5, 23, 183, 187), the “2+1 IgG Crossfab (anti-CD3)” (see SEQ ID NOs
5, 23, 215, 217) and the “2+1 IgG Crossfab, inverted (anti-CD3)” (see SEQ ID NOs 5, 23, 215,
219) constructs.
ed ption of the Invention
Definitions
Terms are used herein as generally used in the art, unless otherwise defined in the following.
As used herein, the term "antigen binding molecule" refers in its st sense to a molecule
that specifically binds an antigenic determinant. Examples of antigen binding molecules are
immunoglobulins and derivatives, e.g. fragments, thereof.
The term “bispecific” means that the antigen binding molecule is able to specifically bind to at
least two distinct antigenic determinants. Typically, a bispecific antigen binding molecule
comprises two antigen binding sites, each of which is specific for a different antigenic
determinant. In certain embodiments the bispecific antigen binding molecule is e of
simultaneously g two antigenic determinants, particularly two antigenic determinants
expressed on two distinct cells.
The term “valent” as used herein s the presence of a specified number of n binding
sites in an antigen binding molecule. As such, the term “monovalent binding to an antigen”
denotes the presence of one (and not more than one) antigen binding site specific for the antigen
in the n binding le.
An “antigen binding site” refers to the site, i.e. one or more amino acid residues, of an antigen
binding molecule which provides interaction with the n. For example, the antigen binding
site of an antibody comprises amino acid residues from the complementarity determining regions
(CDRs). A native immunoglobulin molecule typically has two antigen binding sites, a Fab
molecule typically has a single n binding site.
As used herein, the term "antigen binding moiety" refers to a polypeptide molecule that
specifically binds to an antigenic determinant. In one embodiment, an antigen binding moiety is
able to direct the entity to which it is attached (e.g. a second antigen binding moiety) to a target
site, for example to a specific type of tumor cell or tumor stroma bearing the nic
determinant. In another embodiment an antigen binding moiety is able to activate ing
through its target antigen, for example a T cell receptor complex antigen. Antigen binding
moieties include antibodies and fragments thereof as further defined herein. Particular antigen
binding moieties include an antigen binding domain of an antibody, comprising an antibody
heavy chain le region and an antibody light chain variable region. In certain embodiments,
the antigen binding es may comprise antibody constant regions as r d herein
and known in the art. Useful heavy chain constant regions include any of the five isotypes: α, δ,
ε, γ, or μ. Useful light chain constant regions include any of the two isotypes: κ and λ.
As used herein, the term "antigenic inant" is synonymous with "antigen" and "epitope,"
and refers to a site (e.g. a contiguous stretch of amino acids or a conformational configuration
made up of ent regions of non-contiguous amino acids) on a ptide macromolecule to
which an antigen g moiety binds, forming an antigen g moiety-antigen complex.
Useful antigenic determinants can be found, for example, on the surfaces of tumor cells, on the
surfaces of virus-infected cells, on the surfaces of other diseased cells, on the surface of immune
cells, free in blood serum, and/or in the extracellular matrix (ECM). The proteins ed to as
antigens herein (e.g. MCSP, FAP, CEA, EGFR, CD33, CD3) can be any native form the proteins
from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g.
mice and rats), unless otherwise indicated. In a ular embodiment the antigen is a human
n. Where reference is made to a specific protein herein, the term encompasses the “fulllength”
, unprocessed protein as well as any form of the protein that results from processing in the
cell. The term also encompasses naturally occurring variants of the protein, e.g. splice ts or
allelic variants. Exemplary human ns useful as antigens include, but are not limited to:
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), also known as oitin
Sulfate Proteoglycan 4 (UniProt no. Q6UVK1 (version 70), NCBI RefSeq no. NP_001888.2);
Fibroblast Activation Protein (FAP), also known as Seprase (Uni Prot nos. Q12884, Q86Z29,
Q99998, NCBI Accession no. NP_004451); Carcinoembroynic antigen (CEA), also known as
Carcinoembryonic antigen-related cell adhesion molecule 5 (UniProt no. P06731 (version 119),
NCBI RefSeq no. 354.2); CD33, also known as gp67 or Siglec-3 (UniProt no. P20138,
NCBI Accession nos. NP_001076087, 171079); Epidermal Growth Factor Receptor
(EGFR), also known as ErbB-1 or Her1 (UniProt no. P0053, NCBI Accession nos. NP_958439,
NP_958440), and CD3, particularly the epsilon subunit of CD3 (see UniProt no. P07766 (version
130), NCBI RefSeq no. NP_000724.1, SEQ ID NO: 265 for the human sequence; or UniProt no.
Q95LI5 (version 49), NCBI GenBank no. BAB71849.1, SEQ ID NO: 266 for the cynomolgus
[Macaca fascicularis] sequence). In certain embodiments the T cell activating bispecific antigen
binding molecule described binds to an epitope of an ting T cell antigen or a target cell
n that is conserved among the ting T cell antigen or target antigen from different
species.
By "specific binding" is meant that the binding is selective for the antigen and can be
discriminated from unwanted or non-specific ctions. The ability of an antigen binding
moiety to bind to a specific antigenic determinant can be measured either through an enzymelinked
immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g.
surface plasmon nce (SPR) technique (analyzed on a BIAcore instrument) (Liljeblad et al.,
Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229
(2002)). In one embodiment, the extent of binding of an antigen binding moiety to an unrelated
protein is less than about 10% of the binding of the antigen g moiety to the antigen as
ed, e.g., by SPR. In certain embodiments, an antigen binding moiety that binds to the
antigen, or an antigen binding molecule sing that antigen binding moiety, has a
dissociation constant (KD) of ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤
0.001 nM (e.g. 10-8 M or less, e.g. from 10-8 M to 10-13 M, e.g., from 10-9 M to 10-13 M).
ity” refers to the strength of the sum total of non-covalent interactions n a single
binding site of a molecule (e.g., a or) and its binding partner (e.g., a ). Unless
indicated otherwise, as used , “binding affinity” refers to intrinsic binding affinity which
reflects a 1:1 interaction n members of a binding pair (e.g., an antigen binding moiety and
an antigen, or a receptor and its ligand). The affinity of a molecule X for its partner Y can
generally be represented by the dissociation constant (KD), which is the ratio of dissociation and
association rate constants (koff and kon, respectively). Thus, equivalent affinities may comprise
different rate constants, as long as the ratio of the rate constants remains the same. Affinity can
be measured by well established s known in the art, including those described herein. A
particular method for measuring affinity is Surface Plasmon Resonance (SPR).
“Reduced binding”, for example reduced binding to an Fc receptor, refers to a decrease in
affinity for the respective interaction, as measured for example by SPR. For y the term
includes also reduction of the ty to zero (or below the detection limit of the analytic
), i.e. complete abolishment of the interaction. Conversely, “increased binding” refers to
an increase in binding affinity for the respective interaction.
An “activating T cell antigen” as used herein refers to an antigenic determinant sed on the
surface of a T lymphocyte, particularly a cytotoxic T lymphocyte, which is capable of inducing T
cell activation upon interaction with an antigen binding molecule. Specifically, interaction of an
antigen binding molecule with an activating T cell antigen may induce T cell activation by
triggering the signaling cascade of the T cell or complex. In a particular embodiment the
activating T cell antigen is CD3.
“T cell activation” as used herein refers to one or more cellular response of a T lymphocyte,
ularly a cytotoxic T lymphocyte, ed from: proliferation, differentiation, cytokine
secretion, xic effector molecule release, cytotoxic activity, and expression of activation
markers. The T cell activating bispecific antigen binding molecules described are capable of
inducing T cell activation. Suitable assays to measure T cell activation are known in the art
described herein.
A “target cell antigen” as used herein refers to an antigenic determinant presented on the surface
of a target cell, for example a cell in a tumor such as a cancer cell or a cell of the tumor stroma.
As used herein, the terms “first” and “second” with respect to antigen binding moieties etc., are
used for convenience of distinguishing when there is more than one of each type of moiety. Use
of these terms is not ed to confer a specific order or orientation of the T cell activating
bispecific antigen binding molecule unless explicitly so stated.
A “Fab le” refers to a protein consisting of the VH and CH1 domain of the heavy chain
(the “Fab heavy chain”) and the VL and CL domain of the light chain (the “Fab light chain”) of
an immunoglobulin.
By ” is meant that the components (e.g. a Fab molecule and an Fc domain subunit) are
linked by peptide bonds, either directly or via one or more peptide linkers.
As used herein, the term "single-chain" refers to a molecule comprising amino acid monomers
linearly linked by peptide bonds. In certain embodiments, one of the n binding moieties is
a -chain Fab le, i.e. a Fab molecule wherein the Fab light chain and the Fab heavy
chain are connected by a peptide linker to form a single peptide chain. In a particular such
embodiment, the C-terminus of the Fab light chain is connected to the N-terminus of the Fab
heavy chain in the single-chain Fab molecule.
By a “crossover” Fab molecule (also termed “Crossfab”) is meant a Fab molecule wherein either
the variable regions or the constant regions of the Fab heavy and light chain are exchanged, i.e.
the crossover Fab molecule comprises a peptide chain composed of the light chain variable
region and the heavy chain constant region, and a peptide chain composed of the heavy chain
variable region and the light chain constant region. For clarity, in a crossover Fab molecule
wherein the variable regions of the Fab light chain and the Fab heavy chain are exchanged, the
peptide chain comprising the heavy chain constant region is ed to herein as the “heavy
chain” of the crossover Fab molecule. Conversely, in a ver Fab molecule wherein the
constant regions of the Fab light chain and the Fab heavy chain are exchanged, the e chain
comprising the heavy chain variable region is referred to herein as the “heavy chain” of the
crossover Fab molecule.
The term “immunoglobulin molecule” refers to a protein having the structure of a naturally
occurring antibody. For example, immunoglobulins of the IgG class are heterotetrameric
glycoproteins of about 0 daltons, composed of two light chains and two heavy chains that
are disulfide-bonded. From N- to inus, each heavy chain has a variable region (VH), also
called a variable heavy domain or a heavy chain variable domain, followed by three constant
domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from N- to
C-terminus, each light chain has a variable region (VL), also called a variable light domain or a
light chain variable domain, followed by a nt light (CL) domain, also called a light chain
constant region. The heavy chain of an immunoglobulin may be assigned to one of five types,
called α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which may be further divided into
subtypes, e.g. γ1 (IgG1), γ2 (IgG2), γ3 , γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chain of
an immunoglobulin may be assigned to one of two types, called kappa (κ) and lambda (λ), based
on the amino acid sequence of its constant domain. An globulin essentially consists of
two Fab molecules and an Fc domain, linked via the immunoglobulin hinge region.
The term "antibody" herein is used in the broadest sense and encompasses various antibody
structures, including but not d to monoclonal antibodies, polyclonal antibodies, and
antibody fragments so long as they exhibit the desired antigen-binding activity.
An "antibody nt" refers to a molecule other than an intact dy that comprises a
portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples
of antibody fragments include but are not limited to Fv, Fab, Fab', Fab’-SH, F(ab')2, diabodies,
linear antibodies, single-chain antibody molecules (e.g. scFv), and single-domain antibodies. For
a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a
review of scFv fragments, see e.g. Plückthun, in The Pharmacology of Monoclonal Antibodies,
vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see also
WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For sion of Fab and F(ab')2
fragments comprising salvage receptor binding epitope residues and having sed in vivo
half-life, see U.S. Patent No. 5,869,046. Diabodies are antibody fragments with two antigenbinding
sites that may be nt or bispecific. See, for example, EP 404,097; ;
Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90,
6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9,
129-134 (2003). Single-domain antibodies are antibody fragments sing all or a portion of
the heavy chain variable domain or all or a portion of the light chain variable domain of an
antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody
(Domantis, Inc., Waltham, MA; see e.g. U.S. Patent No. 6,248,516 B1). dy fragments can
be made by various techniques, ing but not limited to proteolytic ion of an intact
antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described
herein.
The term "antigen binding domain" refers to the part of an antibody that comprises the area
which specifically binds to and is complementary to part or all of an antigen. An n g
domain may be provided by, for example, one or more antibody variable domains (also called
antibody variable regions). ularly, an antigen binding domain comprises an antibody light
chain variable region (VL) and an antibody heavy chain variable region (VH).
The term “variable region” or “variable ” refers to the domain of an antibody heavy or
light chain that is involved in binding the antibody to antigen. The variable domains of the heavy
chain and light chain (VH and VL, tively) of a native dy generally have similar
structures, with each domain comprising four ved framework regions (FRs) and three
hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman
and Co., page 91 . A single VH or VL domain may be sufficient to confer antigen-binding
specificity.
The term “hypervariable region” or “HVR”, as used herein, refers to each of the s of an
antibody variable domain which are ariable in sequence and/or form structurally defined
loops (“hypervariable loops”). Generally, native four-chain antibodies comprise six HVRs; three
in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid
residues from the hypervariable loops and/or from the complementarity determining regions
(CDRs), the latter being of highest sequence variability and/or ed in antigen recognition.
With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form
the hypervariable loops. Hypervariable regions (HVRs) are also referred to as “complementarity
determining regions” (CDRs), and these terms are used herein interchangeably in reference to
ns of the variable region that form the antigen binding regions. This particular region has
been described by Kabat et al., U.S. Dept. of Health and Human Services, ces of Proteins
of Immunological st (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987), where
the definitions include overlapping or subsets of amino acid residues when compared against
each other. Nevertheless, application of either definition to refer to a CDR of an antibody or
variants thereof is intended to be within the scope of the term as defined and used herein. The
appropriate amino acid residues which ass the CDRs as defined by each of the above
cited references are set forth below in Table 1 as a comparison. The exact residue numbers which
encompass a particular CDR will vary depending on the sequence and size of the CDR. Those
skilled in the art can routinely determine which residues comprise a particular CDR given the
le region amino acid sequence of the antibody.
TABLE 1. CDR Definitions1
CDR Kabat Chothia AbM2
VH CDR1 31-35 26-32 26-35
VH CDR2 50-65 52-58 50-58
VH CDR3 95-102 95-102 95-102
VL CDR1 24-34 26-32 24-34
VL CDR2 50-56 50-52 50-56
VL CDR3 89-97 91-96 89-97
1 Numbering of all CDR definitions in Table 1 is according to the numbering conventions
set forth by Kabat et al. (see below).
2 "AbM" with a lowercase “b” as used in Table 1 refers to the CDRs as
defined by Oxford Molecular's "AbM" antibody modeling software.
Kabat et al. also defined a numbering system for variable region sequences that is applicable to
any antibody. One of ordinary skill in the art can unambiguously assign this system of "Kabat
numbering" to any variable region sequence, without reliance on any experimental data beyond
the sequence itself. As used herein, "Kabat numbering" refers to the numbering system set forth
by Kabat et al., U.S. Dept. of Health and Human Services, nce of Proteins of
logical Interest" (1983). Unless otherwise specified, references to the numbering of
specific amino acid residue ons in an antibody variable region are according to the Kabat
numbering system.
The polypeptide sequences of the sequence listing (i.e., SEQ ID NOs 1, 3, 5, 7, 9, 11, 13, 15 etc.)
are not numbered according to the Kabat ing system. However, it is well within the
ordinary skill of one in the art to convert the ing of the sequences of the Sequence Listing
to Kabat numbering.
"Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR)
residues. The FR of a variable domain generally ts of four FR domains: FR1, FR2, FR3,
and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in
VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
The ” of an antibody or immunoglobulin refers to the type of constant domain or constant
region possessed by its heavy chain. There are five major s of antibodies: IgA, IgD, IgE,
IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1,
IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the
different classes of immunoglobulins are called α, δ, ε, γ, and μ, tively.
The term “Fc domain” or “Fc region” herein is used to define a C-terminal region of an
immunoglobulin heavy chain that contains at least a portion of the constant region. The term
es native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc
region of an IgG heavy chain might vary slightly, the human IgG heavy chain Fc region is
usually defined to extend from Cys226, or from Pro230, to the carboxyl-terminus of the heavy
chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be t.
Unless otherwise specified herein, ing of amino acid residues in the Fc region or nt
region is according to the EU numbering system, also called the EU index, as described in Kabat
et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, al
Institutes of Health, Bethesda, MD, 1991. A “subunit” of an Fc domain as used herein refers to
one of the two polypeptides g the dimeric Fc domain, i.e. a polypeptide comprising C-
terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association.
For example, a subunit of an IgG Fc domain comprises an IgG CH2 and an IgG CH3 constant
domain.
A “modification promoting the association of the first and the second subunit of the Fc domain”
is a manipulation of the peptide backbone or the post-translational modifications of an Fc
domain subunit that reduces or prevents the association of a polypeptide comprising the Fc
domain subunit with an identical polypeptide to form a homodimer. A modification promoting
association as used herein particularly includes separate modifications made to each of the two
Fc domain subunits desired to associate (i.e. the first and the second subunit of the Fc domain),
wherein the modifications are complementary to each other so as to promote association of the
two Fc domain subunits. For e, a modification promoting association may alter the
structure or charge of one or both of the Fc domain subunits so as to make their association
sterically or electrostatically favorable, respectively. Thus, (hetero)dimerization occurs between
a ptide comprising the first Fc domain subunit and a ptide comprising the second
Fc domain subunit, which might be non-identical in the sense that r components fused to
each of the subunits (e.g. antigen binding moieties) are not the same. In some embodiments the
modification promoting association comprises an amino acid mutation in the Fc domain,
specifically an amino acid substitution. In a particular embodiment, the modification promoting
ation comprises a separate amino acid mutation, ically an amino acid substitution, in
each of the two subunits of the Fc .
The term “effector functions” refers to those biological activities attributable to the Fc region of
an antibody, which vary with the antibody isotype. Examples of antibody effector functions
include: C1q binding and complement ent cytotoxicity (CDC), Fc receptor binding,
antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP), cytokine ion, immune complex-mediated antigen uptake by n
presenting cells, down regulation of cell surface receptors (e.g. B cell or), and B cell
activation.
As used herein, the terms “engineer, engineered, engineering”, are ered to include any
manipulation of the peptide backbone or the post-translational modifications of a naturally
occurring or inant polypeptide or fragment thereof. Engineering es modifications of
the amino acid sequence, of the glycosylation pattern, or of the side chain group of individual
amino acids, as well as combinations of these approaches.
The term “amino acid mutation” as used herein is meant to encompass amino acid substitutions,
deletions, insertions, and modifications. Any combination of substitution, deletion, insertion, and
modification can be made to arrive at the final construct, provided that the final uct
possesses the desired characteristics, e.g., reduced binding to an Fc receptor, or increased
association with another peptide. Amino acid sequence deletions and insertions e amino-
and/or carboxy-terminal deletions and insertions of amino acids. Particular amino acid mutations
are amino acid substitutions. For the purpose of altering e.g. the binding characteristics of an Fc
region, non-conservative amino acid substitutions, i.e. replacing one amino acid with another
amino acid having different structural and/or chemical properties, are ularly preferred.
Amino acid tutions include replacement by non-naturally occurring amino acids or by
naturally occurring amino acid derivatives of the twenty standard amino acids (e.g. 4-
hydroxyproline, ylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid
mutations can be generated using genetic or chemical methods well known in the art. Genetic
methods may include site-directed mutagenesis, PCR, gene sis and the like. It is
contemplated that methods of altering the side chain group of an amino acid by s other
than genetic engineering, such as al modification, may also be useful. Various
designations may be used herein to te the same amino acid mutation. For example, a
substitution from proline at position 329 of the Fc domain to glycine can be indicated as 329G,
G329, G329, P329G, or Pro329Gly.
As used herein, term "polypeptide" refers to a molecule composed of monomers (amino acids)
linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to
any chain of two or more amino acids, and does not refer to a specific length of the product.
Thus, peptides, dipeptides, tripeptides, oligopeptides, "protein," "amino acid chain," or any other
term used to refer to a chain of two or more amino acids, are included within the definition of
"polypeptide," and the term "polypeptide" may be used instead of, or interchangeably with any
of these terms. The term "polypeptide" is also intended to refer to the ts of post-expression
modifications of the ptide, including without limitation glycosylation, acetylation,
phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic
cleavage, or modification by non-naturally occurring amino acids. A polypeptide may be derived
from a natural biological source or produced by inant technology, but is not necessarily
translated from a designated nucleic acid sequence. It may be generated in any , including
by al synthesis. A polypeptide bed may be of a size of about 3 or more, 5 or more,
or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or
more, 1,000 or more, or 2,000 or more amino acids. Polypeptides may have a defined threedimensional
structure, although they do not necessarily have such structure. Polypeptides with a
defined three-dimensional structure are referred to as folded, and polypeptides which do not
possess a defined three-dimensional structure, but rather can adopt a large number of different
conformations, and are referred to as unfolded.
By an ted" polypeptide or a variant, or derivative thereof is intended a polypeptide that is
not in its natural milieu. No particular level of purification is required. For example, an ed
polypeptide can be removed from its native or natural environment. inantly produced
polypeptides and proteins expressed in host cells are considered isolated for the purpose of
thedescription, as are native or recombinant polypeptides which have been separated,
fractionated, or partially or substantially purified by any suitable technique.
“Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is
defined as the percentage of amino acid residues in a ate ce that are identical with
the amino acid residues in the reference polypeptide sequence, after aligning the sequences and
introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not
considering any conservative substitutions as part of the sequence identity. Alignment for
purposes of determining percent amino acid ce ty can be ed in various ways
that are within the skill in the art, for instance, using publicly available computer software such
as BLAST, 2, ALIGN or Megalign AR) software. Those skilled in the art can
determine appropriate ters for aligning sequences, including any algorithms needed to
achieve maximal alignment over the full length of the sequences being compared. For purposes
herein, however, % amino acid sequence identity values are generated using the sequence
comparison computer program ALIGN-2. The ALIGN-2 sequence comparison er
program was authored by Genentech, Inc., and the source code has been filed with user
documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered
under U.S. Copyright Registration No. TXU510087. The 2 program is publicly ble
from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
The ALIGN-2 program should be ed for use on a UNIX operating system, including
digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and
do not vary. In situations where ALIGN-2 is employed for amino acid sequence comparisons,
the % amino acid sequence ty of a given amino acid sequence A to, with, or against a given
amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A
that has or ses a certain % amino acid ce identity to, with, or against a given amino
acid ce B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by the sequence
alignment program ALIGN-2 in that program’s alignment of A and B, and where Y is the total
number of amino acid residues in B. It will be appreciated that where the length of amino acid
sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence
identity of A to B will not equal the % amino acid sequence identity of B to A. Unless
specifically stated otherwise, all % amino acid sequence identity values used herein are obtained
as described in the immediately preceding paragraph using the ALIGN-2 computer program.
The term "polynucleotide" refers to an isolated c acid molecule or construct, e.g.
messenger RNA (mRNA), virally-derived RNA, or plasmid DNA (pDNA). A polynucleotide
may comprise a conventional odiester bond or a non-conventional bond (e.g. an amide
bond, such as found in peptide nucleic acids (PNA). The term "nucleic acid molecule" refers to
any one or more nucleic acid segments, e.g. DNA or RNA fragments, present in a
polynucleotide.
By "isolated" nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA
or RNA, which has been removed from its native environment. For example, a inant
polynucleotide encoding a polypeptide contained in a vector is considered isolated for the
es of the presentdescription. Further examples of an isolated polynucleotide include
inant polynucleotides maintained in heterologous host cells or purified (partially or
substantially) polynucleotides in solution. An isolated cleotide includes a polynucleotide
molecule contained in cells that ordinarily contain the cleotide molecule, but the
polynucleotide molecule is present extrachromosomally or at a chromosomal location that is
different from its natural chromosomal location. Isolated RNA molecules include in vivo or in
vitro RNA transcripts, as well as positive and negative strand forms, and -stranded forms.
Isolated polynucleotides or nucleic acids according to the present description further include
such molecules produced synthetically. In addition, a polynucleotide or a nucleic acid may be or
may include a regulatory element such as a promoter, ribosome binding site, or a transcription
terminator.
By a nucleic acid or polynucleotide having a nucleotide sequence at least, for e, 95%
"identical" to a reference tide ce described, it is intended that the tide
ce of the polynucleotide is identical to the reference sequence except that the
polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the
reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide
sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides
in the reference sequence may be deleted or substituted with another nucleotide, or a number of
nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the
reference sequence. These alterations of the reference sequence may occur at the 5’ or 3’
terminal positions of the reference tide sequence or re between those terminal
positions, interspersed either dually among residues in the reference sequence or in one or
more contiguous groups within the reference sequence. As a practical matter, r any
particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%
identical to a nucleotide sequence described can be determined conventionally using known
er programs, such as the ones discussed above for polypeptides (e.g. ALIGN-2).
The term "expression te" refers to a polynucleotide generated inantly or
synthetically, with a series of specified c acid elements that permit transcription of a
particular c acid in a target cell. The recombinant expression cassette can be incorporated
into a plasmid, chromosome, ondrial DNA, plastid DNA, virus, or nucleic acid fragment.
Typically, the inant expression cassette portion of an expression vector includes, among
other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain
embodiments, the expression cassette comprises polynucleotide sequences that encode bispecific
antigen binding molecules described or fragments thereof.
The term “vector” or "expression vector" is synonymous with "expression construct" and refers
to a DNA molecule that is used to introduce and direct the expression of a specific gene to which
it is operably associated in a target cell. The term includes the vector as a self-replicating nucleic
acid structure as well as the vector orated into the genome of a host cell into which it has
been introduced. The expression vector described comprises an expression cassette. sion
s allow transcription of large amounts of stable mRNA. Once the expression vector is
inside the target cell, the ribonucleic acid molecule or protein that is encoded by the gene is
produced by the cellular transcription and/or translation machinery. In one embodiment, the
expression vector described comprises an expression cassette that comprises polynucleotide
sequences that encode bispecific n binding molecules described or fragments thereof.
The terms "host cell", "host cell line," and "host cell culture" are used interchangeably and refer
to cells into which exogenous nucleic acid has been introduced, ing the progeny of such
cells. Host cells include "transformants" and "transformed cells," which include the primary
transformed cell and progeny derived therefrom t regard to the number of passages.
Progeny may not be tely identical in nucleic acid content to a parent cell, but may contain
mutations. Mutant progeny that have the same function or biological activity as ed or
selected for in the originally transformed cell are included herein. A host cell is any type of
cellular system that can be used to generate the bispecific antigen binding molecules described.
Host cells include ed cells, e.g. mammalian cultured cells, such as CHO cells, BHK cells,
NS0 cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6
cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also
cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.
An “activating Fc receptor” is an Fc receptor that following ment by an Fc domain of an
antibody elicits signaling events that stimulate the receptor-bearing cell to perform effector
functions. Human activating Fc receptors e FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa
(CD32), and FcαRI (CD89).
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism g to the
lysis of antibody-coated target cells by immune or cells. The target cells are cells to which
antibodies or derivatives thereof comprising an Fc region specifically bind, generally via the
protein part that is inal to the Fc region. As used herein, the term ed ADCC” is
defined as either a reduction in the number of target cells that are lysed in a given time, at a
given concentration of antibody in the medium nding the target cells, by the mechanism of
ADCC d above, and/or an se in the concentration of antibody in the medium
surrounding the target cells, required to achieve the lysis of a given number of target cells in a
given time, by the mechanism of ADCC. The ion in ADCC is ve to the ADCC
mediated by the same antibody produced by the same type of host cells, using the same standard
production, purification, formulation and storage s (which are known to those skilled in
the art), but that has not been engineered. For example the reduction in ADCC ed by an
antibody sing in its Fc domain an amino acid substitution that reduces ADCC, is relative
to the ADCC mediated by the same antibody without this amino acid substitution in the Fc
. Suitable assays to measure ADCC are well known in the art (see e.g. PCT publication
no. or PCT patent application no. ).
An "effective amount" of an agent refers to the amount that is necessary to result in a
physiological change in the cell or tissue to which it is administered.
A "therapeutically effective amount" of an agent, e.g. a pharmaceutical composition, refers to an
amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic
or prophylactic . A therapeutically effective amount of an agent for example eliminates,
decreases, delays, minimizes or prevents adverse effects of a disease.
An “individual” or “subject” is a mammal. Mammals include, but are not limited to,
domesticated animals (e.g. cows, sheep, cats, dogs, and horses), primates (e.g. humans and non-
human primates such as monkeys), rabbits, and rodents (e.g. mice and rats). Particularly, the
individual or subject is a human.
The term "pharmaceutical composition" refers to a preparation which is in such form as to permit
the biological activity of an active ingredient contained therein to be effective, and which
contains no additional components which are ptably toxic to a subject to which the
formulation would be administered.
A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical composition,
other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable
carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”)
refers to clinical intervention in an attempt to alter the natural course of a disease in the
individual being treated, and can be performed either for prophylaxis or during the course of
clinical pathology. Desirable effects of ent include, but are not limited to, preventing
occurrence or recurrence of disease, alleviation of ms, diminishment of any direct or
indirect pathological consequences of the e, ting metastasis, decreasing the rate of
disease ssion, amelioration or palliation of the disease state, and remission or improved
prognosis. In some embodiments, T cell activating bispecific antigen binding molecules
described are used to delay development of a disease or to slow the progression of a disease.
The term “package insert” is used to refer to instructions customarily included in commercial
packages of therapeutic products, that contain information about the indications, usage, dosage,
administration, combination therapy, contraindications and/or warnings concerning the use of
such therapeutic ts.
The term “comprising” as used in this specification means “consisting at least in part of”. When
interpreting each statement in this specification that includes the term ising”, features
other than that or those ed by the term may also be present. Related terms such as
“comprise” and “comprises” are to be interpreted in the same manner.
Detailed Description of the Embodiments
Described is a T cell activating bispecific antigen binding molecule comprising a first and a
second antigen binding moiety, one of which is a Fab molecule capable of specific binding to an
activating T cell antigen and the other one of which is a Fab molecule e of specific binding
to a target cell antigen, and an Fc domain composed of a first and a second subunit capable of
stable association;
wherein the first antigen binding moiety is
(a) a single chain Fab molecule n the Fab light chain and the Fab heavy chain are
connected by a peptide linker, or
(b) a crossover Fab molecule wherein either the variable or the constant regions of the Fab
light chain and the Fab heavy chain are exchanged.
T cell ting bispecific antigen binding molecule formats
The components of the T cell activating bispecific n binding molecule can be fused to each
other in a variety of configurations. Exemplary urations are depicted in Figure 1.
In some ments, the second antigen g moiety is fused at the C-terminus of the Fab
heavy chain to the N-terminus of the first or the second subunit of the Fc domain.
In a particular such embodiment, the first antigen binding moiety is fused at the C-terminus of
the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding
. In a specific such embodiment, the T cell activating bispecific n binding molecule
essentially consists of a first and a second antigen binding moiety, an Fc domain composed of a
first and a second subunit, and optionally one or more peptide linkers, wherein the first antigen
binding moiety is fused at the C-terminus of the Fab heavy chain to the inus of the Fab
heavy chain of the second antigen binding moiety, and the second n binding moiety is
fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second
subunit of the Fc domain. In an even more specific embodiment, the first antigen binding moiety
is a single chain Fab molecule. Alternatively, in a particular embodiment, the first antigen
binding moiety is a crossover Fab molecule. Optionally, if the first antigen binding moiety is a
crossover Fab molecule, the Fab light chain of the first antigen binding moiety and the Fab light
chain of the second antigen binding moiety may additionally be fused to each other.
In an alternative such embodiment, the first n binding moiety is fused at the C-terminus of
the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In a
specific such embodiment, the T cell activating bispecific antigen binding molecule essentially
consists of a first and a second antigen binding moiety, an Fc domain composed of a first and a
second subunit, and optionally one or more peptide linkers, wherein the first and the second
antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-
terminus of one of the subunits of the Fc domain. In an even more specific embodiment, the first
antigen binding moiety is a single chain Fab molecule. Alternatively, in a particular embodiment,
the first antigen binding moiety is a crossover Fab molecule.
In yet another such embodiment, the second antigen binding moiety is fused at the C-terminus of
the Fab light chain to the N-terminus of the Fab light chain of the first antigen g moiety. In
a specific such embodiment, the T cell activating ific n binding molecule essentially
consists of a first and a second n binding moiety, an Fc domain composed of a first and a
second subunit, and optionally one or more peptide linkers, wherein the first antigen binding
moiety is fused at the N-terminus of the Fab light chain to the C-terminus of the Fab light chain
of the second antigen binding moiety, and the second n binding moiety is fused at the C-
us of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc
domain. In an even more specific embodiment, the first antigen binding moiety is a crossover
Fab molecule.
In other embodiments, the first antigen binding moiety is fused at the C-terminus of the Fab
heavy chain to the N-terminus of the first or second subunit of the Fc domain.
In a particular such embodiment, the second antigen g moiety is fused at the inus of
the Fab heavy chain to the N-terminus of the Fab heavy chain of the first n binding moiety.
In a specific such embodiment, the T cell activating ific antigen binding molecule
ially consists of a first and a second antigen binding moiety, an Fc domain ed of a
first and a second subunit, and optionally one or more e linkers, wherein the second
antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of
the Fab heavy chain of the first antigen binding moiety, and the first antigen binding moiety is
fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second
subunit of the Fc domain. In an even more specific embodiment, the first antigen g moiety
is a crossover Fab molecule. Optionally, the Fab light chain of the first antigen binding moiety
and the Fab light chain of the second antigen binding moiety may additionally be fused to each
other.
In ular of these ments, the first antigen binding moiety is capable of specific
binding to an ting T cell antigen. In other embodiments, the first antigen binding moiety is
capable of specific binding to a target cell antigen.
The antigen binding moieties may be fused to the Fc domain or to each other directly or through
a peptide linker, comprising one or more amino acids, typically about 2-20 amino acids. Peptide
linkers are known in the art and are described herein. Suitable, non-immunogenic peptide linkers
include, for e, (G4S)n, (SG4)n, (G4S)n or G4(SG4)n peptide linkers. “n” is generally a
number between 1 and 10, typically between 2 and 4. A particularly suitable peptide linker for
fusing the Fab light chains of the first and the second antigen binding moiety to each other is
(G4S)2. An exemplary peptide linker suitable for connecting the Fab heavy chains of the first and
the second antigen binding moiety is EPKSC(D)-(G4S)2 (SEQ ID NOs 150 and 151).
Additionally, linkers may comprise (a portion of) an immunoglobulin hinge region. Particularly
where an antigen binding moiety is fused to the N-terminus of an Fc domain subunit, it may be
fused via an immunoglobulin hinge region or a portion thereof, with or without an onal
peptide linker.
A T cell activating bispecific antigen binding molecule with a single antigen binding moiety
capable of specific binding to a target cell antigen (for example as shown in Figure 1A, 1B, 1D,
1E, 1H, 1I, 1K or 1M) is useful, particularly in cases where internalization of the target cell
n is to be expected following binding of a high affinity antigen binding moiety. In such
cases, the presence of more than one antigen binding moiety specific for the target cell n
may e internalization of the target cell n, thereby reducing its availablity.
In many other cases, however, it will be advantageous to have a T cell activating bispecific
antigen binding molecule comprising two or more antigen binding moieties specific for a target
cell antigen (see examples in shown in Figure 1C, 1F, 1G, 1J or 1L), for example to optimize
targeting to the target site or to allow crosslinking of target cell antigens.
Accordingly, in certain embodiments, the T cell activating bispecific antigen g molecule
described further comprises a third antigen binding moiety which is a Fab molecule capable of
ic binding to a target cell antigen. In one embodiment, the third antigen g moiety is
capable of ic g to the same target cell antigen as the first or second antigen binding
moiety. In a particular embodiment, the first n binding moiety is capable of specific
binding to an ting T cell antigen, and the second and third antigen binding moieties are
capable of ic binding to a target cell antigen.
In one embodiment, the third antigen binding moiety is fused at the C-terminus of the Fab heavy
chain to the N-terminus of the first or second subunit of the Fc domain. In a particular
embodiment, the second and the third antigen binding moiety are each fused at the C-terminus of
the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the first
antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of
the Fab heavy chain of the second antigen binding moiety. In one such embodiment the first
antigen binding moiety is a single chain Fab molecule. In a particular such embodiment the first
antigen g moiety is a crossover Fab molecule. Optionally, if the first antigen binding
moiety is a crossover Fab molecule, the Fab light chain of the first antigen binding moiety and
the Fab light chain of the second antigen binding moiety may additionally be fused to each other.
The second and the third antigen g moiety may be fused to the Fc domain directly or
through a peptide linker. In a particular ment the second and the third antigen binding
moiety are each fused to the Fc domain through an immunoglobulin hinge region. In a specific
ment, the immunoglobulin hinge region is a human IgG1 hinge region. In one
embodiment the second and the third antigen binding moiety and the Fc domain are part of an
immunoglobulin molecule. In a particular embodiment the immunoglobulin le is an IgG
class immunoglobulin. In an even more particular embodiment the immunoglobulin is an IgG1
subclass immunoglobulin. In another embodiment the immunoglobulin is an IgG4 subclass
immunoglobulin. In a further particular embodiment the immunoglobulin is a human
immunoglobulin. In other embodiments the immunoglobulin is a chimeric immunoglobulin or a
humanized immunoglobulin. In one embodiment, the T cell activating bispecific antigen binding
molecule essentially consists of an immunoglobulin molecule capable of specific binding to a
target cell antigen, and an antigen binding moiety capable of ic binding to an activating T
cell antigen wherein the antigen binding moiety is a single chain Fab molecule or a crossover
Fab molecule, particularly a crossover Fab le, fused to the N-terminus of one of the
immunoglobulin heavy chains, optionally via a peptide linker.
In an alternative embodiment, the first and the third antigen binding moiety are each fused at the
C-terminus of the Fab heavy chain to the inus of one of the subunits of the Fc domain,
and the second n binding moiety is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the Fab heavy chain of the first antigen binding moiety. In a specific such
embodiment, the T cell activating bispecific antigen binding molecule essentially ts of a
first, a second and a third antigen binding , an Fc domain composed of a first and a second
subunit, and ally one or more peptide linkers, wherein the second antigen binding moiety
is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the
first antigen binding moiety, and the first antigen binding moiety is fused at the C-terminus of
the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and wherein the
third antigen binding moiety is fused at the inus of the Fab heavy chain to the N-terminus
of the second subunit of the Fc domain. In a particular such embodiment the first antigen binding
moiety is a ver Fab molecule. Optionally, the Fab light chain of the first antigen g
moiety and the Fab light chain of the second antigen binding moiety may additionally be fused to
each other.
In some of the T cell activating bispecific antigen binding molecule described, the Fab light
chain of the first antigen binding moiety and the Fab light chain of the second antigen binding
moiety are fused to each other, optionally via a linker peptide. Depending on the configuration of
the first and the second antigen binding moiety, the Fab light chain of the first antigen binding
moiety may be fused at its C-terminus to the N-terminus of the Fab light chain of the second
antigen binding , or the Fab light chain of the second antigen binding moiety may be
fused at its C-terminus to the N-terminus of the Fab light chain of the first n g
moiety. Fusion of the Fab light chains of the first and the second antigen binding moiety further
reduces mispairing of unmatched Fab heavy and light chains, and also reduces the number of
plasmids needed for expression of some of the T cell activating bispecific antigen binding
molecules described.
In n ments the T cell activating bispecific antigen binding molecule comprises a
polypeptide wherein a first Fab light chain shares a carboxy-terminal peptide bond with a peptide
linker, which in turn shares a carboxy-terminal peptide bond with a first Fab heavy chain, which
in turn shares a carboxy-terminal peptide bond with an Fc domain subunit (VL-CL-linker-VHCH1-CH2-CH2
(-CH4)), and a polypeptide wherein a second Fab heavy chain shares a carboxyterminal
peptide bond with an Fc domain subunit (VH-CH1-CH2-CH3(-CH4)). In some
embodiments the T cell activating bispecific antigen binding molecule further comprises a
second Fab light chain polypeptide (VL-CL). In certain embodiments the polypeptides are
covalently linked, e.g., by a disulfide bond.
In some embodiments, the T cell ting ific antigen binding molecule comprises a
polypeptide wherein a first Fab light chain shares a carboxy-terminal peptide bond with a peptide
linker, which in turn shares a carboxy-terminal peptide bond with a first Fab heavy chain, which
in turn shares a carboxy-terminal peptide bond with a second Fab heavy chain, which in turn
shares a carboxy-terminal peptide bond with an Fc domain subunit (VL-CL-linker-VH-CH1-
VH-CH1-CH2-CH3(-CH4)). In one of these embodiments that T cell activating bispecific
antigen g molecule further comprises a second Fab light chain polypeptide (VL-CL). The
T cell ting bispecific antigen binding molecule according to these embodiments may
further se (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide
wherein a third Fab heavy chain shares a carboxy-terminal e bond with an Fc domain
subunit (VH-CH1-CH2-CH3(-CH4)) and a third Fab light chain polypeptide ). In n
embodiments the polypeptides are covalently linked, e.g., by a disulfide bond.
In certain embodiments the T cell activating bispecific antigen binding molecule comprises a
polypeptide wherein a first Fab light chain variable region shares a y-terminal peptide
bond with a first Fab heavy chain constant region (i.e. a ver Fab heavy chain, wherein the
heavy chain variable region is replaced by a light chain variable region), which in turn shares a
carboxy-terminal peptide bond with an Fc domain subunit (VL-CH1-CH2-CH2(-CH4)), and a
polypeptide wherein a second Fab heavy chain shares a carboxy-terminal e bond with an
Fc domain subunit (VH-CH1-CH2-CH3(-CH4)). In some ments the T cell activating
bispecific antigen binding molecule further comprises a ptide wherein a Fab heavy chain
variable region shares a carboxy-terminal e bond with a Fab light chain constant region
(VH-CL) and a Fab light chain polypeptide (VL-CL). In certain embodiments the polypeptides
are covalently linked, e.g., by a disulfide bond.
In alternative ments the T cell activating bispecific antigen binding molecule comprises a
polypeptide wherein a first Fab heavy chain variable region shares a carboxy-terminal peptide
bond with a first Fab light chain constant region (i.e. a crossover Fab heavy chain, wherein the
heavy chain constant region is replaced by a light chain constant ), which in turn shares a
carboxy-terminal peptide bond with an Fc domain subunit (VH-CL-CH2-CH2(-CH4)), and a
polypeptide wherein a second Fab heavy chain shares a carboxy-terminal peptide bond with an
Fc domain subunit (VH-CH1-CH2-CH3(-CH4)). In some embodiments the T cell activating
bispecific antigen g molecule further ses a polypeptide wherein a Fab light chain
variable region shares a carboxy-terminal peptide bond with a Fab heavy chain constant region
(VL-CH1) and a Fab light chain polypeptide (VL-CL). In certain embodiments the polypeptides
are covalently linked, e.g., by a ide bond.
In some embodiments, the T cell activating bispecific antigen binding molecule comprises a
polypeptide wherein a first Fab light chain variable region shares a carboxy-terminal peptide
bond with a first Fab heavy chain constant region (i.e. a crossover Fab heavy chain, wherein the
heavy chain le region is replaced by a light chain variable region), which in turn shares a
carboxy-terminal peptide bond with a second Fab heavy chain, which in turn shares a carboxyterminal
e bond with an Fc domain subunit (VL-CH1-VH-CH1-CH2-CH3(-CH4)). In
other embodiments, the T cell activating bispecific antigen binding le comprises a
polypeptide n a first Fab heavy chain variable region shares a carboxy-terminal peptide
bond with a first Fab light chain constant region (i.e. a crossover Fab heavy chain, wherein the
heavy chain constant region is replaced by a light chain nt ), which in turn shares a
carboxy-terminal peptide bond with a second Fab heavy chain, which in turn shares a carboxy-
terminal peptide bond with an Fc domain t (VH-CL-VH-CH1-CH2-CH3(-CH4)). In still
other embodiments, the T cell activating bispecific antigen binding molecule comprises a
polypeptide wherein a second Fab heavy chain shares a carboxy-terminal peptide bond with a
first Fab light chain variable region which in turn shares a carboxy-terminal peptide bond with a
first Fab heavy chain constant region (i.e. a ver Fab heavy chain, wherein the heavy chain
variable region is replaced by a light chain variable region), which in turn shares a carboxyterminal
peptide bond with an Fc domain t (VH-CH1-VL-CH1-CH2-CH3(-CH4)). In
other embodiments, the T cell activating bispecific antigen binding molecule comprises a
polypeptide wherein a second Fab heavy chain shares a carboxy-terminal peptide bond with a
first Fab heavy chain le region which in turn shares a carboxy-terminal peptide bond with
a first Fab light chain constant region (i.e. a crossover Fab heavy chain, wherein the heavy chain
constant region is replaced by a light chain constant region), which in turn shares a carboxyterminal
peptide bond with an Fc domain subunit (VH-CH1-VH-CL-CH2-CH3(-CH4)).
In some of these embodiments the T cell activating bispecific antigen binding molecule further
comprises a crossover Fab light chain polypeptide, wherein a Fab heavy chain variable region
shares a carboxy-terminal peptide bond with a Fab light chain constant region (VH-CL), and a
Fab light chain ptide (VL-CL). In others of these embodiments the T cell activating
bispecific antigen binding molecule further comprises a crossover Fab light chain polypeptide,
wherein a Fab light chain variable region shares a carboxy-terminal peptide bond with a Fab
heavy chain constant region (VL-CH1), and a Fab light chain polypeptide (VL-CL). In still
others of these embodiments the T cell activating bispecific antigen binding molecule further
ses a polypeptide wherein a Fab light chain variable region shares a carboxy-terminal
peptide bond with a Fab heavy chain constant region which in turn shares a carboxy-terminal
peptide bond with a Fab light chain polypeptide (VL-CH1-VL-CL), a ptide wherein a Fab
heavy chain variable region shares a carboxy-terminal peptide bond with a Fab light chain
constant region which in turn shares a carboxy-terminal e bond with a Fab light chain
polypeptide (VH-CL-VL-CL), a polypeptide wherein a Fab light chain polypeptide shares a
carboxy-terminal peptide bond with a Fab light chain le region which in turn shares a
carboxy-terminal peptide bond with a Fab heavy chain constant region (VL-CL-VL-CH1), or a
polypeptide wherein a Fab light chain polypeptide shares a carboxy-terminal peptide bond with a
Fab heavy chain variable region which in turn shares a carboxy-terminal peptide bond with a Fab
light chain constant region (VL-CL-VH-CL).
The T cell activating bispecific n binding molecule according to these embodiments may
further comprise (i) an Fc domain subunit ptide (CH2-CH3(-CH4)), or (ii) a ptide
wherein a third Fab heavy chain shares a carboxy-terminal e bond with an Fc domain
subunit (VH-CH1-CH2-CH3(-CH4)) and a third Fab light chain polypeptide ). In certain
embodiments the polypeptides are ntly linked, e.g., by a disulfide bond.
In one embodiment, the T cell ting bispecific antigen binding molecule comprises a
polypeptide wherein a second Fab light chain shares a carboxy-terminal peptide bond with a first
Fab light chain variable region which in turn shares a carboxy-terminal peptide bond with a first
Fab heavy chain constant region (i.e. a crossover Fab light chain, wherein the light chain
constant region is replaced by a heavy chain constant region) -VL-CH1), a polypeptide
n a second Fab heavy chain shares a carboxy-terminal peptide bond with an Fc domain
subunit (VH-CH1-CH2-CH3(-CH4)), and a polypeptide wherein a first Fab heavy chain variable
region shares a carboxy-terminal peptide bond with a first Fab light chain constant region (VHCL
). In another embodiment, the T cell activating bispecific antigen binding molecule comprises
a polypeptide wherein a second Fab light chain shares a carboxy-terminal peptide bond with a
first Fab heavy chain variable region which in turn shares a carboxy-terminal peptide bond with
a first Fab light chain constant region (i.e. a crossover Fab light chain, wherein the light chain
variable region is replaced by a heavy chain variable region) -VH-CL), a polypeptide
wherein a second Fab heavy chain shares a carboxy-terminal peptide bond with an Fc domain
subunit (VH-CH1-CH2-CH3(-CH4)), and a polypeptide wherein a first Fab light chain variable
region shares a carboxy-terminal peptide bond with a first Fab heavy chain constant region (VL-
CH1). The T cell activating bispecific antigen binding molecule according to these embodiments
may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a
polypeptide wherein a third Fab heavy chain shares a carboxy-terminal e bond with an Fc
domain subunit (VH-CH1-CH2-CH3(-CH4)) and a third Fab light chain polypeptide (VL-CL).
In certain ments the polypeptides are covalently linked, e.g., by a disulfide bond.
According to any of the above embodiments, ents of the T cell activating bispecific
antigen binding molecule (e.g. antigen binding moiety, Fc domain) may be fused directly or
through s linkers, ularly peptide linkers comprising one or more amino acids,
typically about 2-20 amino acids, that are described herein or are known in the art. Suitable, nonimmunogenic
peptide linkers include, for example, , , (G4S)n or G4(SG4)n peptide
linkers, wherein n is generally a number between 1 and 10, typically n 2 and 4.
Fc domain
The Fc domain of the T cell activating bispecific antigen binding molecule consists of a pair of
polypeptide chains comprising heavy chain domains of an immunoglobulin le. For
example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of
which comprises the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the
Fc domain are capable of stable association with each other. In one embodiment the T cell
activating bispecific antigen binding molecule described comprises not more than one Fc domain.
In one embodiment the Fc domain of the T cell activating bispecific n binding molecule is
an IgG Fc domain. In a particular ment the Fc domain is an IgG1 Fc domain. In another
embodiment the Fc domain is an IgG4 Fc domain. In a more specific embodiment, the Fc domain
is an IgG4 Fc domain comprising an amino acid substitution at position S228 (EU numbering),
particularly the amino acid substitution S228P. This amino acid tution reduces in vivo Fab
arm exchange of IgG4 antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38,
84-91 (2010)). In a further particular embodiment the Fc domain is human. An exemplary
sequence of a human IgG1 Fc region is given in SEQ ID NO: 149.
Fc domain modifications promoting heterodimerization
T cell activating bispecific antigen binding molecules described comprise different antigen
binding moieties, fused to one or the other of the two subunits of the Fc domain, thus the two
subunits of the Fc domain are typically comprised in two non-identical polypeptide chains.
Recombinant co-expression of these polypeptides and subsequent dimerization leads to l
possible combinations of the two polypeptides. To improve the yield and purity of T cell
activating bispecific antigen binding molecules in recombinant production, it will thus be
advantageous to introduce in the Fc domain of the T cell activating bispecific antigen binding
molecule a modification promoting the association of the desired polypeptides.
Accordingly, in particular embodiments the Fc domain of the T cell activating bispecific antigen
binding molecule described comprises a modification promoting the association of the first and
the second subunit of the Fc domain. The site of most ive protein-protein interaction
between the two ts of a human IgG Fc domain is in the CH3 domain of the Fc domain.
Thus, in one embodiment said cation is in the CH3 domain of the Fc domain.
In a specific embodiment said modification is a so-called “knob-into-hole” modification,
comprising a “knob” modification in one of the two subunits of the Fc domain and a “hole”
cation in the other one of the two ts of the Fc .
The knob-into-hole technology is described e.g. in US 5,731,168; US 936; Ridgway et al.,
Prot Eng 9, 617-621 (1996) and Carter, J l Meth 248, 7-15 (2001). Generally, the
method es introducing a protuberance (“knob”) at the interface of a first polypeptide and a
corresponding cavity (“hole”) in the interface of a second polypeptide, such that the
protuberance can be positioned in the cavity so as to promote dimer formation and hinder
homodimer formation. erances are ucted by replacing small amino acid side chains
from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan).
Compensatory cavities of identical or similar size to the protuberances are created in the
interface of the second polypeptide by replacing large amino acid side chains with smaller ones
(e.g. alanine or threonine).
ingly, in a particular embodiment, in the CH3 domain of the first subunit of the Fc
domain of the T cell activating bispecific antigen binding molecule an amino acid residue is
replaced with an amino acid residue having a larger side chain volume, thereby generating a
protuberance within the CH3 domain of the first subunit which is onable in a cavity within
the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc
domain an amino acid residue is replaced with an amino acid residue having a smaller side chain
, thereby generating a cavity within the CH3 domain of the second subunit within which
the protuberance within the CH3 domain of the first subunit is positionable.
The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides,
e.g. by site-specific mutagenesis, or by peptide synthesis.
In a specific embodiment, in the CH3 domain of the first subunit of the Fc domain the threonine
residue at position 366 is replaced with a phan residue (T366W), and in the CH3 domain of
the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine
residue (Y407V). In one embodiment, in the second subunit of the Fc domain additionally the
threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine
residue at position 368 is replaced with an alanine residue (L368A).
In yet a further embodiment, in the first subunit of the Fc domain additionally the serine residue
at on 354 is replaced with a cysteine e (S354C), and in the second subunit of the Fc
domain additionally the tyrosine residue at position 349 is ed by a cysteine e
(Y349C). Introduction of these two cysteine es results in formation of a ide bridge
between the two subunits of the Fc domain, further stabilizing the dimer (Carter, J Immunol
Methods 248, 7-15 (2001)).
In a particular embodiment the antigen binding moiety e of binding to an activating T cell
antigen is fused (optionally via the antigen binding moiety capable of binding to a target cell
antigen) to the first subunit of the Fc domain (comprising the “knob” modification). Without
wishing to be bound by theory, fusion of the n binding moiety capable of binding to an
activating T cell n to the knob-containing subunit of the Fc domain will (further) minimize
the generation of antigen binding molecules comprising two antigen binding moieties capable of
binding to an activating T cell antigen (steric clash of two knob-containing ptides).
In an alternative embodiment a cation promoting association of the first and the second
t of the Fc domain comprises a modification mediating electrostatic steering effects, e.g.
as described in PCT publication . Generally, this method involves replacement
of one or more amino acid residues at the interface of the two Fc domain subunits by charged
amino acid residues so that homodimer formation becomes electrostatically unfavorable but
heterodimerization electrostatically favorable.
Fc domain modifications reducing Fc receptor binding and/or effector on
The Fc domain s to the T cell activating bispecific antigen binding molecule favorable
pharmacokinetic properties, including a long serum half-life which butes to good
accumulation in the target tissue and a favorable tissue-blood distribution ratio. At the same time
it may, however, lead to undesirable targeting of the T cell ting bispecific antigen binding
molecule to cells expressing Fc ors rather than to the preferred antigen-bearing cells.
Moreover, the co-activation of Fc receptor signaling pathways may lead to cytokine release
which, in combination with the T cell activating properties and the long half-life of the antigen
binding molecule, results in excessive activation of cytokine receptors and severe side effects
upon ic administration. Activation of (Fc receptor-bearing) immune cells other than T
cells may even reduce cy of the T cell activating bispecific antigen g molecule due to
the potential destruction of T cells e.g. by NK cells.
Accordingly, in particular embodiments the Fc domain of the T cell ting bispecific antigen
binding molecules described exhibits reduced binding affinity to an Fc or and/or reduced
effector function, as compared to a native IgG1 Fc domain. In one such embodiment the Fc
domain (or the T cell activating bispecific n binding molecule comprising said Fc domain)
exhibits less than 50%, preferably less than 20%, more preferably less than 10% and most
preferably less than 5% of the binding affinity to an Fc receptor, as compared to a native IgG1 Fc
domain (or a T cell activating bispecific antigen binding molecule comprising a native IgG1 Fc
domain), and/or less than 50%, preferably less than 20%, more preferably less than 10% and
most preferably less than 5% of the effector function, as compared to a native IgG1 Fc domain
domain (or a T cell activating bispecific antigen binding le comprising a native IgG1 Fc
domain). In one embodiment, the Fc domain domain (or the T cell activating bispecific antigen
binding molecule comprising said Fc domain) does not ntially bind to an Fc receptor
and/or induce effector function. In a particular embodiment the Fc receptor is an Fcγ receptor. In
one embodiment the Fc receptor is a human Fc receptor. In one embodiment the Fc receptor is an
activating Fc receptor. In a specific embodiment the Fc receptor is an activating human Fcγ
or, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most ically human
FcγRIIIa. In one embodiment the effector function is one or more selected from the group of
CDC, ADCC, ADCP, and cytokine secretion. In a particular embodiment the effector function is
ADCC. In one embodiment the Fc domain domain exhibits substantially similar binding affinity
to neonatal Fc receptor , as compared to a native IgG1 Fc domain domain. Substantially
similar binding to FcRn is achieved when the Fc domain (or the T cell activating bispecific
n binding molecule comprising said Fc domain) ts greater than about 70%,
particularly greater than about 80%, more particularly greater than about 90% of the binding
affinity of a native IgG1 Fc domain (or the T cell activating ific antigen binding molecule
sing a native IgG1 Fc domain) to FcRn.
In certain embodiments the Fc domain is engineered to have reduced binding affinity to an Fc
receptor and/or reduced effector function, as compared to a non-engineered Fc domain. In
ular embodiments, the Fc domain of the T cell activating bispecific antigen binding
molecule comprises one or more amino acid mutation that reduces the binding affinity of the Fc
domain to an Fc receptor and/or effector on. Typically, the same one or more amino acid
mutation is present in each of the two subunits of the Fc domain. In one embodiment the amino
acid on reduces the binding affinity of the Fc domain to an Fc receptor. In one
embodiment the amino acid on reduces the binding affinity of the Fc domain to an Fc
receptor by at least 2-fold, at least 5-fold, or at least 10-fold. In embodiments where there is
more than one amino acid mutation that reduces the binding affinity of the Fc domain to the Fc
receptor, the combination of these amino acid mutations may reduce the binding ty of the
Fc domain to an Fc receptor by at least 10-fold, at least 20-fold, or even at least 50-fold. In one
embodiment the T cell activating bispecific antigen binding molecule comprising an engineered
Fc domain exhibits less than 20%, particularly less than 10%, more particularly less than 5% of
the binding affinity to an Fc receptor as compared to a T cell activating bispecific n
binding molecule comprising a non-engineered Fc domain. In a particular embodiment the Fc
receptor is an Fcγ receptor. In some embodiments the Fc or is a human Fc receptor. In
some embodiments the Fc receptor is an activating Fc receptor. In a specific embodiment the Fc
receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or
FcγRIIa, most specifically human FcγRIIIa. Preferably, binding to each of these receptors is
d. In some embodiments binding affinity to a complement component, specifically
binding affinity to C1q, is also reduced. In one embodiment g affinity to neonatal Fc
receptor (FcRn) is not reduced. Substantially similar g to FcRn, i.e. preservation of the
g ty of the Fc domain to said receptor, is achieved when the Fc domain (or the T cell
ting bispecific antigen binding molecule sing said Fc ) exhibits greater than
about 70% of the binding affinity of a non-engineered form of the Fc domain (or the T cell
activating bispecific antigen binding molecule comprising said non-engineered form of the Fc
domain) to FcRn. The Fc domain, or T cell activating bispecific n g molecules
described comprising said Fc domain, may exhibit greater than about 80% and even greater than
about 90% of such affinity. In certain embodiments the Fc domain of the T cell ting
bispecific antigen binding molecule is engineered to have d effector function, as ed
to a non-engineered Fc domain. The reduced effector function can include, but is not limited to,
one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced
antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular
phagocytosis (ADCP), reduced cytokine secretion, reduced immune x-mediated antigen
uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to
macrophages, reduced binding to monocytes, d binding to polymorphonuclear cells,
reduced direct signaling inducing apoptosis, reduced crosslinking of target-bound antibodies,
reduced dendritic cell maturation, or reduced T cell priming. In one embodiment the reduced
effector function is one or more selected from the group of reduced CDC, reduced ADCC,
reduced ADCP, and reduced cytokine secretion. In a particular embodiment the reduced effector
function is reduced ADCC. In one embodiment the reduced ADCC is less than 20% of the
ADCC induced by a non-engineered Fc domain (or a T cell activating bispecific antigen binding
le comprising a non-engineered Fc domain).
In one embodiment the amino acid mutation that reduces the binding affinity of the Fc domain to
an Fc receptor and/or effector function is an amino acid substitution. In one embodiment the Fc
domain comprises an amino acid substitution at a position selected from the group of E233,
L234, L235, N297, P331 and P329. In a more specific embodiment the Fc domain comprises an
amino acid substitution at a position selected from the group of L234, L235 and P329. In some
embodiments the Fc domain comprises the amino acid substitutions L234A and L235A. In one
such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. In
one embodiment the Fc domain comprises an amino acid substitution at position P329. In a more
specific embodiment the amino acid substitution is P329A or P329G, particularly P329G. In one
embodiment the Fc domain ses an amino acid substitution at position P329 and a further
amino acid substitution at a position selected from E233, L234, L235, N297 and P331. In a more
specific embodiment the r amino acid substitution is E233P, L234A, L235A, L235E,
N297A, N297D or P331S. In particular ments the Fc domain comprises amino acid
substitutions at positions P329, L234 and L235. In more particular ments the Fc domain
comprises the amino acid mutations L234A, L235A and P329G (“P329G LALA”). In one such
embodiment, the Fc domain is an IgG1 Fc domain, ularly a human IgG1 Fc domain. The
“P329G LALA” ation of amino acid substitutions almost completely abolishes Fcγ
receptor binding of a human IgG1 Fc domain, as described in PCT patent application no.
, orated herein by reference in its entirety. also
describes methods of preparing such mutant Fc domains and methods for determining its
properties such as Fc receptor binding or effector functions.
IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions as
compared to IgG1 antibodies. Hence, in some ments the Fc domain of the T cell
activating ific antigen binding les described is an IgG4 Fc domain, particularly a
human IgG4 Fc domain. In one embodiment the IgG4 Fc domain ses amino acid
substitutions at position S228, specifically the amino acid substitution S228P. To further reduce
its binding affinity to an Fc receptor and/or its or function, in one ment the IgG4 Fc
domain comprises an amino acid substitution at on L235, specifically the amino acid
substitution L235E. In another embodiment, the IgG4 Fc domain comprises an amino acid
substitution at position P329, specifically the amino acid substitution P329G. In a particular
embodiment, the IgG4 Fc domain comprises amino acid substitutions at positions S228, L235
and P329, ically amino acid tutions S228P, L235E and P329G. Such IgG4 Fc domain
mutants and their Fcγ receptor binding properties are described in PCT patent application no.
, incorporated herein by nce in its entirety.
In a particular embodiment the Fc domain exhibiting reduced binding affinity to an Fc receptor
and/or reduced effector function, as compared to a native IgG1 Fc domain, is a human IgG1 Fc
domain comprising the amino acid tutions L234A, L235A and optionally P329G, or a
human IgG4 Fc domain sing the amino acid substitutions S228P, L235E and optionally
P329G.
In certain embodiments N-glycosylation of the Fc domain has been ated. In one such
embodiment the Fc domain comprises an amino acid mutation at position N297, particularly an
amino acid substitution replacing asparagine by alanine (N297A) or aspartic acid (N297D).
In addition to the Fc domains described hereinabove and in PCT patent application no.
, Fc domains with d Fc receptor g and/or effector function also
include those with substitution of one or more of Fc domain residues 238, 265, 269, 270, 297,
327 and 329 (U.S. Patent No. 6,737,056). Such Fc mutants include Fc s with substitutions
at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called
“DANA” Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No.
7,332,581).
Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or
modification using genetic or chemical methods well known in the art. Genetic methods may
include site-specific nesis of the encoding DNA sequence, PCR, gene synthesis, and the
like. The correct nucleotide changes can be verified for e by sequencing.
Binding to Fc receptors can be easily determined e.g. by ELISA, or by Surface Plasmon
Resonance (SPR) using standard instrumentation such as a BIAcore instrument (GE Healthcare),
and Fc receptors such as may be obtained by recombinant expression. A suitable such binding
assay is described herein. Alternatively, binding affinity of Fc domains or cell activating
bispecific n g molecules sing an Fc domain for Fc receptors may be evaluated
using cell lines known to express particular Fc ors, such as human NK cells expressing
FcγIIIa receptor.
Effector function of an Fc domain, or a T cell activating bispecific antigen binding molecule
comprising an Fc domain, can be measured by methods known in the art. A suitable assay for
measuring ADCC is described herein. Other examples of in vitro assays to assess ADCC activity
of a molecule of interest are described in U.S. Patent No. 5,500,362; Hellstrom et al. Proc Natl
Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-
1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166, 361 (1987).
Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ nonradioactive
cytotoxicity assay for flow try (CellTechnology, Inc. Mountain View, CA);
and CytoTox 96® non-radioactive cytotoxicity assay (Promega, n, WI)). Useful effector
cells for such assays e peripheral blood mononuclear cells (PBMC) and Natural Killer (NK)
cells. Alternatively, or additionally, ADCC activity of the molecule of st may be assessed
in vivo, e.g. in a animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95,
652-656 (1998).
In some embodiments, binding of the Fc domain to a complement component, specifically to
C1q, is reduced. Accordingly, in some embodiments wherein the Fc domain is engineered to
have reduced effector function, said reduced effector function includes reduced CDC. C1q
binding assays may be carried out to determine whether the T cell activating bispecific antigen
binding molecule is able to bind C1q and hence has CDC activity. See e.g., C1q and C3c binding
ELISA in WO 29879 and . To assess complement activation, a CDC
assay may be performed (see, for e, Gazzano-Santoro et al., J Immunol s 202, 163
(1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-
2743 (2004)).
Antigen g Moieties
The antigen binding molecule described is bispecific, i.e. it comprises at least two antigen
binding moieties e of specific binding to two distinct antigenic determinants. According to
the description, the antigen binding moieties are Fab molecules (i.e. antigen binding domains
composed of a heavy and a light chain, each comprising a variable and a constant region). In one
embodiment said Fab molecules are human. In another embodiment said Fab molecules are
humanized. In yet another embodiment said Fab molecules comprise human heavy and light
chain constant regions.
At least one of the n g moieties is a single chain Fab molecule or a crossover Fab
molecule. Such modifications prevent mispairing of heavy and light chains from different Fab
molecules, thereby improving the yield and purity of the T cell activating ific antigen
binding molecule described in recombinant production. In a particular single chain Fab molecule
useful for the T cell activating bispecific antigen binding le described, the C-terminus of
the Fab light chain is connected to the N-terminus of the Fab heavy chain by a peptide linker.
The peptide linker allows arrangement of the Fab heavy and light chain to form a functional
antigen binding moiety. Peptide linkers le for connecting the Fab heavy and light chain
include, for e, -GG (SEQ ID NO: 152) or (SG3)2-(SEG3)4-(SG3)-SG (SEQ ID NO:
153). In a particular ver Fab molecule useful for the T cell activating bispecific antigen
g molecule described, the constant regions of the Fab light chain and the Fab heavy chain
are exchanged. In r crossover Fab le useful for the T cell activating bispecific
antigen g molecule described, the variable regions of the Fab light chain and the Fab
heavy chain are exchanged.
In a particular embodiment described, the T cell activating bispecific antigen binding molecule is
e of simultaneous binding to a target cell antigen, particularly a tumor cell antigen, and an
activating T cell n. In one ment, the T cell activating bispecific antigen binding
le is capable of crosslinking a T cell and a target cell by simultaneous binding to a target
cell antigen and an activating T cell antigen. In an even more particular ment, such
simultaneous binding results in lysis of the target cell, particularly a tumor cell. In one
embodiment, such simultaneous binding results in tion of the T cell. In other embodiments,
such aneous binding results in a cellular response of a T lymphocyte, particularly a
cytotoxic T lymphocyte, selected from the group of: proliferation, differentiation, cytokine
secretion, xic effector molecule release, cytotoxic activity, and expression of activation
s. In one ment, binding of the T cell activating bispecific antigen binding molecule
to the activating T cell antigen without simultaneous binding to the target cell antigen does not
result in T cell activation.
In one embodiment, the T cell activating bispecific antigen binding molecule is capable of cting
cytotoxic activity of a T cell to a target cell. In a particular embodiment, said re-
direction is independent of MHC-mediated peptide antigen tation by the target cell and
and/or specificity of the T cell.
Particularly, a T cell according to any of the embodiments described is a cytotoxic T cell. In
some embodiments the T cell is a CD4+ or a CD8+ T cell, particularly a CD8+ T cell.
Activating T cell antigen binding moiety
The T cell activating bispecific antigen binding molecule described comprises at least one
antigen binding moiety capable of binding to an activating T cell antigen (also referred to herein
as an “activating T cell antigen binding moiety”). In a particular embodiment, the T cell
activating bispecific antigen binding molecule comprises not more than one antigen binding
moiety capable of specific binding to an activating T cell antigen. In one embodiment the T cell
activating bispecific antigen binding molecule provides monovalent binding to the activating T
cell antigen. The activating T cell antigen g moiety can either be a conventional Fab
molecule or a modified Fab molecule, i.e. a single chain or crossover Fab molecule. In
embodiments where there is more than one antigen binding moiety capable of specific binding to
a target cell antigen comprised in the T cell ting bispecific antigen binding molecule, the
antigen binding moiety capable of specific binding to an activating T cell n preferably is a
modified Fab molecule.
In a particular embodiment the activating T cell antigen is CD3, particularly human CD3 (SEQ
ID NO: 265) or cynomolgus CD3 (SEQ ID NO: 266), most particularly human CD3. In a
particular embodiment the activating T cell antigen binding moiety is cross-reactive for (i.e.
ically binds to) human and cynomolgus CD3. In some embodiments, the activating T cell
antigen is the n subunit of CD3.
In one embodiment, the activating T cell antigen binding moiety can compete with monoclonal
antibody H2C (described in PCT publication no. WO2008/119567) for binding an epitope of
CD3. In another embodiment, the activating T cell antigen binding moiety can compete with
monoclonal antibody V9 (described in Rodrigues et al., Int J Cancer Suppl 7, 45-50 (1992) and
US patent no. 6,054,297) for binding an e of CD3. In yet another embodiment, the
ting T cell n binding moiety can compete with monoclonal dy FN18
(described in Nooij et al., Eur J Immunol 19, 981-984 (1986)) for binding an epitope of CD3. In
a particular embodiment, the activating T cell n binding moiety can compete with
monoclonal antibody SP34 (described in Pessano et al., EMBO J 4, 337-340 (1985)) for binding
an epitope of CD3. In one embodiment, the activating T cell antigen binding moiety binds to the
same epitope of CD3 as monoclonal antibody SP34. In one embodiment, the activating T cell
antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 163, the heavy chain
CDR2 of SEQ ID NO: 165, the heavy chain CDR3 of SEQ ID NO: 167, the light chain CDR1 of
SEQ ID NO: 171, the light chain CDR2 of SEQ ID NO: 173, and the light chain CDR3 of SEQ
ID NO: 175. In a further ment, the activating T cell antigen binding moiety comprises a
heavy chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%,
98%, 99% or 100% identical to SEQ ID NO: 169 and a light chain variable region sequence that
is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
177, or variants thereof that retain functionality.
In a particular ment, the activating T cell antigen binding moiety comprises the heavy
chain CDR1 of SEQ ID NO: 249, the heavy chain CDR2 of SEQ ID NO: 251, the heavy chain
CDR3 of SEQ ID NO: 253, the light chain CDR1 of SEQ ID NO: 257, the light chain CDR2 of
SEQ ID NO: 259, and the light chain CDR3 of SEQ ID NO: 261. In one embodiment, the
activating T cell antigen binding moiety can compete for binding an epitope of CD3 with an
antigen g moiety comprising the heavy chain CDR1 of SEQ ID NO: 249, the heavy chain
CDR2 of SEQ ID NO: 251, the heavy chain CDR3 of SEQ ID NO: 253, the light chain CDR1 of
SEQ ID NO: 257, the light chain CDR2 of SEQ ID NO: 259, and the light chain CDR3 of SEQ
ID NO: 261. In one embodiment, the ting T cell antigen binding moiety binds to the same
epitope of CD3 as an n binding moiety comprising the heavy chain CDR1 of SEQ ID NO:
249, the heavy chain CDR2 of SEQ ID NO: 251, the heavy chain CDR3 of SEQ ID NO: 253, the
light chain CDR1 of SEQ ID NO: 257, the light chain CDR2 of SEQ ID NO: 259, and the light
chain CDR3 of SEQ ID NO: 261. In a further ment, the activating T cell antigen binding
moiety ses a heavy chain variable region sequence that is at least about 80%, 85%, 90%,
95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 255 and a light chain variable
region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%
identical to SEQ ID NO: 263, or variants thereof that retain functionality. In one embodiment,
the activating T cell antigen binding moiety can compete for binding an epitope of CD3 with an
antigen g moiety comprising the heavy chain variable region sequence of SEQ ID NO:
255 and the light chain variable region ce of SEQ ID NO: 263. In one embodiment, the
activating T cell antigen binding moiety binds to the same epitope of CD3 as an antigen g
moiety comprising the heavy chain variable region sequence of SEQ ID NO: 255 and the light
chain variable region sequence of SEQ ID NO: 263. In another embodiment, the activating T cell
n binding moiety comprises a humanized version of the heavy chain variable region
sequence of SEQ ID NO: 255 and a humanized version of the light chain variable region
sequence of SEQ ID NO: 263. In one ment, the activating T cell n binding moiety
comprises the heavy chain CDR1 of SEQ ID NO: 249, the heavy chain CDR2 of SEQ ID NO:
251, the heavy chain CDR3 of SEQ ID NO: 253, the light chain CDR1 of SEQ ID NO: 257, the
light chain CDR2 of SEQ ID NO: 259, the light chain CDR3 of SEQ ID NO: 261, and human
heavy and light chain variable region framework sequences.
Target cell antigen binding moiety
The T cell activating bispecific antigen binding molecule described comprises at least one
antigen binding moiety capable of binding to a target cell antigen (also referred to herein as an
“target cell antigen binding moiety”). In certain embodiments, the T cell activating bispecific
antigen binding molecule comprises two antigen binding moieties capable of binding to a target
cell antigen. In a particular such embodiment, each of these n binding moieties specifically
binds to the same antigenic determinant. In one embodiment, the T cell activating bispecific
antigen binding molecule comprises an immunoglobulin molecule e of ic binding to
a target cell antigen. In one ment the T cell activating bispecific antigen binding molecule
comprises not more than two antigen binding moieties e of binding to a target cell antigen.
The target cell antigen binding moiety is generally a Fab molecule that binds to a specific
antigenic determinant and is able to direct the T cell activating bispecific antigen binding
molecule to a target site, for example to a specific type of tumor cell that bears the antigenic
determinant.
In certain embodiments the target cell antigen binding moiety is directed to an antigen associated
with a pathological condition, such as an antigen presented on a tumor cell or on a virus-infected
cell. Suitable antigens are cell surface antigens, for example, but not limited to, cell surface
receptors. In particular embodiments the antigen is a human antigen. In a specific embodiment
the target cell antigen is ed from the group of Fibroblast Activation Protein (FAP),
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor
Receptor (EGFR), Carcinoembryonic Antigen (CEA),CD19, CD20 and CD33.
In particular embodiments the T cell activating bispecific antigen binding le comprises at
least one n binding moiety that is specific for ma-associated Chondroitin Sulfate
Proteoglycan (MCSP). In one embodiment the T cell activating bispecific antigen binding
molecule comprises at least one, typically two or more antigen binding moieties that can
compete with monoclonal antibody LC007 (see SEQ ID NOs 75 and 83, and European patent
ation no. EP 11178393.2, incorporated herein by reference in its ty) for binding to an
epitope of MCSP. In one embodiment, the antigen binding moiety that is specific for MCSP
ses the heavy chain CDR1 of SEQ ID NO: 69, the heavy chain CDR2 of SEQ ID NO: 71,
the heavy chain CDR3 of SEQ ID NO: 73, the light chain CDR1 of SEQ ID NO: 77, the light
chain CDR2 of SEQ ID NO: 79, and the light chain CDR3 of SEQ ID NO: 81. In a further
embodiment, the antigen binding moiety that is specific for MCSP comprises a heavy chain
variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
100% identical to SEQ ID NO: 75 and a light chain le region ce that is at least
about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 83, or
variants thereof that retain functionality. In particular embodiments the T cell activating
ific antigen binding le comprises at least one, typically two or more antigen
binding moieties that can compete with monoclonal antibody M4-3 ML2 (see SEQ ID NOs 239
and 247, and European patent application no. EP 11178393.2, incorporated herein by reference
in its ty) for binding to an epitope of MCSP. In one ment, the antigen binding
moiety that is specific for MCSP binds to the same epitope of MCSP as monoclonal antibody
M4-3 ML2. In one embodiment, the antigen binding moiety that is specific for MCSP comprises
the heavy chain CDR1 of SEQ ID NO: 233, the heavy chain CDR2 of SEQ ID NO: 235, the
heavy chain CDR3 of SEQ ID NO: 237, the light chain CDR1 of SEQ ID NO: 241, the light
chain CDR2 of SEQ ID NO: 243, and the light chain CDR3 of SEQ ID NO: 245. In a further
embodiment, the antigen binding moiety that is specific for MCSP comprises a heavy chain
variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
100%, particularly about 98%, 99% or 100%, identical to SEQ ID NO: 239 and a light chain
variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
100%, particularly about 98%, 99% or 100%, identical to SEQ ID NO: 247, or variants thereof
that retain functionality. In one embodiment, the antigen binding moiety that is specific for
MCSP comprises the heavy and light chain variable region sequences of an affinity matured
n of monoclonal antibody M4-3 ML2. In one embodiment, the antigen binding moiety that
is specific for MCSP comprises the heavy chain variable region sequence of SEQ ID NO: 239
with one, two, three, four, five, six or seven, particularly two, three, four or five, amino acid
substitutions; and the light chain le region sequence of SEQ ID NO: 247 with one, two,
three, four, five, six or seven, particularly two, three, four or five, amino acid substitutions. Any
amino acid residue within the variable region sequences may be substituted by a different amino
acid, including amino acid residues within the CDR regions, provided that binding to MCSP,
particularly human MCSP, is preserved. Preferred variants are those having a binding affinity for
MCSP at least equal (or er) to the binding ty of the antigen binding moiety
comprising the unsubstituted variable region sequences.
In one embodiment the T cell activating bispecific antigen binding molecule ses the
polypeptide sequence of SEQ ID NO: 1, the polypeptide sequence of SEQ ID NO: 3 and the
polypeptide sequence of SEQ ID NO: 5, or variants thereof that retain functionality. In a further
embodiment the T cell activating bispecific antigen binding molecule comprises the polypeptide
sequence of SEQ ID NO: 7, the polypeptide sequence of SEQ ID NO: 9 and the polypeptide
sequence of SEQ ID NO: 11, or variants f that retain functionality. In yet another
embodiment the T cell activating bispecific antigen binding molecule comprises the ptide
sequence of SEQ ID NO: 13, the polypeptide ce of SEQ ID NO: 15 and the polypeptide
sequence of SEQ ID NO: 5, or variants f that retain functionality. In yet another
embodiment the T cell activating bispecific antigen binding molecule comprises the polypeptide
sequence of SEQ ID NO: 17, the polypeptide sequence of SEQ ID NO: 19 and the polypeptide
sequence of SEQ ID NO: 5, or variants f that retain functionality. In another embodiment
the T cell activating bispecific antigen binding molecule comprises the polypeptide sequence of
SEQ ID NO: 21, the polypeptide sequence of SEQ ID NO: 23 and the ptide sequence of
SEQ ID NO: 5, or variants thereof that retain functionality. In still another embodiment the T
cell activating ific antigen g le comprises the polypeptide sequence of SEQ
ID NO: 25, the ptide sequence of SEQ ID NO: 27 and the polypeptide sequence of SEQ
ID NO: 5, or variants thereof that retain onality. In another embodiment the T cell
ting bispecific antigen binding molecule comprises the polypeptide sequence of SEQ ID
NO: 29, the polypeptide sequence of SEQ ID NO: 31, the polypeptide sequence of SEQ ID NO:
33, and the polypeptide ce of SEQ ID NO: 5, or variants f that retain functionality.
In another embodiment the T cell activating bispecific antigen binding molecule comprises the
polypeptide sequence of SEQ ID NO: 29, the polypeptide sequence of SEQ ID NO: 3, the
polypeptide ce of SEQ ID NO: 33, and the ptide sequence of SEQ ID NO: 5, or
variants f that retain functionality. In r embodiment the T cell ting bispecific
antigen binding molecule comprises the polypeptide sequence of SEQ ID NO: 35, the
polypeptide sequence of SEQ ID NO: 3, the polypeptide sequence of SEQ ID NO: 37, and the
polypeptide sequence of SEQ ID NO: 5, or variants thereof that retain functionality. In another
embodiment the T cell activating bispecific antigen binding le comprises the polypeptide
ce of SEQ ID NO: 39, the polypeptide sequence of SEQ ID NO: 3, the polypeptide
sequence of SEQ ID NO: 41, and the polypeptide sequence of SEQ ID NO: 5, or variants thereof
that retain functionality. In yet another embodiment the T cell activating bispecific antigen
binding le comprises the ptide sequence of SEQ ID NO: 29, the polypeptide
sequence of SEQ ID NO: 3, the polypeptide sequence of SEQ ID NO: 5 and the polypeptide
sequence of SEQ ID NO: 179, or variants thereof that retain functionality. In one embodiment
the T cell activating bispecific antigen binding molecule comprises the polypeptide sequence of
SEQ ID NO: 5, the polypeptide sequence of SEQ ID NO: 29, the polypeptide sequence of SEQ
ID NO: 33 and the polypeptide sequence of SEQ ID NO: 181, or variants thereof that retain
functionality. In one embodiment the T cell activating bispecific n binding molecule
comprises the polypeptide sequence of SEQ ID NO: 5, the polypeptide sequence of SEQ ID NO:
23, the polypeptide sequence of SEQ ID NO: 183 and the polypeptide ce of SEQ ID NO:
185, or variants thereof that retain functionality. In one embodiment the T cell activating
bispecific antigen binding molecule comprises the polypeptide sequence of SEQ ID NO: 5, the
polypeptide sequence of SEQ ID NO: 23, the polypeptide sequence of SEQ ID NO: 183 and the
polypeptide sequence of SEQ ID NO: 187, or variants thereof that retain functionality. In one
embodiment the T cell activating ific antigen binding molecule comprises the polypeptide
sequence of SEQ ID NO: 33, the polypeptide sequence of SEQ ID NO: 189, the polypeptide
ce of SEQ ID NO: 191 and the polypeptide sequence of SEQ ID NO: 193, or variants
thereof that retain functionality. In one embodiment the T cell activating bispecific antigen
binding le comprises the polypeptide sequence of SEQ ID NO: 183, the polypeptide
ce of SEQ ID NO: 189, the polypeptide sequence of SEQ ID NO: 193 and the polypeptide
sequence of SEQ ID NO: 195, or variants thereof that retain functionality. In one embodiment
the T cell activating bispecific antigen g molecule comprises the polypeptide sequence of
SEQ ID NO: 189, the polypeptide sequence of SEQ ID NO: 193, the polypeptide sequence of
SEQ ID NO: 199 and the polypeptide sequence of SEQ ID NO: 201, or variants thereof that
retain functionality. In one ment the T cell activating bispecific antigen g molecule
comprises the polypeptide sequence of SEQ ID NO: 5, the polypeptide sequence of SEQ ID NO:
23, the polypeptide sequence of SEQ ID NO: 215 and the ptide sequence of SEQ ID NO:
217, or variants thereof that retain functionality. In one embodiment the T cell activating
bispecific antigen binding molecule ses the ptide sequence of SEQ ID NO: 5, the
polypeptide sequence of SEQ ID NO: 23, the polypeptide sequence of SEQ ID NO: 215 and the
polypeptide sequence of SEQ ID NO: 219, or variants thereof that retain functionality.
In a specific embodiment the T cell activating bispecific antigen binding molecule comprises a
polypeptide sequence encoded by a cleotide sequence that is at least about 80%, 85%,
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence selected from the group of
SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID
NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 234, SEQ ID NO: 236, SEQ ID NO:
238, SEQ ID NO: 240, SEQ ID NO: 242, SEQ ID NO: 244, SEQ ID NO: 246, SEQ ID NO: 248,
SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO:
12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ
ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO:
34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 180, SEQ
ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID NO: 190, SEQ ID
NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 200, SEQ ID NO: 202, SEQ ID NO:
216, SEQ ID NO: 218 and SEQ ID NO: 220.
In one embodiment the T cell ting bispecific antigen binding molecule comprises at least
one antigen binding moiety that is specific for Epidermal Growth Factor Receptor (EGFR). In
another ment the T cell activating bispecific antigen binding le comprises at least
one, typically two or more antigen binding moieties that can compete with monoclonal antibody
GA201 for binding to an epitope of EGFR. See PCT publication , incorporated
herein by reference in its entirety. In one embodiment, the n binding moiety that is specific
for EGFR comprises the heavy chain CDR1 of SEQ ID NO: 85, the heavy chain CDR2 of SEQ
ID NO: 87, the heavy chain CDR3 of SEQ ID NO: 89, the light chain CDR1 of SEQ ID NO: 93,
the light chain CDR2 of SEQ ID NO: 95, and the light chain CDR3 of SEQ ID NO: 97. In a
further embodiment, the antigen binding moiety that is specific for EGFR comprises a heavy
chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%
or 100% identical to SEQ ID NO: 91 and a light chain variable region sequence that is at least
about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 99, or
variants thereof that retain functionality.
In yet another embodiment the T cell activating bispecific antigen binding molecule comprises
the polypeptide sequence of SEQ ID NO: 43, the polypeptide sequence of SEQ ID NO: 45 and
the ptide sequence of SEQ ID NO: 47, or variants thereof that retain functionality. In a
further embodiment the T cell activating bispecific antigen binding molecule comprises the
polypeptide sequence of SEQ ID NO: 49, the polypeptide ce of SEQ ID NO: 51 and the
polypeptide ce of SEQ ID NO: 11, or variants thereof that retain functionality. In yet
another embodiment the T cell activating bispecific antigen binding molecule comprises the
polypeptide sequence of SEQ ID NO: 53, the polypeptide sequence of SEQ ID NO: 45 and the
ptide sequence of SEQ ID NO: 47, or variants thereof that retain functionality.
In a specific embodiment the T cell activating bispecific antigen g le comprises a
polypeptide sequence encoded by a polynucleotide sequence that is at least about 80%, 85%,
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence selected from the group of
SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID
NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48,
SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54 and SEQ ID NO: 12.
In one embodiment the T cell activating bispecific antigen binding molecule comprises at least
one antigen binding moiety that is specific for Fibroblast Activation Protein (FAP). In another
embodiment the T cell activating bispecific n binding molecule comprises at least one,
typically two or more antigen binding moieties that can compete with monoclonal antibody 3F2
for binding to an epitope of FAP. See PCT publication WO 20006, incorporated herein by
nce in its entirety. In one embodiment, the antigen binding moiety that is specific for FAP
comprises the heavy chain CDR1 of SEQ ID NO: 101, the heavy chain CDR2 of SEQ ID NO:
103, the heavy chain CDR3 of SEQ ID NO: 105, the light chain CDR1 of SEQ ID NO: 109, the
light chain CDR2 of SEQ ID NO: 111, and the light chain CDR3 of SEQ ID NO: 113. In a
further embodiment, the antigen binding moiety that is specific for FAP comprises a heavy chain
variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
100% identical to SEQ ID NO: 107 and a light chain variable region sequence that is at least
about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 115, or
variants thereof that retain functionality.
In yet another embodiment the T cell activating ific antigen binding molecule comprises
the polypeptide sequence of SEQ ID NO: 55, the ptide sequence of SEQ ID NO: 51 and
the ptide sequence of SEQ ID NO: 11, or variants thereof that retain functionality. In a
further embodiment the T cell activating bispecific antigen binding molecule comprises the
polypeptide sequence of SEQ ID NO: 57, the polypeptide sequence of SEQ ID NO: 59 and the
polypeptide ce of SEQ ID NO: 61, or variants thereof that retain functionality.
In a specific ment the T cell activating bispecific antigen binding molecule comprises a
polypeptide sequence encoded by a polynucleotide sequence that is at least about 80%, 85%,
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence selected from the group of
SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ
ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID
NO: 60, SEQ ID NO: 62, SEQ ID NO: 52 and SEQ ID NO: 12.
In particular embodiments the T cell activating bispecific antigen binding le comprises at
least one antigen binding moiety that is specific for Carcinoembryonic n (CEA). In one
embodiment the T cell activating bispecific antigen binding molecule comprises at least one,
typically two or more antigen binding es that can compete with monoclonal antibody
BW431/26 ibed in European patent no. EP 160 897, and Bosslet et al., Int J Cancer 36, 75-
84 (1985)) for g to an epitope of CEA. In one embodiment the T cell activating bispecific
antigen binding molecule comprises at least one, typically two or more antigen binding moieties
that can compete with monoclonal antibody CH1A1A (see SEQ ID NOs 123 and 131) for
g to an epitope of CEA. See PCT patent publication number ,
incorporated herein by reference in its entirety. In one embodiment, the antigen binding moiety
that is specific for CEA binds to the same epitope of CEA as monoclonal dy CH1A1A. In
one embodiment, the antigen binding moiety that is specific for CEA ses the heavy chain
CDR1 of SEQ ID NO: 117, the heavy chain CDR2 of SEQ ID NO: 119, the heavy chain CDR3
of SEQ ID NO: 121, the light chain CDR1 of SEQ ID NO: 125, the light chain CDR2 of SEQ ID
NO: 127, and the light chain CDR3 of SEQ ID NO: 129. In a further embodiment, the antigen
binding moiety that is specific for CEA comprises a heavy chain variable region sequence that is
at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, particularly about 98%,
99% or 100%, identical to SEQ ID NO: 123 and a light chain variable region sequence that is at
least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, particularly about 98%, 99%
or 100%, identical to SEQ ID NO: 131, or variants thereof that retain functionality. In one
embodiment, the antigen binding moiety that is specific for CEA comprises the heavy and light
chain variable region sequences of an affinity matured version of monoclonal antibody
CH1A1A. In one embodiment, the n binding moiety that is specific for CEA comprises the
heavy chain le region sequence of SEQ ID NO: 123 with one, two, three, four, five, six or
seven, particularly two, three, four or five, amino acid substitutions; and the light chain variable
region sequence of SEQ ID NO: 131 with one, two, three, four, five, six or seven, particularly
two, three, four or five, amino acid substitutions. Any amino acid e within the variable
region sequences may be substituted by a different amino acid, including amino acid residues
within the CDR s, provided that binding to CEA, particularly human CEA, is preserved.
Preferred variants are those having a binding affinity for CEA at least equal (or stronger) to the
g affinity of the antigen binding moiety comprising the unsubstituted variable region
sequences.
In one embodiment the T cell activating bispecific antigen binding molecule comprises the
polypeptide sequence of SEQ ID NO: 63, the polypeptide sequence of SEQ ID NO: 65, the
polypeptide ce of SEQ ID NO: 67 and the polypeptide sequence of SEQ ID NO: 33, or
variants thereof that retain onality. In one embodiment the T cell activating bispecific
antigen binding molecule comprises the ptide sequence of SEQ ID NO: 65, the
polypeptide sequence of SEQ ID NO: 67, the polypeptide sequence of SEQ ID NO: 183 and the
polypeptide sequence of SEQ ID NO: 197, or variants thereof that retain functionality. In one
embodiment the T cell activating bispecific antigen binding molecule comprises the polypeptide
sequence of SEQ ID NO: 183, the polypeptide sequence of SEQ ID NO: 203, the ptide
sequence of SEQ ID NO: 205 and the ptide sequence of SEQ ID NO: 207, or variants
thereof that retain functionality. In one embodiment the T cell activating bispecific antigen
binding molecule comprises the polypeptide sequence of SEQ ID NO: 183, the polypeptide
sequence of SEQ ID NO: 209, the polypeptide sequence of SEQ ID NO: 211 and the polypeptide
sequence of SEQ ID NO: 213, or variants thereof that retain functionality.
In a specific embodiment the T cell activating bispecific antigen binding molecule comprises a
polypeptide sequence d by a polynucleotide ce that is at least about 80%, 85%,
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a ce selected from the group of
SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126, SEQ
ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID
NO: 68, SEQ ID NO: 34, SEQ ID NO: 184, SEQ ID NO: 198, SEQ ID NO: 204, SEQ ID NO:
206, SEQ ID NO: 208, SEQ ID NO: 210, SEQ ID NO: 212 and SEQ ID NO: 214.
In one embodiment the T cell activating bispecific antigen binding le comprises at least
one antigen binding moiety that is specific for CD33. In one embodiment, the n binding
moiety that is specific for CD33 comprises the heavy chain CDR1 of SEQ ID NO: 133, the
heavy chain CDR2 of SEQ ID NO: 135, the heavy chain CDR3 of SEQ ID NO: 137, the light
chain CDR1 of SEQ ID NO: 141, the light chain CDR2 of SEQ ID NO: 143, and the light chain
CDR3 of SEQ ID NO: 145. In a further embodiment, the antigen binding moiety that is specific
for CD33 ses a heavy chain variable region sequence that is at least about 80%, 85%,
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 139 and a light chain
variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
100% identical to SEQ ID NO: 147, or ts thereof that retain functionality.
In one embodiment the T cell activating bispecific antigen binding molecule comprises the
polypeptide sequence of SEQ ID NO: 33, the polypeptide sequence of SEQ ID NO: 213, the
polypeptide sequence of SEQ ID NO: 221 and the polypeptide sequence of SEQ ID NO: 223, or
variants f that retain functionality. In one embodiment the T cell activating bispecific
antigen binding molecule comprises the polypeptide sequence of SEQ ID NO: 33, the
polypeptide sequence of SEQ ID NO: 221, the polypeptide sequence of SEQ ID NO: 223 and the
polypeptide sequence of SEQ ID NO: 225, or ts thereof that retain functionality.
In a specific embodiment the T cell activating bispecific antigen binding molecule comprises a
ptide sequence encoded by a polynucleotide sequence that is at least about 80%, 85%,
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence selected from the group of
SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 142, SEQ
ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 34, SEQ ID NO: 214, SEQ ID
NO: 222, SEQ ID NO: 224 and SEQ ID NO: 226.
Polynucleotides
Also described are isolated polynucleotides encoding a T cell activating bispecific antigen
binding molecule as bed herein or a fragment thereof.
Polynucleotides described include those that are at least about 80%, 85%, 90%, 95%, 96%, 97%,
98%, 99%, or 100% identical to the sequences set forth in SEQ ID NOs 2, 4, 6, 8, 10, 12, 14, 16,
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68,
70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114,
116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 164, 166,
168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204,
206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242,
244, 246, 248, 250, 252, 254, 256, 258, 260, 262 and 264, including functional fragments or
ts thereof.
The polynucleotides ng T cell activating bispecific antigen g molecules bed
may be sed as a single cleotide that encodes the entire T cell activating bispecific
antigen binding molecule or as multiple (e.g., two or more) polynucleotides that are co-
expressed. Polypeptides encoded by polynucleotides that are co-expressed may ate
through, e.g., disulfide bonds or other means to form a onal T cell activating bispecific
antigen binding molecule. For example, the light chain portion of an antigen binding moiety may
be encoded by a separate polynucleotide from the portion of the T cell activating bispecific
antigen binding molecule comprising the heavy chain portion of the antigen binding moiety, an
Fc domain subunit and ally (part of) another antigen binding moiety. When co-expressed,
the heavy chain polypeptides will associate with the light chain polypeptides to form the n
binding moiety. In another example, the portion of the T cell activating bispecific antigen
binding molecule comprising one of the two Fc domain subunits and optionally (part of) one or
more antigen binding moieties could be encoded by a separate polynucleotide from the portion
of the T cell activating bispecific antigen binding molecule comprising the the other of the two
Fc domain subunits and optionally (part of) an antigen binding moiety. When co-expressed, the
Fc domain subunits will associate to form the Fc domain.
In certain embodiments, an isolated polynucleotide encodes a fragment of a T cell activating
bispecific antigen binding molecule comprising a first and a second antigen binding moiety, and
an Fc domain consisting of two subunits, wherein the first antigen binding moiety is a single
chain Fab molecule. In one embodiment, an isolated polynucleotide described encodes the first
antigen binding moiety and a t of the Fc domain. In a more ic embodiment the
isolated polynucleotide encodes a polypeptide wherein a single chain Fab molecule shares a
carboxy-terminal peptide bond with an Fc domain subunit. In another embodiment, an isolated
polynucleotide described encodes the heavy chain of the second antigen binding moiety and a
subunit of the Fc domain. In a more specific embodiment the isolated cleotide encodes a
ptide wherein a Fab heavy chain shares a carboxy terminal e bond with an Fc
domain subunit. In yet another embodiment, an ed polynucleotide described encodes the
first antigen binding moiety, the heavy chain of the second antigen binding moiety and a subunit
of the Fc domain. In a more specific embodiment, the ed polynucleotide encodes a
polypeptide wherein a single chain Fab molecule shares a carboxy-terminal peptide bond with a
Fab heavy chain, which in turn shares a carboxy-terminal peptide bond with an Fc domain
subunit.
In certain embodiments, an isolated polynucleotide bed encodes a fragment of a T cell
activating bispecific antigen binding molecule comprising a first and a second antigen binding
moiety, and an Fc domain consisting of two subunits, wherein the first antigen g moiety is
a crossover Fab molecule. In one embodiment, an isolated polynucleotide described encodes the
heavy chain of the first antigen binding moiety and a subunit of the Fc domain. In a more
specific ment the ed polynucleotide s a polypeptide n Fab light chain
variable region shares a carboxy terminal peptide bond with a Fab heavy chain constant region,
which in turn shares a carboxy-terminal e bond with an Fc domain subunit. In another
specific embodiment the isolated polynucleotide encodes a polypeptide wherein Fab heavy chain
variable region shares a carboxy terminal peptide bond with a Fab light chain nt region,
which in turn shares a carboxy-terminal peptide bond with an Fc domain subunit. In another
embodiment, an isolated cleotide described encodes the heavy chain of the second antigen
binding moiety and a t of the Fc domain. In a more specific embodiment the isolated
polynucleotide encodes a polypeptide wherein a Fab heavy chain shares a carboxy al
peptide bond with an Fc domain subunit. In yet another embodiment, an isolated polynucleotide
described encodes the heavy chain of the first antigen binding moiety, the heavy chain of the
second antigen binding moiety and a subunit of the Fc domain. In a more specific embodiment,
the isolated polynucleotide encodes a polypeptide wherein a Fab light chain variable region
shares a carboxy-terminal peptide bond with a Fab heavy chain nt region, which in turn
shares a carboxy-terminal peptide bond with a Fab heavy chain, which in turn shares a carboxyterminal
peptide bond with an Fc domain subunit. In another specific embodiment, the ed
polynucleotide encodes a polypeptide wherein a Fab heavy chain variable region shares a
carboxy-terminal peptide bond with a Fab light chain constant region, which in turn shares a
carboxy-terminal peptide bond with a Fab heavy chain, which in turn shares a y-terminal
e bond with an Fc domain subunit. In yet another specific ment the isolated
polynucleotide encodes a polypeptide wherein a Fab heavy chain shares a carboxy-terminal
peptide bond with a Fab light chain variable region, which in turn shares a carboxy-terminal
peptide bond with a Fab heavy chain constant region, which in turn shares a carboxy-terminal
peptide bond with an Fc domain subunit. In still another specific embodiment the isolated
polynucleotide encodes a polypeptide wherein a Fab heavy chain shares a carboxy-terminal
peptide bond with a Fab heavy chain variable region, which in turn shares a carboxy-terminal
peptide bond with a Fab light chain constant region, which in turn shares a carboxy-terminal
peptide bond with an Fc domain subunit.
In further embodiments, an isolated polynucleotide described encodes the heavy chain of a third
antigen binding moiety and a subunit of the Fc domain. In a more specific embodiment the
isolated polynucleotide encodes a polypeptide wherein a Fab heavy chain shares a carboxy
terminal peptide bond with an Fc domain subunit.
In further ments, an isolated polynucleotide described encodes the light chain of an
antigen binding moiety. In some embodiments, the ed polynucleotide s a
ptide wherein a Fab light chain variable region shares a y-terminal e bond
with a Fab heavy chain constant region. In other embodiments, the isolated polynucleotide
encodes a polypeptide wherein a Fab heavy chain variable region shares a carboxy-terminal
peptide bond with a Fab light chain constant region. In still other embodiments, an isolated
polynucleotide described encodes the light chain of the first antigen g moiety and the light
chain of the second antigen binding moiety. In a more specific embodiment, the isolated
cleotide encodes a polypeptide wherein a Fab heavy chain variable region shares a
carboxy-terminal peptide bond with a Fab light chain constant region, which in turn shares a
carboxy-terminal peptide bond with a Fab light chain. In another specific embodiment the
isolated cleotide encodes a polypeptide wherein a Fab light chain shares a yterminal
peptide bond with a Fab heavy chain variable , which in turn shares a carboxyterminal
peptide bond with a Fab light chain nt . In yet another specific
embodiment, the isolated polynucleotide encodes a polypeptide wherein a Fab light chain
variable region shares a carboxy-terminal peptide bond with a Fab heavy chain constant region,
which in turn shares a carboxy-terminal peptide bond with a Fab light chain. In yet r
specific embodiment the isolated polynucleotide encodes a polypeptide wherein a Fab light chain
shares a carboxy-terminal peptide bond with a Fab light chain variable region, which in turn
shares a carboxy-terminal peptide bond with a Fab heavy chain constant region.
In another embodiment, described is an isolated polynucleotide encoding a T cell activating
bispecific antigen binding le bed or a fragment thereof, wherein the polynucleotide
comprises a sequence that encodes a variable region sequence as shown in SEQ ID NOs 75, 83,
91, 99, 107, 115, 123, 131, 139, 147, 169, 177, 239, 247, 255 and 263. In r embodiment,
bed an isolated polynucleotide encoding a T cell activating bispecific antigen binding
molecule or fragment thereof, wherein the polynucleotide comprises a sequence that encodes a
polypeptide sequence as shown in SEQ ID NOs 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27,
29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 179, 181, 183, 185,
187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223,
225, 227, 229 and 231. In another embodiment, described is an isolated polynucleotide encoding
a T cell activating bispecific antigen binding molecule bed or a fragment thereof, wherein
the polynucleotide comprises a ce that is at least about 80%, 85%, 90%, 95%, 96%, 97%,
98%, or 99% identical to a nucleotide sequence shown in SEQ ID NOs 2, 4, 6, 8, 10, 12, 14, 16,
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68,
70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114,
116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 164, 166,
168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204,
206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242,
244, 246, 248, 250, 252, 254, 256, 258, 260, 262 or 264. In another embodiment, described is an
isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule
bed or a fragment thereof, wherein the polynucleotide comprises a nucleic acid sequence
shown in SEQ ID NOs 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42,
44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94,
96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134,
136, 138, 140, 142, 144, 146, 148, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186,
188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224,
226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262 or
264. In another embodiment, described is an isolated polynucleotide encoding a T cell activating
bispecific antigen binding molecule described or a fragment thereof, wherein the polynucleotide
comprises a sequence that encodes a variable region sequence that is at least about 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence in SEQ ID NOs 75, 83,
91, 99, 107, 115, 123, 131, 139, 147, 169, 177, 239, 247, 255 or 263. In another embodiment,
described is an ed polynucleotide encoding a T cell activating bispecific antigen binding
molecule or fragment thereof, wherein the polynucleotide comprises a sequence that encodes a
polypeptide ce that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to
an amino acid sequence in SEQ ID NOs 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31,
33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 179, 181, 183, 185, 187, 189,
191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227,
229 or 231. Described is an isolated polynucleotide encoding a T cell activating ific
antigen binding molecule described or a fragment thereof, wherein the polynucleotide comprises
a sequence that encodes the variable region sequence of SEQ ID NOs 75, 83, 91, 99, 107, 115,
123, 131, 139, 147, 169, 177, 239, 247, 255 or 263 with vative amino acid substitutions.
Also described is an isolated polynucleotide encoding a T cell activating bispecific antigen
binding molecule described or fragment thereof, wherein the polynucleotide comprises a
sequence that encodes the polypeptide sequence of SEQ ID NOs 1, 3, 5, 7, 9, 11, 13, 15, 17, 19,
21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 179,
181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217,
219, 221, 223, 225, 227, 229 or 231 with vative amino acid substitutions.
In certain embodiments the polynucleotide or nucleic acid is DNA. In other embodiments, a
polynucleotide described is RNA, for example, in the form of messenger RNA . RNA
bed may be single stranded or double stranded.
inant Methods
T cell activating bispecific antigen binding molecules described may be obtained, for example,
by solid-state e synthesis (e.g. Merrifield solid phase sis) or recombinant
production. For recombinant production one or more polynucleotide encoding the T cell
ting bispecific n binding le (fragment), e.g., as described above, is isolated
and inserted into one or more vectors for further cloning and/or expression in a host cell. Such
polynucleotide may be readily isolated and sequenced using conventional procedures. In one
embodiment a vector, preferably an expression vector, comprises one or more of the
polynucleotides described. Methods which are well known to those skilled in the art can be used
to construct expression vectors containing the coding sequence of a T cell activating bispecific
antigen binding molecule (fragment) along with appropriate transcriptional/translational control
signals. These methods include in vitro recombinant DNA ques, synthetic techniques and
in vivo recombination/genetic ination. See, for example, the techniques described in
Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor
Laboratory, N.Y. (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR Y,
Greene Publishing Associates and Wiley cience, N.Y (1989). The expression vector can be
part of a plasmid, virus, or may be a nucleic acid nt. The expression vector includes an
sion cassette into which the polynucleotide encoding the T cell activating ific
antigen binding molecule (fragment) (i.e. the coding region) is cloned in operable association
with a promoter and/or other transcription or translation l elements. As used herein, a
"coding region" is a portion of nucleic acid which consists of codons translated into amino acids.
Although a "stop codon" (TAG, TGA, or TAA) is not translated into an amino acid, it may be
considered to be part of a coding region, if present, but any ng sequences, for example
promoters, ribosome binding sites, transcriptional terminators, introns, 5' and 3' untranslated
regions, and the like, are not part of a coding region. Two or more coding regions can be present
in a single polynucleotide construct, e.g. on a single , or in separate polynucleotide
constructs, e.g. on separate (different) vectors. Furthermore, any vector may contain a single
coding , or may comprise two or more coding regions, e.g. a vector described may encode
one or more polypeptides, which are post- or co-translationally separated into the final proteins
via proteolytic cleavage. In on, a vector, cleotide, or nucleic acid bed may
encode heterologous coding regions, either fused or unfused to a polynucleotide encoding the T
cell activating bispecific antigen binding le (fragment) bed, or variant or derivative
thereof. Heterologous coding regions include without limitation specialized elements or motifs,
such as a secretory signal peptide or a heterologous functional domain. An operable association
is when a coding region for a gene product, e.g. a polypeptide, is ated with one or more
regulatory sequences in such a way as to place expression of the gene product under the
influence or control of the regulatory sequence(s). Two DNA fragments (such as a polypeptide
coding region and a promoter associated therewith) are bly associated" if induction of
er function results in the transcription of mRNA encoding the desired gene product and if
the nature of the linkage between the two DNA fragments does not interfere with the ability of
the expression tory sequences to direct the expression of the gene product or interfere with
the ability of the DNA template to be transcribed. Thus, a promoter region would be operably
associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting
transcription of that nucleic acid. The promoter may be a cell-specific er that directs
substantial transcription of the DNA only in predetermined cells. Other transcription control
elements, besides a promoter, for example enhancers, operators, sors, and transcription
termination signals, can be operably associated with the polynucleotide to direct cell-specific
transcription. Suitable promoters and other transcription control regions are disclosed herein. A
variety of transcription control regions are known to those skilled in the art. These include,
without limitation, transcription l regions, which on in vertebrate cells, such as, but
not limited to, promoter and enhancer segments from galoviruses (e.g. the immediate
early promoter, in conjunction with intron-A), simian virus 40 (e.g. the early er), and
retroviruses (such as, e.g. Rous sarcoma virus). Other transcription control regions include those
derived from vertebrate genes such as actin, heat shock protein, bovine growth e and
rabbit â-globin, as well as other sequences capable of controlling gene expression in eukaryotic
cells. Additional suitable transcription control regions include -specific promoters and
enhancers as well as inducible ers (e.g. promoters ble tetracyclins). Similarly, a
variety of translation control ts are known to those of ry skill in the art. These
include, but are not limited to ribosome binding sites, translation tion and termination
codons, and elements derived from viral systems (particularly an al ribosome entry site, or
IRES, also referred to as a CITE sequence). The expression cassette may also e other
features such as an origin of replication, and/or some integration elements such as
retroviral long terminal s (LTRs), or adeno-associated viral (AAV) inverted terminal
repeats (ITRs).
Polynucleotide and nucleic acid coding regions described may be associated with additional
coding regions which encode secretory or signal peptides, which direct the secretion of a
polypeptide encoded by a polynucleotide described. For example, if secretion of the T cell
activating bispecific antigen binding molecule is desired, DNA encoding a signal sequence may
be placed upstream of the nucleic acid encoding a T cell activating bispecific antigen binding
molecule described or a fragment thereof. According to the signal hypothesis, proteins secreted
by mammalian cells have a signal peptide or secretory leader sequence which is cleaved from the
mature protein once export of the g protein chain across the rough endoplasmic reticulum
has been initiated. Those of ordinary skill in the art are aware that polypeptides secreted by
rate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which
is cleaved from the translated polypeptide to e a secreted or "mature" form of the
polypeptide. In certain embodiments, the native signal peptide, e.g. an immunoglobulin heavy
chain or light chain signal peptide is used, or a functional derivative of that sequence that retains
the ability to direct the secretion of the polypeptide that is operably associated with it.
Alternatively, a heterologous mammalian signal peptide, or a functional derivative thereof, may
be used. For e, the wild-type leader sequence may be substituted with the leader sequence
of human tissue plasminogen activator (TPA) or mouse β-glucuronidase. Exemplary amino acid
and polynucleotide sequences of secretory signal peptides are given in SEQ ID NOs 154-162.
DNA encoding a short protein sequence that could be used to facilitate later purification (e.g. a
histidine tag) or assist in labeling the T cell activating bispecific antigen binding molecule may
be included within or at the ends of the T cell activating bispecific antigen binding molecule
(fragment) encoding polynucleotide.
Also described is a host cell sing one or more polynucleotides described herein. In certain
embodiments bed is a host cell comprising one or more vectors described . The
polynucleotides and vectors may incorporate any of the features, singly or in combination,
described herein in relation to polynucleotides and vectors, respectively. In one such
ment a host cell comprises (e.g. has been ormed or transfected with) a vector
comprising a cleotide that encodes (part of) a T cell activating bispecific antigen binding
molecule described. As used herein, the term "host cell" refers to any kind of cellular system
which can be engineered to generate the T cell activating bispecific antigen g molecules
described or fragments thereof. Host cells suitable for replicating and for supporting expression
of T cell activating bispecific antigen binding molecules are well known in the art. Such cells
may be transfected or transduced as riate with the particular expression vector and large
quantities of vector containing cells can be grown for seeding large scale fermenters to obtain
sufficient quantities of the T cell ting bispecific antigen binding molecule for clinical
applications. Suitable host cells include prokaryotic microorganisms, such as E. coli, or various
eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, or the like. For
example, polypeptides may be produced in bacteria in particular when glycosylation is not
needed. After expression, the polypeptide may be ed from the bacterial cell paste in a
soluble fraction and can be further purified. In addition to yotes, eukaryotic microbes such
as filamentous fungi or yeast are suitable cloning or sion hosts for polypeptide-encoding
s, including fungi and yeast strains whose glycosylation pathways have been “humanized”,
resulting in the production of a polypeptide with a partially or fully human glycosylation pattern.
See Gerngross, Nat Biotech 22, 414 (2004), and Li et al., Nat Biotech 24, 210-215 (2006).
Suitable host cells for the expression of (glycosylated) polypeptides are also derived from
multicellular organisms (invertebrates and vertebrates). es of ebrate cells include
plant and insect cells. Numerous baculoviral strains have been identified which may be used in
conjunction with insect cells, particularly for transfection of Spodoptera erda cells. Plant
cell cultures can also be ed as hosts. See e.g. US Patent Nos. 5,959,177, 6,040,498,
6,420,548, 7,125,978, and 6,417,429 (describing BODIESTM technology for producing
antibodies in transgenic plants). Vertebrate cells may also be used as hosts. For example,
mammalian cell lines that are d to grow in suspension may be useful. Other examples of
useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7);
human nic kidney line (293 or 293T cells as described, e.g., in Graham et al., J Gen Virol
36, 59 (1977)), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells as described,
e.g., in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green
monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells
(MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep
G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, e.g., in Mather et al.,
Annals N.Y. Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian
host cell lines include Chinese hamster ovary (CHO) cells, including dhfr- CHO cells b et
al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63
and Sp2/0. For a review of certain mammalian host cell lines suitable for protein production, see,
e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press,
Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, e.g., mammalian cultured
cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells
comprised within a transgenic animal, transgenic plant or ed plant or animal tissue. In one
embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese
Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or a lymphoid cell (e.g., Y0,
NS0, Sp20 cell).
Standard technologies are known in the art to s foreign genes in these systems. Cells
expressing a polypeptide comprising either the heavy or the light chain of an antigen binding
domain such as an dy, may be engineered so as to also express the other of the antibody
chains such that the expressed product is an antibody that has both a heavy and a light chain.
In one embodiment, bed is a method of producing a T cell activating bispecific antigen
binding molecule described, wherein the method comprises culturing a host cell comprising a
cleotide encoding the T cell activating bispecific antigen binding molecule, as described
herein, under ions suitable for sion of the T cell activating bispecific antigen binding
molecule, and recovering the T cell activating bispecific antigen binding molecule from the host
cell (or host cell culture medium).
The components of the T cell activating bispecific antigen binding molecule are genetically
fused to each other. T cell ting ific antigen binding molecule can be designed such
that its components are fused ly to each other or indirectly through a linker sequence. The
composition and length of the linker may be determined in accordance with methods well known
in the art and may be tested for efficacy. Examples of linker sequences between different
components of T cell activating bispecific antigen binding molecules are found in the sequences
described herein. Additional sequences may also be ed to incorporate a cleavage site to
te the individual components of the fusion if desired, for example an endopeptidase
recognition sequence.
In certain embodiments the one or more n g moieties of the T cell activating
bispecific antigen binding molecules se at least an antibody variable region e of
binding an nic inant. Variable regions can form part of and be derived from
naturally or non-naturally ing dies and fragments thereof. Methods to produce
polyclonal antibodies and monoclonal antibodies are well known in the art (see e.g. Harlow and
Lane, "Antibodies, a laboratory ", Cold Spring Harbor Laboratory, 1988). Non-naturally
occurring antibodies can be constructed using solid phase-peptide synthesis, can be produced
recombinantly (e.g. as bed in U.S. patent No. 4,186,567) or can be obtained, for example,
by screening combinatorial libraries comprising variable heavy chains and variable light chains
(see e.g. U.S. Patent. No. 5,969,108 to McCafferty).
Any animal species of antibody, antibody fragment, antigen binding domain or variable region
can be used in the T cell activating bispecific antigen binding molecules described. miting
antibodies, antibody fragments, antigen binding domains or variable regions useful herein can be
of murine, primate, or human origin. If the T cell activating bispecific antigen binding molecule
is intended for human use, a ic form of antibody may be used wherein the constant
regions of the antibody are from a human. A humanized or fully human form of the dy can
also be prepared in accordance with s well known in the art (see e. g. U.S. Patent No.
,565,332 to Winter). Humanization may be achieved by various methods including, but not
limited to (a) grafting the non-human (e.g., donor antibody) CDRs onto human (e.g. recipient
antibody) framework and constant s with or without retention of critical framework
residues (e.g. those that are important for retaining good antigen binding affinity or antibody
functions), (b) grafting only the non-human specificity-determining regions (SDRs or a-CDRs;
the residues critical for the antibody-antigen ction) onto human framework and constant
regions, or (c) lanting the entire non-human variable domains, but "cloaking" them with a
human-like section by replacement of surface residues. Humanized antibodies and methods of
making them are reviewed, e.g., in Almagro and Fransson, Front Biosci 13, 1619-1633 (2008),
and are further described, e.g., in Riechmann et al., Nature 332, 323-329 (1988); Queen et al.,
Proc Natl Acad Sci USA 86, 10029-10033 (1989); US Patent Nos. 5,821,337, 7,527,791,
6,982,321, and 7,087,409; Jones et al., Nature 321, 522-525 (1986); Morrison et al., Proc Natl
Acad Sci 81, 6851-6855 ; Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et
al., Science 239, 536 (1988); Padlan, Molec Immun 31(3), 169-217 (1994); Kashmiri et
al., Methods 36, 25-34 (2005) (describing SDR (a-CDR) grafting); , Mol Immunol 28,
489-498 (1991) (describing “resurfacing”); Dall’Acqua et al., Methods 36, 43-60 (2005)
(describing “FR shuffling”); and Osbourn et al., Methods 36, 61-68 (2005) and Klimka et al., Br
J Cancer 83, 252-260 (2000) (describing the “guided selection” approach to FR ing).
Human antibodies and human variable regions can be produced using various techniques known
in the art. Human antibodies are described lly in van Dijk and van de Winkel, Curr Opin
Pharmacol 5, 368-74 (2001) and g, Curr Opin Immunol 20, 450-459 (2008). Human
variable regions can form part of and be derived from human monoclonal antibodies made by the
hybridoma method (see e.g. Monoclonal Antibody Production Techniques and Applications, pp.
51-63 (Marcel Dekker, Inc., New York, . Human antibodies and human variable regions
may also be prepared by stering an immunogen to a transgenic animal that has been
modified to produce intact human antibodies or intact antibodies with human variable regions in
response to antigenic challenge (see e.g. Lonberg, Nat Biotech 23, 1117-1125 (2005). Human
dies and human variable regions may also be generated by ing Fv clone le
region sequences selected from derived phage display libraries (see e.g., Hoogenboom et
al. in Methods in Molecular Biology 178, 1-37 (O’Brien et al., ed., Human Press, Totowa, NJ,
2001); and McCafferty et al., Nature 348, 552-554; Clackson et al., Nature 352, 624-628 (1991)).
Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab
fragments.
In certain embodiments, the antigen binding moieties useful herein are engineered to have
enhanced binding affinity according to, for example, the methods disclosed in U.S. Pat. Appl.
Publ. No. 2004/0132066, the entire contents of which are hereby incorporated by reference. The
ability of the T cell activating bispecific antigen binding molecule described to bind to a specific
antigenic determinant can be ed either through an enzyme-linked immunosorbent assay
(ELISA) or other techniques ar to one of skill in the art, e.g. surface plasmon resonance
technique (analyzed on a BIACORE T100 system) (Liljeblad, et al., Glyco J 17, 323-329 (2000)),
and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competition assays
may be used to identify an antibody, antibody nt, n binding domain or variable
domain that competes with a reference antibody for binding to a particular antigen, e.g. an
antibody that competes with the V9 antibody for binding to CD3. In certain embodiments, such a
competing antibody binds to the same epitope (e.g. a linear or a mational epitope) that is
bound by the nce dy. Detailed ary methods for mapping an epitope to which
an antibody binds are provided in Morris (1996) “Epitope Mapping Protocols,” in Methods in
Molecular Biology vol. 66 (Humana Press, Totowa, NJ). In an exemplary competition assay,
immobilized antigen (e.g. CD3) is incubated in a solution comprising a first labeled antibody that
binds to the antigen (e.g. V9 antibody) and a second unlabeled antibody that is being tested for
its ability to compete with the first antibody for g to the antigen. The second antibody may
be present in a oma supernatant. As a control, immobilized antigen is incubated in a
solution comprising the first d antibody but not the second led antibody. After
incubation under conditions permissive for binding of the first antibody to the antigen, excess
unbound antibody is removed, and the amount of label associated with lized antigen is
measured. If the amount of label associated with immobilized antigen is substantially reduced in
the test sample relative to the control sample, then that indicates that the second antibody is
competing with the first antibody for binding to the antigen. See Harlow and Lane (1988)
Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor,
NY).
T cell activating bispecific antigen binding molecules prepared as described herein may be
purified by art-known techniques such as high performance liquid chromatography, ion
ge chromatography, gel electrophoresis, affinity tography, size exclusion
chromatography, and the like. The actual conditions used to purify a particular protein will
depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity etc., and will be
apparent to those having skill in the art. For affinity chromatography purification an antibody,
ligand, receptor or antigen can be used to which the T cell activating bispecific n binding
molecule binds. For example, for affinity chromatography purification of T cell activating
bispecific antigen binding molecules described, a matrix with protein A or n G may be
used. Sequential n A or G affinity chromatography and size exclusion chromatography can
be used to isolate a T cell activating bispecific antigen binding molecule essentially as described
in the Examples. The purity of the T cell activating bispecific antigen binding molecule can be
determined by any of a variety of well known ical s including gel electrophoresis,
high pressure liquid chromatography, and the like. For example, the heavy chain fusion proteins
sed as described in the Examples were shown to be intact and properly led as
demonstrated by reducing SDS-PAGE (see e.g. Figure 2). Three bands were resolved at
approximately Mr 25,000, Mr 50,000 and Mr 75,000, corresponding to the predicted molecular
weights of the T cell activating bispecific antigen binding le light chain, heavy chain and
heavy chain/light chain fusion protein.
Assays
T cell activating bispecific antigen g molecules bed herein may be identified,
screened for, or characterized for their physical/chemical properties and/or biological activities
by various assays known in the art.
Affinity assays
The affinity of the T cell activating bispecific n binding le for an Fc receptor or a
target antigen can be determined in accordance with the methods set forth in the Examples by
surface plasmon resonance (SPR), using standard instrumentation such as a BIAcore instrument
(GE Healthcare), and receptors or target proteins such as may be obtained by inant
expression. Alternatively, binding of T cell activating bispecific antigen binding molecules for
different ors or target antigens may be evaluated using cell lines expressing the particular
receptor or target antigen, for example by flow cytometry (FACS). A specific illustrative and
exemplary embodiment for ing binding affinity is described in the following and in the
Examples below.
According to one embodiment, KD is measured by surface plasmon resonance using a
E® T100 machine (GE Healthcare) at 25 °C.
To analyze the interaction between the Fc-portion and Fc receptors, His-tagged recombinant Fcreceptor
is captured by an anti-Penta His antibody (Qiagen) immobilized on CM5 chips and the
bispecific constructs are used as analytes. Briefly, carboxymethylated dextran biosensor chips
(CM5, GE Healthcare) are activated with N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier’s instructions.
Anti Penta-His antibody is diluted with 10 mM sodium acetate, pH 5.0, to 40 μg/ml before
injection at a flow rate of 5 μl/min to achieve approximately 6500 se units (RU) of
coupled protein. Following the injection of the ligand, 1 M ethanolamine is injected to block
unreacted groups. Subsequently the Fc-receptor is captured for 60 s at 4 or 10 nM. For c
measurements, four-fold serial dilutions of the bispecific construct (range between 500 nM and
4000 nM) are ed in HBS-EP (GE Healthcare, 10 mM HEPES, 150 mM NaCl, 3 mM EDTA,
0.05 % Surfactant P20, pH 7.4) at 25 °C at a flow rate of 30 μl/min for 120 s.
To determine the affinity to the target antigen, bispecific ucts are captured by an anti
human Fab specific antibody (GE care) that is lized on an ted CM5-sensor
chip surface as described for the anti Penta-His antibody. The final amount of coupled protein is
is approximately 12000 RU. The bispecific constructs are captured for 90 s at 300 nM. The
target ns are passed through the flow cells for 180 s at a concentration range from 250 to
1000 nM with a flowrate of 30 μl/min. The dissociation is monitored for 180 s.
Bulk refractive index ences are corrected for by cting the response obtained on
reference flow cell. The steady state response was used to derive the dissociation constant KD by
non-linear curve fitting of the Langmuir binding isotherm. Association rates (kon) and
iation rates (koff) are calculated using a simple one-to-one Langmuir binding model
(BIACORE® T100 Evaluation Software version 1.1.1) by simultaneously fitting the association
and dissociation grams. The equilibrium dissociation constant (KD) is calculated as the
ratio koff/kon. See, e.g., Chen et al., J Mol Biol 293, 865-881 .
Activity assays
Biological activity of the T cell activating bispecific antigen binding molecules described can be
measured by various assays as described in the Examples. Biological activities may for example
include the induction of eration of T cells, the induction of signaling in T cells, the
induction of expression of activation markers in T cells, the induction of cytokine secretion by T
cells, the induction of lysis of target cells such as tumor cells, and the induction of tumor
regression and/or the improvement of survival.
Compositions, Formulations, and Routes of Administration
Also described are pharmaceutical compositions comprising any of the T cell ting
bispecific antigen binding molecules described herein, e.g., for use in any of the below
therapeutic methods. In one embodiment, a pharmaceutical composition ses any of the T
cell activating bispecific antigen g molecules described herein and a pharmaceutically
acceptable carrier. In another embodiment, a pharmaceutical composition comprises any of the T
cell activating bispecific antigen binding molecules described herein and at least one additional
therapeutic agent, e.g., as described below.
Further described is a method of producing a T cell activating bispecific antigen binding
molecule described in a form suitable for stration in vivo, the method comprising (a)
obtaining a T cell activating bispecific antigen binding le described, and (b) formulating
the T cell ting bispecific antigen binding molecule with at least one pharmaceutically
acceptable carrier, whereby a preparation of T cell activating bispecific antigen binding molecule
is formulated for administration in vivo.
Pharmaceutical compositions described comprise a therapeutically ive amount of one or
more T cell activating bispecific n g molecule ved or sed in a
pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically
acceptable" refers to molecular entities and itions that are generally non-toxic to
recipients at the dosages and concentrations employed, i.e. do not produce an adverse, allergic or
other untoward reaction when administered to an animal, such as, for example, a human, as
appropriate. The preparation of a pharmaceutical composition that contains at least one T cell
activating bispecific antigen binding molecule and optionally an additional active ingredient will
be known to those of skill in the art in light of the present disclosure, as exemplified by
Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated
herein by reference. Moreover, for animal (e.g., human) stration, it will be understood that
preparations should meet sterility, pyrogenicity, l safety and purity standards as required
by FDA Office of ical Standards or ponding authorities in other countries. Preferred
compositions are lyophilized formulations or aqueous solutions. As used herein,
"pharmaceutically acceptable carrier" includes any and all solvents, buffers, dispersion media,
coatings, surfactants, antioxidants, preservatives (e.g. antibacterial agents, ngal agents),
ic agents, tion delaying agents, salts, preservatives, antioxidants, proteins, drugs,
drug stabilizers, polymers, gels, binders, excipients, disintegration agents, ants, sweetening
agents, flavoring agents, dyes, such like materials and ations thereof, as would be known
to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th
Ed. Mack Printing Company, 1990, pp. 1289-1329, orated herein by reference). Except
insofar as any conventional carrier is incompatible with the active ingredient, its use in the
therapeutic or pharmaceutical compositions is contemplated.
The composition may se different types of carriers depending on whether it is to be
administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of
administration as injection. T cell activating bispecific antigen binding molecules bed (and
any additional therapeutic agent) can be administered intravenously, intradermally,
intraarterially, eritoneally, intralesionally, intracranially, intraarticularly, intraprostatically,
intrasplenically, intrarenally, intrapleurally, intratracheally, intranasally, intravitreally,
intravaginally, ectally, intratumorally, intramuscularly, intraperitoneally, subcutaneously,
subconjunctivally, intravesicularlly, mucosally, intrapericardially, intraumbilically,
intraocularally, orally, lly, locally, by inhalation (e.g. aerosol inhalation), injection,
infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via
a lavage, in cremes, in lipid compositions (e.g. liposomes), or by other method or any
combination of the forgoing as would be known to one of ordinary skill in the art (see, for
example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990,
incorporated herein by reference). eral administration, in particular intravenous injection,
is most commonly used for administering polypeptide molecules such as the T cell activating
bispecific antigen binding molecules described.
Parenteral compositions include those designed for administration by injection, e.g.
subcutaneous, ermal, intralesional, intravenous, rterial intramuscular, hecal or
intraperitoneal injection. For injection, the T cell activating bispecific antigen binding molecules
described may be ated in aqueous solutions, preferably in physiologically compatible
buffers such as Hanks' on, Ringer's solution, or physiological saline buffer. The solution
may contain formulatory agents such as suspending, izing and/or dispersing agents.
Alternatively, the T cell activating bispecific antigen binding molecules may be in powder form
for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Sterile
injectable ons are prepared by incorporating the T cell activating bispecific antigen binding
molecules described in the required amount in the riate solvent with various of the other
ingredients enumerated below, as required. Sterility may be readily lished, e.g., by
filtration through sterile filtration nes. Generally, dispersions are prepared by
incorporating the various sterilized active ingredients into a sterile vehicle which contains the
basic dispersion medium and/or the other ingredients. In the case of sterile powders for the
preparation of sterile injectable solutions, suspensions or emulsion, the preferred methods of
preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active
ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium
thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first
rendered isotonic prior to injection with sufficient saline or glucose. The composition must be
stable under the conditions of cture and storage, and preserved against the contaminating
action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin
contamination should be kept minimally at a safe level, for example, less that 0.5 ng/mg protein.
Suitable ceutically able carriers include, but are not d to: buffers such as
phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;
benzalkonium chloride; honium chloride; phenol, butyl or benzyl alcohol; alkyl parabens
such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol);
low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum
albumin, n, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;
amino acids such as glycine, glutamine, gine, histidine, arginine, or lysine;
monosaccharides, disaccharides, and other carbohydrates including e, mannose, or
dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol;
salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein xes); and/or
non-ionic surfactants such as polyethylene glycol (PEG). s injection suspensions may
contain compounds which increase the viscosity of the suspension, such as sodium
carboxymethyl ose, sorbitol, dextran, or the like. Optionally, the suspension may also
contain le stabilizers or agents which increase the lity of the compounds to allow for
the preparation of highly concentrated solutions. Additionally, sions of the active
compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic
solvents or vehicles e fatty oils such as sesame oil, or synthetic fatty acid esters, such as
ethyl cleats or triglycerides, or liposomes.
Active ingredients may be entrapped in microcapsules prepared, for e, by coacervation
techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatinmicrocapsules
and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug
delivery systems (for example, liposomes, albumin pheres, microemulsions, nanoparticles
and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's
Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained-release
preparations may be prepared. le examples of sustained-release preparations include
semipermeable matrices of solid hydrophobic polymers containing the ptide, which
matrices are in the form of shaped articles, e.g. films, or microcapsules. In particular
embodiments, prolonged absorption of an injectable composition can be brought about by the
use in the compositions of agents delaying absorption, such as, for example, aluminum
monostearate, gelatin or combinations thereof.
In addition to the compositions described previously, the T cell activating bispecific antigen
binding molecules may also be ated as a depot preparation. Such long acting formulations
may be administered by implantation (for example aneously or intramuscularly) or by
uscular injection. Thus, for example, the T cell activating bispecific antigen binding
molecules may be formulated with le polymeric or hydrophobic materials (for example as
an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for
e, as a sparingly soluble salt.
Pharmaceutical compositions comprising the T cell activating bispecific antigen binding
molecules bed may be ctured by means of conventional , dissolving,
emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions
may be formulated in conventional manner using one or more physiologically acceptable
carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into
preparations that can be used pharmaceutically. Proper formulation is dependent upon the route
of administration chosen.
The T cell activating bispecific antigen binding molecules may be formulated into a composition
in a free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that
substantially retain the biological ty of the free acid or base. These include the acid addition
salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are
formed with inorganic acids such as for e, hydrochloric or phosphoric acids, or such
organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl
groups can also be derived from nic bases such as for example, sodium, potassium,
ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine,
trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous
and other protic solvents than are the corresponding free base forms.
Therapeutic s and Compositions
Any of the T cell ting bispecific antigen binding les bed herein may be used
in therapeutic methods. T cell activating bispecific antigen binding molecules described can be
used as immunotherapeutic agents, for example in the treatment of cancers.
For use in therapeutic methods, T cell activating bispecific antigen binding molecules described
would be formulated, dosed, and stered in a fashion consistent with good l practice.
Factors for consideration in this context include the particular disorder being treated, the
particular mammal being treated, the clinical condition of the individual patient, the cause of the
disorder, the site of delivery of the agent, the method of stration, the scheduling of
administration, and other factors known to medical practitioners.
Described are T cell activating bispecific antigen binding molecules described for use as a
medicament. Aso described are T cell activating bispecific antigen binding molecules described
for use in treating a disease. In certain ments, T cell activating bispecific antigen binding
molecules described for use in a method of treatment are described. In one embodiment,
described is a T cell activating bispecific antigen binding molecule as described herein for use in
the treatment of a disease in an individual in need thereof. In certain embodiments, described is
a T cell activating bispecific antigen binding le for use in a method of treating an
individual having a disease comprising administering to the individual a therapeutically ive
amount of the T cell ting bispecific antigen binding molecule. In certain embodiments the
disease to be treated is a proliferative disorder. In a ular ment the disease is cancer.
In certain embodiments the method further comprises administering to the individual a
therapeutically effective amount of at least one onal therapeutic agent, e.g., an anti-cancer
agent if the disease to be treated is cancer. In further embodiments, described is a T cell
activating bispecific antigen binding molecule as bed herein for use in inducing lysis of a
target cell, particularly a tumor cell. In certain embodiments, described is a T cell activating
bispecific antigen binding molecule for use in a method of inducing lysis of a target cell,
particularly a tumor cell, in an individual comprising administering to the individual an effective
amount of the T cell activating bispecific antigen g molecule to induce lysis of a target
cell. An “individual” according to any of the above embodiments is a mammal, preferably a
human.
Also described is the use of a T cell activating bispecific antigen binding molecule described in
the manufacture or preparation of a ment. In one embodiment the medicament is for the
ent of a e in an individual in need thereof. In a further embodiment, the medicament
is for use in a method of treating a disease comprising administering to an individual having the
e a therapeutically effective amount of the medicament. In n embodiments the
disease to be treated is a proliferative disorder. In a particular embodiment the disease is cancer.
In one embodiment, the method further comprises administering to the individual a
therapeutically effective amount of at least one additional therapeutic agent, e.g., an anti-cancer
agent if the disease to be treated is cancer. In a further embodiment, the ment is for
inducing lysis of a target cell, particularly a tumor cell. In still a further embodiment, the
medicament is for use in a method of inducing lysis of a target cell, particularly a tumor cell, in
an individual comprising administering to the individual an effective amount of the ment
to induce lysis of a target cell. An “individual” according to any of the above embodiments may
be a mammal, preferably a human.
Also described is a method for treating a disease. In one embodiment, the method comprises
administering to an individual having such disease a therapeutically effective amount of a T cell
activating bispecific antigen binding molecule described. In one embodiment a composition is
administered to said invididual, comprising the T cell activating bispecific n binding
molecule described in a pharmaceutically acceptable form. In certain embodiments the disease to
be treated is a proliferative er. In a ular embodiment the disease is cancer. In certain
ments the method further comprises administering to the individual a therapeutically
effective amount of at least one additional eutic agent, e.g., an anti-cancer agent if the
e to be treated is cancer. An “individual” according to any of the above embodiments may
be a mammal, preferably a human.
Also described is a method for inducing lysis of a target cell, particularly a tumor cell. In one
embodiment the method comprises contacting a target cell with a T cell activating bispecific
antigen binding molecule described in the presence of a T cell, particularly a cytotoxic T cell. In
a further aspect, a method for inducing lysis of a target cell, particularly a tumor cell, in an
individual is described. In one such embodiment, the method comprises administering to the
dual an effective amount of a T cell activating bispecific n binding molecule to
induce lysis of a target cell. In one embodiment, an “individual” is a human.
In certain embodiments the disease to be treated is a erative disorder, particularly cancer.
Non-limiting examples of cancers include r cancer, brain cancer, head and neck ,
pancreatic cancer, lung , breast cancer, n cancer, uterine cancer, cervical cancer,
endometrial cancer, esophageal cancer, colon , colorectal cancer, rectal cancer, gastric
, prostate , blood cancer, skin cancer, squamous cell carcinoma, bone , and
kidney cancer. Other cell proliferation disorders that can be treated using a T cell activating
bispecific antigen binding molecule described include, but are not limited to neoplasms located
in the: abdomen, bone, , digestive system, liver, pancreas, peritoneum, endocrine glands
al, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous
system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, ic
region, and urogenital system. Also included are pre-cancerous conditions or s and cancer
metastases. In certain embodiments the cancer is chosen from the group consisting of renal cell
cancer, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck
cancer. A skilled artisan readily recognizes that in many cases the T cell activating bispecific
antigen binding molecule may not provide a cure but may only provide l benefit. In some
embodiments, a physiological change having some benefit is also considered therapeutically
beneficial. Thus, in some embodiments, an amount of T cell activating bispecific antigen binding
molecule that es a physiological change is considered an "effective amount" or a
peutically effective amount". The subject, patient, or dual in need of treatment is
typically a mammal, more specifically a human.
In some ments, an effective amount of a T cell activating bispecific antigen binding
molecule described is administered to a cell. In other embodiments, a therapeutically effective
amount of a T cell activating bispecific antigen binding molecule described is administered to an
individual for the treatment of disease.
For the prevention or treatment of disease, the appropriate dosage of a T cell activating bispecific
antigen binding molecule described (when used alone or in combination with one or more other
additional therapeutic agents) will depend on the type of disease to be treated, the route of
administration, the body weight of the t, the type of T cell activating bispecific antigen
binding molecule, the severity and course of the disease, whether the T cell activating bispecific
n binding molecule is administered for tive or therapeutic purposes, previous or
concurrent therapeutic interventions, the patient's clinical history and response to the T cell
activating bispecific n binding molecule, and the discretion of the attending physician. The
practitioner responsible for administration will, in any event, determine the concentration of
active ingredient(s) in a composition and appropriate dose(s) for the individual subject. Various
dosing schedules including but not limited to single or multiple administrations over s
time-points, bolus stration, and pulse infusion are contemplated herein.
The T cell activating bispecific antigen binding molecule is suitably administered to the patient
at one time or over a series of treatments. Depending on the type and severity of the disease,
about 1 µg/kg to 15 mg/kg (e.g. 0.1 mg/kg – 10 mg/kg) of T cell activating bispecific antigen
binding molecule can be an initial candidate dosage for administration to the patient, whether,
for example, by one or more separate administrations, or by continuous infusion. One typical
daily dosage might range from about 1 µg/kg to 100 mg/kg or more, ing on the factors
mentioned above. For repeated administrations over several days or longer, depending on the
ion, the ent would generally be sustained until a desired suppression of disease
symptoms occurs. One exemplary dosage of the T cell activating bispecific antigen binding
molecule would be in the range from about 0.005 mg/kg to about 10 mg/kg. In other nonlimiting
examples, a dose may also comprise from about 1 microgram/kg body weight, about 5
microgram/kg body , about 10 microgram/kg body weight, about 50 microgram/kg body
weight, about 100 microgram/kg body weight, about 200 microgram/kg body weight, about 350
microgram/kg body weight, about 500 microgram/kg body weight, about 1 milligram/kg body
weight, about 5 milligram/kg body , about 10 milligram/kg body weight, about 50
ram/kg body weight, about 100 milligram/kg body weight, about 200 milligram/kg body
weight, about 350 ram/kg body weight, about 500 milligram/kg body weight, to about
1000 mg/kg body weight or more per administration, and any range derivable therein. In nonlimiting
examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg
body weight to about 100 mg/kg body weight, about 5 microgram/kg body weight to about 500
milligram/kg body weight, etc., can be stered, based on the numbers bed above.
Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 5.0 mg/kg or 10 mg/kg (or any
combination thereof) may be administered to the patient. Such doses may be administered
intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from
about two to about twenty, or e.g. about six doses of the T cell activating bispecific antigen
binding molecule). An initial higher loading dose, followed by one or more lower doses may be
administered. However, other dosage regimens may be useful. The progress of this therapy is
easily monitored by conventional techniques and assays.
The T cell activating bispecific antigen binding molecules described will generally be used in an
amount ive to achieve the intended purpose. For use to treat or prevent a disease condition,
the T cell activating bispecific antigen binding molecules described, or pharmaceutical
compositions thereof, are administered or applied in a eutically effective amount.
Determination of a therapeutically effective amount is well within the capabilities of those
skilled in the art, especially in light of the detailed sure provided herein.
For systemic administration, a therapeutically effective dose can be estimated initially from in
vitro assays, such as cell e assays. A dose can then be formulated in animal models to
achieve a circulating concentration range that includes the IC50 as determined in cell culture.
Such information can be used to more accurately determine useful doses in humans.
Initial dosages can also be estimated from in vivo data, e.g., animal models, using techniques that
are well known in the art. One having ordinary skill in the art could readily optimize
administration to humans based on animal data.
Dosage amount and interval may be adjusted individually to provide plasma levels of the T cell
activating bispecific antigen binding molecules which are sufficient to maintain therapeutic
effect. Usual patient dosages for administration by injection range from about 0.1 to 50
mg/kg/day, typically from about 0.5 to 1 mg/kg/day. eutically effective plasma levels may
be achieved by administering multiple doses each day. Levels in plasma may be measured, for
example, by HPLC.
In cases of local administration or ive uptake, the effective local tration of the T cell
activating bispecific n binding molecules may not be related to plasma concentration. One
having skill in the art will be able to optimize eutically effective local dosages without
undue experimentation.
A therapeutically effective dose of the T cell activating bispecific antigen binding molecules
described herein will lly provide therapeutic benefit without causing substantial toxicity.
Toxicity and therapeutic efficacy of a T cell activating bispecific antigen binding molecule can
be determined by standard pharmaceutical procedures in cell culture or mental s.
Cell e assays and animal studies can be used to determine the LD50 (the dose lethal to 50%
of a population) and the ED50 (the dose eutically effective in 50% of a population). The
dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed
as the ratio LD50/ED50. T cell ting bispecific antigen binding molecules that exhibit large
eutic indices are preferred. In one embodiment, the T cell activating bispecific antigen
g molecule described exhibits a high eutic index. The data obtained from cell culture
assays and animal studies can be used in formulating a range of dosages suitable for use in
humans. The dosage lies preferably within a range of circulating concentrations that include the
ED50 with little or no toxicity. The dosage may vary within this range ing upon a variety
of factors, e.g., the dosage form employed, the route of administration utilized, the condition of
the subject, and the like. The exact formulation, route of administration and dosage can be
chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975,
in: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1, incorporated herein by reference in
its entirety).
The attending physician for patients treated with T cell activating ific antigen binding
molecules described would know how and when to terminate, interrupt, or adjust administration
due to toxicity, organ dysfunction, and the like. Conversely, the attending physician would also
know to adjust ent to higher levels if the clinical response were not adequate (precluding
ty). The magnitude of an administered dose in the management of the disorder of interest
will vary with the severity of the condition to be treated, with the route of administration, and the
like. The severity of the condition may, for example, be evaluated, in part, by standard
prognostic evaluation methods. Further, the dose and perhaps dose frequency will also vary
according to the age, body weight, and response of the individual patient.
Other Agents and Treatments
The T cell activating bispecific antigen binding molecules described may be administered in
combination with one or more other agents in therapy. For instance, a T cell activating bispecific
antigen binding molecule described may be co-administered with at least one additional
eutic agent. The term "therapeutic agent” encompasses any agent administered to treat a
m or disease in an individual in need of such treatment. Such additional therapeutic agent
may comprise any active ingredients suitable for the particular indication being treated,
preferably those with complementary activities that do not adversely affect each other. In certain
embodiments, an onal therapeutic agent is an immunomodulatory agent, a cytostatic agent,
an inhibitor of cell adhesion, a cytotoxic agent, an activator of cell apoptosis, or an agent that
increases the sensitivity of cells to tic inducers. In a particular embodiment, the additional
therapeutic agent is an anti-cancer agent, for e a microtubule disruptor, an tabolite,
a topoisomerase inhibitor, a DNA intercalator, an alkylating agent, a hormonal therapy, a kinase
tor, a receptor antagonist, an tor of tumor cell apoptosis, or an antiangiogenic agent.
Such other agents are suitably present in combination in amounts that are effective for the
purpose intended. The effective amount of such other agents s on the amount of T cell
activating bispecific n binding molecule used, the type of er or treatment, and other
factors discussed above. The T cell activating bispecific antigen binding molecules are generally
used in the same dosages and with administration routes as described herein, or about from 1 to
99% of the dosages described herein, or in any dosage and by any route that is
empirically/clinically determined to be appropriate.
Such ation therapies noted above encompass combined administration (where two or
more therapeutic agents are included in the same or separate compositions), and separate
administration, in which case, administration of the T cell activating bispecific n binding
molecule described can occur prior to, simultaneously, and/or following, administration of the
additional therapeutic agent and/or adjuvant. T cell activating bispecific antigen binding
molecules described can also be used in combination with radiation therapy.
Articles of cture
Also described is an article of manufacture containing materials useful for the treatment,
prevention and/or diagnosis of the disorders described above. The article of manufacture
comprises a container and a label or package insert on or associated with the container. Suitable
containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers
may be formed from a variety of materials such as glass or c. The container holds a
ition which is by itself or combined with another composition effective for treating,
preventing and/or diagnosing the condition and may have a sterile access port (for example the
container may be an intravenous solution bag or a vial having a stopper able by a
rmic injection needle). At least one active agent in the composition is a T cell activating
bispecific n g molecule bed. The label or package insert indicates that the
composition is used for treating the condition of choice. Moreover, the article of manufacture
may se (a) a first container with a composition contained therein, wherein the
composition comprises a T cell activating bispecific antigen binding molecule described; and (b)
a second container with a composition contained therein, wherein the composition comprises a
r cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment
may further comprise a package insert indicating that the compositions can be used to treat a
particular condition. Alternatively, or onally, the article of manufacture may further
comprise a second (or third) container sing a ceutically-acceptable buffer, such as
bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and
dextrose solution. It may further include other materials desirable from a commercial and user
standpoint, including other buffers, ts, filters, needles, and syringes.
Examples
The following are es of methods and compositions described. It is understood that various
other embodiments may be practiced, given the general description provided above.
General methods
Recombinant DNA Techniques
Standard methods were used to manipulate DNA as described in Sambrook et al., Molecular
cloning: A tory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New
York, 1989. The lar biological reagents were used according to the manufacturers’
instructions. General information regarding the nucleotide sequences of human globulins
light and heavy chains is given in: Kabat, E.A. et al., (1991) Sequences of Proteins of
Immunological Interest, 5th ed., NIH Publication No. 2.
DNA Sequencing
DNA sequences were determined by double strand cing.
Gene Synthesis
Desired gene segments where required were either generated by PCR using appropriate
templates or were synthesized by Geneart AG (Regensburg, Germany) from synthetic
oligonucleotides and PCR ts by automated gene synthesis. In cases where no exact gene
sequence was available, oligonucleotide primers were designed based on sequences from closest
homologues and the genes were isolated by RT-PCR from RNA originating from the appropriate
tissue. The gene segments flanked by singular restriction endonuclease cleavage sites were
cloned into standard cloning / cing vectors. The plasmid DNA was purified from
transformed bacteria and concentration determined by UV spectroscopy. The DNA sequence of
the subcloned gene fragments was confirmed by DNA sequencing. Gene segments were
designed with suitable restriction sites to allow sub-cloning into the respective expression
vectors. All constructs were ed with a 5’-end DNA sequence coding for a leader peptide
which targets proteins for secretion in eukaryotic cells. SEQ ID NOs 2 give exemplary
leader peptides and polynucleotide sequences encoding them, respectively.
ion of primary human pan T cells from PBMCs
Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density
centrifugation from enriched cyte preparations (buffy coats) obtained from local blood
banks or from fresh blood from healthy human . Briefly, blood was diluted with sterile
PBS and carefully layered over a Histopaque gradient , H8889). After centrifugation for
minutes at 450 x g at room temperature (brake switched off), part of the plasma above the
PBMC containing interphase was discarded. The PBMCs were transferred into new 50 ml
Falcon tubes and tubes were filled up with PBS to a total volume of 50 ml. The mixture was
centrifuged at room temperature for 10 minutes at 400 x g (brake switched on). The supernatant
was discarded and the PBMC pellet washed twice with sterile PBS (centrifugation steps at 4°C
for 10 minutes at 350 x g). The resulting PBMC population was counted automatically (ViCell)
and stored in RPMI1640 medium, containing 10% FCS and 1% L-alanyl-L-glutamine
(Biochrom, K0302) at 37°C, 5% CO2 in the incubator until assay start.
T cell ment from PBMCs was performed using the Pan T Cell Isolation Kit II (Miltenyi
Biotec #130156), according to the manufacturer’s instructions. Briefly, the cell pellets were
diluted in 40 µl cold buffer per 10 million cells (PBS with 0.5% BSA, 2 mM EDTA, sterile
filtered) and incubated with 10 µl Biotin-Antibody Cocktail per 10 million cells for 10 min at
4°C. 30 µl cold buffer and 20 µl Anti-Biotin magnetic beads per 10 million cells were added, and
the mixture incubated for another 15 min at 4°C. Cells were washed by adding 10-20x the
current volume and a uent centrifugation step at 300 x g for 10 min. Up to 100 n
cells were resuspended in 500 µl buffer. Magnetic separation of unlabeled human pan T cells
was performed using LS columns (Miltenyi Biotec #130401) according to the
cturer’s instructions. The resulting T cell population was counted automatically (ViCell)
and stored in AIM-V medium at 37°C, 5% CO2 in the tor until assay start (not longer than
24 h).
Isolation of primary human naive T cells from PBMCs
Peripheral blood mononuclar cells (PBMCs) were ed by Histopaque density centrifugation
from ed lymphocyte preparations (buffy coats) obtained from local blood banks or from
fresh blood from healthy human donors. T-cell enrichment from PBMCs was performed using
the Naive CD8+ T cell isolation Kit from Miltenyi Biotec (#130244), ing to the
manufacturer’s instructions, but skipping the last isolation step of CD8+ T cells (also see
description for the isolation of primary human pan T cells).
Isolation of murine pan T cells from splenocytes
Spleens were isolated from C57BL/6 mice, transferred into a MACS C-tube (Miltenyi
h #130237) containing MACS buffer (PBS + 0.5% BSA + 2 mM EDTA) and
dissociated with the GentleMACS Dissociator to obtain single-cell suspensions according to the
manufacturer’s instructions. The cell suspension was passed through a paration filter to
remove remaining undissociated tissue particles. After fugation at 400 x g for 4 min at 4°C,
ACK Lysis Buffer was added to lyse red blood cells (incubation for 5 min at room temperature).
The ing cells were washed with MACS buffer twice, counted and used for the isolation of
murine pan T cells. The negative (magnetic) selection was performed using the Pan T Cell
Isolation Kit from Miltenyi Biotec (#130861), following the manufacturer’s instructions.
The resulting T cell population was tically counted (ViCell) and immediately used for
further assays.
Isolation of primary cynomolgus PBMCs from heparinized blood
Peripheral blood mononuclar cells (PBMCs) were prepared by density centrifugation from fresh
blood from healthy cynomolgus , as follows: nized blood was diluted 1:3 with
sterile PBS, and Lymphoprep medium (Axon Lab #1114545) was d to 90% with sterile
PBS. Two volumes of the diluted blood were layered over one volume of the diluted density
gradient and the PBMC on was separated by centrifugation for 30 min at 520 x g, without
brake, at room temperature. The PBMC band was transferred into a fresh 50 ml Falcon tube and
washed with sterile PBS by centrifugation for 10 min at 400 x g at 4°C. One low-speed
centrifugation was performed to remove the platelets (15 min at 150 x g, 4°C), and the resulting
PBMC population was automatically counted (ViCell) and immediately used for further .
Target cells
For the assessment of argeting bispecific antigen g molecules, the following tumor
cell lines were used: the human melanoma cell line WM266-4 (ATCC 676), derived
from a metastatic site of a ant melanoma and expressing high levels of human MCSP; and
the human melanoma cell line MV-3 (a kind gift from The Radboud University Nijmegen
Medical Centre), expressing medium levels of human MCSP.
For the assessment of CEA-targeting bispecific antigen g molecules, the following tumor
cell lines were used: the human gastric cancer cell line MKN45 (DSMZ #ACC 409), expressing
very high levels of human CEA; the human female Caucasian colon adenocarcinoma cell line
LS-174T (ECACC #87060401), expressing medium to low levels of human CEA; the human
epithelioid pancreatic carcinoma cell line Panc-1 (ATCC #CRL-1469), expressing (very) low
levels of human CEA; and a murine colon carcinoma cell line MC38-huCEA, that was
engineered in-house to stably express human CEA.
In on, a human T cell leukaemia cell line, Jurkat (ATCC #TIB-152), was used to assess
binding of different bispecific constructs to human CD3 on cells.
Example 1
Preparation, purification and characterization of bispecific antigen binding molecules
The heavy and light chain variable region sequences were subcloned in frame with either the
constant heavy chain or the constant light chain pre-inserted into the respective recipient
mammalian sion vector. The antibody expression was driven by an MPSV promoter and a
synthetic polyA signal sequence is located at the 3’ end of the CDS. In addition each vector
contained an EBV OriP sequence.
The molecules were produced by co-transfecting HEK293 EBNA cells with the mammalian
expression vectors. Exponentially growing HEK293 EBNA cells were transfected using the
calcium phosphate method. Alternatively, HEK293 EBNA cells growing in sion were
transfected using polyethylenimine (PEI). For preparation of “1+1 IgG scFab, one armed / one
armed inverted” constructs, cells were ected with the corresponding expression vectors in a
1:1:1 ratio (“vector heavy chain” : r light chain” : “vector heavy chain-scFab”). For
preparation of “2+1 IgG scFab” constructs, cells were transfected with the corresponding
sion vectors in a 1:2:1 ratio (“vector heavy chain” : “vector light chain” : “vector heavy
chain-scFab”). For ation of “1+1 IgG Crossfab” constructs, cells were transfected with the
corresponding expression vectors in a 1:1:1:1 ratio (“vector second heavy chain” : “vector first
light chain” : “vector light chain ab” : “vector first heavy chain-heavy chain Crossfab”).
For preparation of “2+1 IgG Crossfab” constructs cells were transfected with the corresponding
expression vectors in a 1:2:1:1 ratio (“vector second heavy chain” : “vector light chain” : “vector
first heavy chain-heavy chain Crossfab)” : “vector light chain Crossfab”. For preparation of the
“2+1 IgG Crossfab, linked light chain” construct, cells were transfected with the ponding
expression vectors in a 1:1:1:1 ratio (“vector heavy chain” : “vector light chain” : r heavy
chain (CrossFab-Fab-Fc)” : “vector linked light chain”). For preparation of the “1+1 CrossMab”
construct, cells were transfected with the corresponding expression s in a 1:1:1:1 ratio
(“vector first heavy chain” : “vector second heavy chain” : “vector first light chain” : r
second light chain”). For preparation of the “1+1 IgG Crossfab light chain fusion ” construct,
cells were transfected with the corresponding expression vectors in a 1:1:1:1 ratio (“vector first
heavy chain” : r second heavy chain” : r light chain Crossfab” : “vector second light
For transfection using calcium phosphate cells were grown as adherent monolayer cultures in T-
flasks using DMEM culture medium supplemented with 10 % (v/v) FCS, and transfected when
they were between 50 and 80 % confluent. For the transfection of a T150 flask, 15 million cells
were seeded 24 hours before transfection in 25 ml DMEM culture medium supplemented with
FCS (at 10% v/v final), and cells were placed at 37°C in an incubator with a 5% CO2 atmosphere
overnight. For each T150 flask to be transfected, a solution of DNA, CaCl2 and water was
prepared by mixing 94 µg total plasmid vector DNA divided in the corresponding ratio, water to
a final volume of 469 µl and 469 µl of a 1 M CaCl2 solution. To this solution, 938 µl of a 50 mM
HEPES, 280 mM NaCl, 1.5 mM Na2HPO4 solution at pH 7.05 were added, mixed immediately
for 10 s and left to stand at room ature for 20 s. The suspension was diluted with 10 ml of
DMEM supplemented with 2 % (v/v) FCS, and added to the T150 in place of the existing
medium. Subsequently, additional 13 ml of transfection medium were added. The cells were
incubated at 37°C, 5% CO2 for about 17 to 20 hours, then medium was replaced with 25 ml
DMEM, 10 % FCS. The conditioned e medium was harvested approximately 7 days postmedia
exchange by centrifugation for 15 min at 210 x g, sterile filtered (0.22 m filter),
supplemented with sodium azide to a final concentration of 0.01 % (w/v), and kept at 4°C.
For transfection using polyethylenimine (PEI) HEK293 EBNA cells were cultivated in
suspension in serum free CD CHO culture . For the production in 500 ml shake flasks,
400 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection
cells were fuged for 5 min at 210 x g, and supernatant was replaced by 20 ml pre-warmed
CD CHO medium. Expression vectors were mixed in 20 ml CD CHO medium to a final amount
of 200 μg DNA. After addition of 540 μl PEI, the mixture was vortexed for 15 s and
subsequently incubated for 10 min at room ature. Afterwards cells were mixed with the
DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours at 37°C in an
incubator with a 5% CO2 atmosphere. After the incubation time 160 ml F17 medium was added
and cells were cultivated for 24 hours. One day after transfection 1 mM valproic acid and 7%
Feed 1 (Lonza) were added. After a cultivation of 7 days, supernatant was collected for
purification by centrifugation for 15 min at 210 x g, the solution was sterile filtered (0.22 μm
filter), supplemented with sodium azide to a final concentration of 0.01 % w/v, and kept at 4°C.
The secreted proteins were ed from cell e supernatants by Protein A affinity
chromatography, followed by a size exclusion chromatography step.
For affinity chromatography supernatant was loaded on a HiTrap ProteinA HP column (CV = 5
ml, GE Healthcare) equilibrated with 25 ml 20 mM sodium phosphate, 20 mM sodium e,
pH 7.5 or 40 ml 20 mM sodium ate, 20 mM sodium e, 0.5 M sodium chloride, pH
7.5. Unbound n was removed by washing with at least ten column volumes 20 mM sodium
phosphate, 20 mM sodium citrate, 0.5 M sodium chloride pH 7.5, followed by an additional
wash step using six column volumes 10 mM sodium phosphate, 20 mM sodium citrate, 0.5 M
sodium de pH 5.45. Subsequently, the column was washed with 20 ml 10 mM MES,
100 mM sodium chloride, pH 5.0, and target protein was eluted in six column volumes 20 mM
sodium citrate, 100 mM sodium chloride, 100 mM glycine, pH 3.0. Alternatively, target protein
was eluted using a gradient over 20 column volumes from 20 mM sodium citrate, 0.5 M sodium
chloride, pH 7.5 to 20 mM sodium citrate, 0.5 M sodium chloride, pH 2.5. The protein on
was neutralized by adding 1/10 of 0.5 M sodium phosphate, pH 8. The target protein was
concentrated and filtrated prior to loading on a HiLoad Superdex 200 column (GE Healthcare)
equilibrated with 25 mM potassium phosphate, 125 mM sodium chloride, 100 mM glycine
solution of pH 6.7. For the purification of 1+1 IgG ab the column was equilibrated with 20
mM ine, 140 mM sodium chloride solution of pH 6.0.
The protein concentration of purified n samples was determined by measuring the optical
density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the
amino acid sequence. Purity and molecular weight of the bispecific constructs were analyzed by
SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and
staining with Coomassie (SimpleBlue™ ain from Invitrogen) using the NuPAGE® Pre-
Cast gel system (Invitrogen, USA) was used according to the manufacturer’s instructions (4-12%
cetate gels or 4-12% Bis-Tris). Alternatively, purity and molecular weight of molecules
were analyzed by CE-SDS analyses in the presence and e of a reducing agent, using the
Caliper p GXII system (Caliper Lifescience) according to the manufacturer’s instructions.
The aggregate content of the protein samples was analyzed using a Superdex 200 10/300GL
analytical size-exclusion chromatography column (GE care) in 2 mM MOPS, 150 mM
NaCl, 0.02% (w/v) NaN3, pH 7.3 running buffer at 25°C. Alternatively, the ate content of
antibody samples was analyzed using a TSKgel G3000 SW XL analytical size-exclusion column
(Tosoh) in 25 mM K2HPO4, 125 mM NaCl, 200 mM L-arginine monohydrocloride, 0.02% (w/v)
NaN3, pH 6.7 g buffer at 25°C.
Figures 2-14 show the results of the SDS PAGE and analytical size exclusion chromatography
and Table 2A shows the yields, aggregate content after Protein A, and final monomer content of
the preparations of the different bispecific constructs.
Figure 47 shows the result of the CE-SDS analyses of the anti-CD3/anti-MCSP bispecific “2+1
IgG Crossfab, linked light chain” construct (see SEQ ID NOs 3, 5, 29 and 179). 2 µg sample was
used for analyses. Figure 48 shows the result of the analytical size exclusion tography of
the final product (20 µg sample injected).
Figure 54 shows the results of the CE-SDS and SDS PAGE analyses of various constructs, and
Table 2A shows the yields, aggregate content after n A and final monomer t of the
preparations of the different bispecific constructs.
TABLE 2A. Yields, aggregate content after Protein A and final r content.
Construct Yield Aggregate HMW LMW Monomer
[mg/l] content after [%] [%] [%]
Protein A [%]
MCSP
2+1 IgG Crossfab; VH/VL 12.8 2.2 0 0 100
exchange (LC007/V9)
(SEQ ID NOs 3, 5, 29, 33)
2+1 IgG Crossfab; VH/VL 3.2 5.7 0.4 0 99.6
exchange (LC007/FN18)
(SEQ ID NOs 3, 5, 35, 37)
2+1 IgG scFab, P329G LALA 11.9 23 0.3 0 99.7
(SEQ ID NOs 5, 21, 23)
2+1 IgG scFab, LALA 9 23 0 0 100
(SEQ ID NOs 5, 17, 19)
2+1 IgG scFab, P329G LALA 12.9 32.7 0 0 100
N297D (SEQ ID NOs 5, 25, 27)
2+1 IgG scFab, wt 15.5 31.8 0 0 100
(SEQ ID NOs 5, 13, 15)
1+1 IgG scFab 7 24.5 0 0 100
(SEQ ID NOs 5, 21, 213)
1+1 IgG scFab “one armed” 7.6 43.7 2.3 0 97.7
(SEQ ID NOs 1, 3, 5)
1+1 IgG scFab “one armed 1 27 7.1 9.1 83.8
inverted” (SEQ ID NOs 7, 9, 11)
1+1 IgG Crossfab; VH/VL 9.8 0 0 0 100
exchange (LC007/V9)
(SEQ ID NOs 5, 29, 31, 33)
2+1 IgG Crossfab, linked light 0.54 40 1.4 0 98.6
chain; VL/VH ge
(LC007/V9)
(SEQ ID NOs 3, 5, 29, 179)
1+1 IgG Crossfab; VL/VH 6.61 8.5 0 0 100
exchange (LC007/V9)
(SEQ ID NOs 5, 29, 33, 181)
1+1 CrossMab; CL/CH1 exchange 6.91 10.5 1.3 1.7 97
(LC00/V9)
(SEQ ID NOs 5, 23, 183, 185)
2+1 IgG ab, inverted; 9.45 6.1 0.8 0 99.2
CL/CH1 exchange (LC007/V9)
(SEQ ID NOs 5, 23, 183, 187)
2+1 IgG Crossfab; VL/VH 36.6 0 9.5 35.3 55.2
exchange (M4-3 ML2/V9)
(SEQ ID NOs 33, 189, 191, 193)
2+1 IgG Crossfab; CL/CH1 2.62 12 2.8 0 97.2
exchange (M4-3 ML2/V9)
(SEQ ID NOs 183, 189, 193, 195)
2+1 IgG ab; CL/CH1 29.75 0 0 0 100
exchange (M4-3 ML2/H2C)
(SEQ ID NOs 189, 193, 199, 201)
2+1 IgG Crossfab; CL/CH1 1.2 0 1.25 1.65 97.1
exchange (LC007/anti-CD3)
(SEQ ID NOs 5, 23, 215, 217)
2+1 IgG Crossfab, inverted; 7.82 0.5 0 0 100
CL/CH1 exchange (LC007/anti-
CD3)
(SEQ ID NOs 5, 23, 215, 219)
EGFR
2+1 IgG scFab 5.2 53 0 30 70
(SEQ ID NOs 45, 47, 53)
1+1 IgG scFab 3.4 66.6 0 1.6 98.4
(SEQ ID NOs 47, 53, 213)
1+1 IgG scFab “one armed” 9.05 60.8 0 0 100
(SEQ ID NOs 43, 45, 47)
1+1 IgG scFab “one armed 3.87 58.8 0 0 100
inverted” (SEQ ID NOs 11, 49, 51)
2+1 IgG scFab 12.57 53 0 0 100
(SEQ ID NOs 57, 59, 61)
1+1 IgG scFab 17.95 41 0.4 0 99.6
(SEQ ID NOs 57, 61, 213)
1+1 IgG scFab “one armed 2.44 69 0.6 0 99.4
ed” (SEQ ID NOs 11, 51, 55)
2+1 IgG Crossfab, inverted; VL/VH 0.34 13 4.4 0 95.6
exchange (CH1A1A/V9)
(SEQ ID NOs 33, 63, 65, 67)
2+1 IgG Crossfab, inverted; 12.7 43 0 0 100
CL/CH1 exchange (CH1A1A/V9)
(SEQ ID NOs 65, 67, 183, 197)
2+1 IgG Crossfab, inverted; 7.1 20 0 0 100
CL/CH1 exchange (431/26/V9)
(SEQ ID NOs 183, 203, 205, 207)
1+1 IgG-Crossfab light chain fusion 7.85 27 4.3 3.2 92.5
(CH1A1A/V9)
(SEQ ID NOs 183, 209, 211, 213)
As controls, bispecific antigen binding molecules were generated in the prior art tandem scFv
format (“(scFv)2”) and by fusing a tandem scFv to an Fc domain (“(scFv)2-Fc”). The molecules
were produced in HEK293-EBNA cells and purified by Protein A affinity chromatography
followed by a size exclusion chromatographic step in an analogous manner as described above
for the bispecific antigen g molecules described. Due to high ate formation, some of
the samples had to be further purified by applying eluted and concentrated samples from the
HiLoad Superdex 200 column (GE Healthcare) to a Superdex 10/300 GL column (GE
Healthcare) brated with 20 mM histidine, 140 mM sodium chloride, pH 6.7 in order to
obtain protein with high monomer t. Subsequently, protein concentration, purity and
molecular weight, and ate content were determined as bed above.
Yields, aggregate content after the first purification step, and final r content for the
control molecules is shown in Table 2B. Comparison of the aggregate content after the first
purification step (Protein A) indicates the superior ity of the IgG Crossfab and IgG scFab
constructs compared to the “(scFv)2-Fc” and the disulfide bridge-stabilized “(dsscFv)2-Fc”
molecules.
TABLE 2B. Yields, aggregate content after Protein A and final monomer t.
Construct Yield Aggregates after Final
[mg/l] ProteinA [%]
HMW LMW Monomer
[%] [%] [%]
(scFv)2-Fc 76.5 40 0.5 0 99.5
(antiMCSP/anti huCD3)
v)2-Fc 2.65 48 7.3 8.0 84.7
(antiMCSP/anti huCD3)
Thermal stability of the proteins was monitored by Dynamic Light Scattering (DLS). 30 g of
ed protein sample with a protein concentration of 1 mg/ml was applied in duplicate to a
Dynapro plate reader (Wyatt Technology Corporation; USA). The temperature was ramped from
to75°C at 0.05°C/min, with the radius and total scattering intensity being ted. The
results are shown in Figure 15 and Table 2C. For the “(scFv)2-Fc” (antiMCSP/anti huCD3)
molecule two aggregation points were observed, at 49°C and 68°C. The “(dsscFv)2-Fc” construct
has an sed aggregation temperature (57°C) as a result of the introduced disulfide bridge
(Figure 15A, Table 2C). Both, the “2+1 IgG scFab” and the “2+1 IgG Crossfab” constructs are
aggregating at temperatures higher than 60°C, demonstrating their superior l stability as
compared to the “(scFv)2-Fc” and Fv)2-Fc” s (Figure 15B, Table 2C).
TABLE 2C. Thermal stability determined by dynamic light scattering.
Construct Tagg [°C]
2+1 IgG scFab (LC007/V9) 68
2+1 IgG Crossfab (LC007/V9) 65
Fc-(scFv)2 (LC007/V9) 49/68
Fc-(dsscFv)2 (LC007/V9) 57
Example 2
Surface Plasmon resonance analysis of Fc receptor and target antigen binding
Method
All surface plasmon resonance (SPR) experiments are performed on a Biacore T100 at 25°C
with HBS-EP as g buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005%
Surfactant P20, Biacore, Freiburg/Germany).
Analysis of FcR binding of different Fc-variants
The assay setup is shown in Figure 16A. For analyzing interaction of different Fc-variants with
human FcγRIIIa-V158 and murine FcγRIV direct ng of around 6,500 resonance units (RU)
of the anti-Penta His antibody (Qiagen) is med on a CM5 chip at pH 5.0 using the standard
amine coupling kit (Biacore, Freiburg/Germany). HuFcγRIIIa-V158-K6H6 and muFcγRIV-
aviHis-biotin are captured for 60 s at 4 and 10 nM respectively.
Constructs with different Fc-mutations are passed h the flow cells for 120 s at a
concentration of 1000 nM with a flow rate of 30 μl/min. The dissociation is monitored for 220 s.
Bulk refractive index differences are corrected for by subtracting the response obtained in a
reference flow cell. Here, the Fc-variants are flown over a surface with immobilized anti-Penta
His antibody but on which HBS-EP has been injected rather than HuFcγRIIIa-V158-K6H6 or
IV-aviHis-biotin. Affinity for human FcγRIIIa-V158 and murine FcγRIV was
determined for wild-type Fc using a concentration range from 500 – 4000 nM.
The steady state response was used to derive the dissociation constant KD by non-linear curve
fitting of the Langmuir binding isotherm. Kinetic constants were derived using the Biacore T100
tion Software (vAA, e AB, a/Sweden), to fit rate equations for 1:1 Langmuir
binding by numerical integration.
Result
The interaction of Fc variants with human FcγRIIIa and murine FcγRIV was monitored by
surface plasmon resonance. Binding to captured IIIa-V158-K6H6 and muFcγRIV-
aviHis-biotin is significantly reduced for all analyzed Fc mutants as compared to the construct
with a wild-type (wt) Fc domain.
The Fc mutants with the lowest binding to the human Fcγ-receptor were P329G L234A L235A
(LALA) and P329G LALA N297D. The LALA on alone was not enough to abrogate
binding to huFcγRIIIa-V158-K6H6. The Fc variant carrying only the LALA mutation had a
residual binding affinity to human FcγRIIIa of 2.100 nM, while the wt Fc bound the human
FcγRIIIa receptor with an affinity of 600 nM (Table 3). Both KD values were derived by 1:1
binding model, using a single tration.
ty to human FcγRIIIa-V158 and murine FcγRIV could only be analyzed for wt Fc. KD
values are listed in Table 3. Binding to the murine FcγRIV was almost completely eliminated for
all analyzed Fc mutants.
TABLE 3. Affinity of Fc-variants to the human FcγRIIIa-V158 and murine FcγRIV.
KD in nM human FcγRIIIa-V158 murine FcγRIV
T = 25°C
kinetic steady state kinetic steady state
Fc-wt 600* (1200) 3470 576 1500
(SEQ ID NOs 5, 13, 15)
Fc-LALA 2130* n.d. n.d.
(SEQ ID NOs 5, 17, 19)
Fc-P329G LALA n.d. n.d.
(SEQ ID NOs 5, 21, 23)
Fc-P329G LALA N297D n.d. n.d.
(SEQ ID NOs 5, 25, 27)
*determined using one concentration (1000 nM)
Analysis of simultaneous binding to tumor antigen and CD3
Analysis of simultaneous binding of the T-cell bispecific constructs to the tumor antigen and the
human CD3ε was performed by direct coupling of 1650 resonance units (RU) of biotinylated D3
domain of MCSP on a sensor chip SA using the standard coupling procedure. Human EGFR was
immobilized using standard amino coupling procedure. 8000 RU were immobilized on a CM5
sensor chip at pH 5.5. The assay setup is shown in Figure 16B.
Different T-cell bispecific constructs were captured for 60 s at 200 nM. Human
CD3γ(G4S)5CD3ε–AcTev–Fc(knob)–Avi/Fc(hole) was subsequently passed at a concentration of
2000 nM and a flow rate of 40 μl/min for 60 s. Bulk refractive index differences were corrected
for by subtracting the response obtained on a nce flow cell where the recombinant CD3ε
was flown over a surface with immobilized D3 domain of MCSP or EGFR without captured T-
cell bispecific constructs.
Result
Simultaneous binding to both tumor antigen and human CD3ε was ed by surface plasmon
resonance (Figure 17, Figure 18). All constructs were able to bind the tumor antigen and the
CD3 simultaneously. For most of the constructs the binding level (RU) after injection of human
CD3ε was higher than the binding level achieved after injection of the construct alone ting
that both tumor antigen and the human CD3ε were bound to the construct.
Example 3
Binding of bispecific constructs to the respective target antigen on cells
Binding of the different bispecific ucts to CD3 on Jurkat cells (ATCC 52), and the
respective tumor n on target cells, was determined by FACS. Briefly, cells were harvested,
counted and checked for ity. 0.15 – 0.2 million cells per well (in PBS containing 0.1%
BSA; 90 µl) were plated in a bottom 96-well plate and incubated with the indicated
tration of the bispecific constructs and corresponding IgG controls (10 µl) for 30 min at
4°C. For a better comparison, all constructs and IgG controls were normalized to same molarity.
After the incubation, cells were centrifuged (5 min, 350 x g), washed with 150 µl PBS
containing 0.1% BSA, resuspended and incubated for further 30 min at 4°C with 12 µl/well of a
FITC-or PE-conjugated secondary antibody. Bound constructs were detected using a
FACSCantoII (Software FACS Diva). The “(scFv)2” molecule was detected using a FITC-
conjugated anti-His antibody (Lucerna, 45F-Z). For all other les, a FITC- or PE-
conjugated AffiniPure F(ab’)2 Fragment goat uman IgG Fcγ Fragment Specific (Jackson
Immuno Research Lab # 109098 / g solution 1:20, or #109170 / working
solution 1:80, respectively) was used. Cells were washed by addition of 120 µl/well PBS
containing 0.1% BSA and centrifugation at 350 x g for 5 min. A second washing step was
performed with 150 µl/well PBS containing 0.1% BSA. Unless otherwise indicated, cells were
fixed with 100 µl/well fixation buffer (BD #554655) for 15 min at 4°C in the dark, centrifuged
for 6 min at 400 x g and kept in 200 µl/well PBS containing 0.1% BSA until the samples were
measured with FACS CantoII. EC50 values were calculated using the GraphPad Prism re.
In a first experiment, different bispecific constructs targeting human MCSP and human CD3
were analyzed by flow cytometry for binding to human CD3 expressed on Jurkat, human T cell
leukaemia cells, or to human MCSP on Colo-38 human melanoma cells.
Results are presented in Figure 19-21, which show the mean fluorescence intensity of cells that
were incubated with the bispecific molecule, l IgG, the secondary antibody only, or left
untreated.
As shown in Figure 19, for both n binding moieties of the “(scFv)2” molecule, i.e. CD3
e 191A) and MCSP (Figure 19B), a clear binding signal is observed compared to the
control samples.
The “2+1 IgG scFab” molecule (SEQ ID NOs 5, 17, 19) shows good binding to huMCSP on
Colo-38 cells (Figure 20A). The CD3 moiety binds CD3 slightly better than the reference antihuman
CD3 IgG (Figure 20B).
As depicted in Figure 21A, the two “1+1” constructs show comparable binding s to human
CD3 on cells. The reference anti-human CD3 IgG gives a slightly weaker signal. In addition,
both constructs tested (“1+1 IgG scFab, one-armed” (SEQ ID NOs 1, 3, 5) and “1+1 IgG scFab,
med ed” (SEQ ID NOs 7, 9, 11)) show able g to human MCSP on cells
(Figure 21B). The binding signal obtained with the reference anti-human MCSP IgG is slightly
weaker.
In another experiment, the ed “2+1 IgG scFab” bispecific construct (SEQ ID NOs 5, 17, 19)
and the corresponding anti human MCSP IgG were analyzed by flow cytometry for dosedependent
binding to human MCSP on Colo-38 human melanoma cells, to determine whether
the bispecific construct binds to MCSP via one or both of its “arms”. As depicted in Figure 22,
the “2+1 IgG scFab” construct shows the same binding pattern as the MCSP IgG.
In yet another experiment, the binding of CD3/CEA “2+1 IgG Crossfab, ed” bispecific
constructs with either a VL/VH (see SEQ ID NOs 33, 63, 65, 67) or a CL/CH1 exchange (see
SEQ ID NOs 66, 67, 183, 197) in the Crossfab fragment to human CD3, expressed by Jurkat
cells, or to human CEA, expressed by LS-174T cells, was assessed. As a control, the equivalent
maximum concentration of the corresponding IgGs and the background staining due to the
labeled 2ndary antibody (goat anti-human FITC-conjugated AffiniPure F(ab’)2 Fragment, Fcγ
Fragment-specific, Jackson Immuno Research Lab # 109098) were assessed as well. As
illustrated in Figure 55, both ucts show good binding to human CEA, as well as to human
CD3 on cells. The ated EC50 values were 4.6 and 3.9 nM (CD3), and 9.3 and 6.7 nM
(CEA) for the “2+1 IgG Crossfab, inverted (VL/VH)” and the “2+1 IgG Crossfab, inverted
(CL/CH1)” constructs, respectively.
In another experiment, the binding of CD3/MCSP “2+1 IgG ab” (see SEQ ID NOs 3, 5, 29,
33) and “2+1 IgG Crossfab, inverted” (see SEQ ID NOs 5, 23, 183, 187) constructs to human
CD3, expressed by Jurkat cells, or to human MCSP, expressed by WM266-4 cells, was assessed.
Figure 56 shows that, while binding of both constructs to MCSP on cells was comparably good,
the binding of the “inverted” construct to CD3 was reduced compared to the other construct. The
calculated EC50 values were 6.1 and 1.66 nM (CD3), and 0.57 and 0.95 nM (MCSP) for the
“2+1 IgG Crossfab, inverted” and the “2+1 IgG Crossfab” constructs, tively.
In a further ment, binding of the “1+1 IgG Crossfab light chain (LC) fusion” construct
(SEQ ID NOs 183, 209, 211, 213) to human CD3, expressed by Jurkat cells, and to human CEA,
expressed by LS-174T cells was ined. As a l, the equivalent maximum
concentration of the corresponding D3 and anti-CEA IgGs and the background staining
due to the d 2ndary antibody (goat anti-human FITC-conjugated AffiniPure F(ab’)2
Fragment, Fcγ Fragment-specific, Jackson Immuno Research Lab #109098) were assessed
as well. As depicted in Figure 57, the binding of the “1+1 IgG Crossfab LC fusion” to CEA
appears to be greatly reduced, whereas the binding to CD3 was at least able to the
reference IgG.
In a final experiment, binding of the “2+1 IgG Crossfab” (SEQ ID NOs 5, 23, 215, 217) and the
“2+1 IgG ab, inverted” (SEQ ID NOs 5, 23, 215, 219) constructs to human CD3,
expressed by Jurkat cells, and to human MCSP, expressed by WM266-4 tumor cells was
determined. As depicted in Figure 58 the g to human CD3 was reduced for the “2+1 IgG
Crossfab, inverted” compared to the other construct, but the binding to human MCSP was
comparably good. The calculated EC50 values were 10.3 and 32.0 nM (CD3), and 3.1 and 3.4
nM (MCSP) for the “2+1 IgG Crossfab” and the “2+1 IgG Crossfab, inverted” uct,
respectively.
Example 4
FACS analysis of surface tion markers on primary
human T cells upon engagement of bispecific constructs
The purified huMCSP-huCD3-targeting bispecific “2+1 IgG scFab” (SEQ ID NOs 5, 17, 19) and
“(scFv)2” molecules were tested by flow cytometry for their ial to up-regulate the early
surface activation marker CD69, or the late activation marker CD25 on CD8+ T cells in the
ce of human MCSP-expressing tumor cells.
Briefly, MCSP-positive Colo-38 cells were harvested with Cell Dissociation buffer, counted and
checked for viability. Cells were adjusted to 0.3 x 106 (viable) cells per ml in AIM-V medium,
100 µl of this cell suspension per well were pipetted into a bottom 96-well plate (as
indicated). 50 µl of the (diluted) bispecific construct were added to the cell-containing wells to
obtain a final concentration of 1 nM. Human PBMC effector cells were isolated from fresh blood
of a healthy donor and adjusted to 6 x 106 (viable) cells per ml in AIM-V medium. 50 µl of this
cell suspension was added per well of the assay plate (see above) to obtain a final E:T ratio of
:1. To analyze whether the bispecific constructs are able to activate T cells exclusively in the
presence of target cells expressing the tumor antigen huMCSP, wells were included that
contained 1 nM of the respective bispecific molecules, as well as PBMCs, but no target cells.
After incubation for 15 h (CD69), or 24 h (CD25) at 37°C, 5% CO2, cells were centrifuged (5
min, 350 x g) and washed twice with 150 l PBS containing 0.1% BSA. Surface staining
for CD8 (mouse IgG1,κ; clone HIT8a; BD #555635), CD69 (mouse IgG1; clone L78; BD
0) and CD25 (mouse IgG1,ĸ; clone M-A251; BD #555434) was med at 4°C for 30
min, according to the supplier’s suggestions. Cells were washed twice with 150 µl/well PBS
containing 0.1% BSA and fixed for 15 min at 4°C, using 100 µl/well fixation buffer (BD
#554655). After centrifugation, the s were resuspended in 200 µl/well PBS with 0.1%
BSA and analyzed using a FACS I machine (Software FACS Diva).
Figure 23 depicts the expression level of the early activation marker CD69 (A), or the late
activation marker CD25 (B) on CD8+ T cells after 15 hours or 24 hours incubation, respectively.
Both constructs induce up-regulation of both activation markers exclusively in the presence of
target cells. The “(scFv)2” molecule seems to be slightly more active in this assay than the “2+1
IgG scFab” construct.
The ed huMCSP-huCD3-targeting bispecific “2+1 IgG scFab” and “(scFv)2” molecules
were further tested by flow cytometry for their ial to up-regulate the late tion marker
CD25 on CD8+ T cells or CD4+ T cells in the presence of human MCSP-expressing tumor cells.
Experimental procedures were as described above, using human pan T effector cells at an E:T
ratio of 5:1 and an incubation time of five days.
Figure 24 shows that both constructs induce up-regulation of CD25 exclusively in the presence
of target cells on both, CD8+ (A) as well as CD4+ (B) T cells. The “2+1 IgG scFab” construct
seems to induce less up-regulation of CD25 in this assay, compared to the “(scFv)2” molecule. In
general, the up-regulation of CD25 is more nced on CD8+ than on CD4+ T cells.
In another experiment, purified “2+1 IgG Crossfab” targeting cynomolgus CD3 and human
MCSP (SEQ ID NOs 3, 5, 35, 37) was analyzed for its potential to up-regulate the surface
activation marker CD25 on CD8+ T cells in the presence of tumor target cells. Briefly, human
MCSP-expressing MV-3 tumor target cells were harvested with Cell Dissociation Buffer,
washed and resuspendend in DMEM containing 2% FCS and 1% GlutaMax. 30 000 cells per
well were plated in a round-bottom 96-well plate and the respective antibody dilution was added
at the indicated concentrations (Figure 25). The bispecific uct and the different IgG
controls were adjusted to the same molarity. Cynomolgus PBMC effector cells, isolated from
blood of two healthy animals, were added to obtain a final E:T ratio of 3:1. After an incubation
for 43 h at 37°C, 5% CO2, the cells were centrifuged at 350 x g for 5 min and washed twice with
PBS, containing 0.1% BSA. Surface staining for CD8 (Miltenyi Biotech #130601) and
CD25 (BD 8) was performed according to the er’s suggestions. Cells were washed
twice with 150 µl/well PBS containing 0.1% BSA and fixed for 15 min at 4°C, using 100 µl/well
fixation buffer (BD #554655). After centrifugation, the samples were resuspended in 200 µl/well
PBS with 0.1% BSA and analyzed using a FACS I machine (Software FACS Diva).
As depicted in Figure 25, the ific construct induces tration-dependent up-regulation
of CD25 on CD8+ T cells only in the presence of target cells. The anti cyno CD3 IgG (clone FN-
18) is also able to induce up-regulation of CD25 on CD8+ T cells, without being crosslinked (see
data obtained with cyno Nestor). There is no hyperactivation of cyno T cells with the maximal
tration of the bispecific construct (in the absence of target cells).
In another experiment, the CD3-MCSP “2+1 IgG Crossfab, linked light chain” (see SEQ ID NOs
3, 5, 29, 179) was compared to the CD3-MCSP “2+1 IgG Crossfab” (see SEQ ID NOs 3, 5, 29,
33) for its ial to up-regulate the early activation marker CD69 or the late activation marker
CD25 on CD8+ T cells in the presence of tumor target cells. Primary human PBMCs (isolated as
described above) were incubated with the indicated concentrations of bispecific constructs for at
least 22 h in the presence or absence of MCSP-positive Colo38 target cells. Briefly, 0.3 million
primary human PBMCs were plated per well of a flat-bottom 96-well plate, containing the
ositive target cells (or medium). The final effector to target cell (E:T) ratio was 10:1.
The cells were incubated with the ted concentration of the bispecific constructs and
controls for the indicated incubation times at 37°C, 5% CO2. The or cells were stained for
CD8, and CD69 or CD25 and analyzed by FACS CantoII.
Figure 53 shows the result of this ment. There were no significant differences detected for
CD69 (A) or CD25 up-regulation (B) between the two 2+1 IgG Crossfab molecules (with or
without the linked light chain).
In yet r experiment, the CD3/MCSP “2+1 IgG ab” (see SEQ ID NOs 3, 5, 29, 33)
and “1+1 IgG Crossfab” (see SEQ ID NOs 5, 29, 33, 181) constructs were compared to the “1+1
CrossMab” construct (see SEQ ID NOs 5, 23, 183, 185) for their potential to up-regulate CD69
or CD25 on CD4+ or CD8+ T cells in the presence of tumor target cells. The assay was
performed as described above, in the presence of absence of human MCSP expressing MV-3
tumor cells, with an incubation time of 24 h.
As shown in Figure 59, the “1+1 IgG Crossfab” and “2+1 IgG Crossfab” ucts d
more pronounced upregulation of activation markers than the “1+1 CrossMab” molecule.
In a final experiment, the CD3/MCSP “2+1 IgG Crossfab” (see SEQ ID NOs 5, 23, 215, 217)
and “2+1 IgG Crossfab, inverted” (see SEQ ID NOs 5, 23, 215, 219) constructs were assessed
for their potential to up-regulate CD25 on CD4+ or CD8+ T cells from two different cynomolgus
monkeys in the presence of tumor target cells. The assay was performed as described above, in
the presence of absence of human MCSP expressing MV-3 tumor cells, with an E:T ratio of 3:1
and an incubation time of about 41 h.
As shown in Figure 60, both constructs were able to up-regulate CD25 on CD4+ and CD8+ T
cells in a concentration-dependent manner, without significant difference between the two
formats. Control samples without antibody and without target cells gave a comparable signal to
the s with dy but no targets (not .
Example 5
Interferon-γ secretion upon activation of human pan T cells with CD3 bispecific constructs
Purified “2+1 IgG scFab” targeting human MCSP and human CD3 (SEQ ID NOs 5, 17, 19) was
analyzed for its potential to induce T cell activation in the ce of human MCSP-positive U-
87MG cells, measured by the release of human interferon (IFN)-γ into the supernatant. As
controls, anti-human MCSP and anti-human CD3 IgGs were used, ed to the same molarity.
Briefly, huMCSP-expressing U-87MG glioblastoma astrocytoma target cells (ECACC
02) were harvested with Cell Dissociation Buffer, washed and resuspendend in AIM-V
medium (Invitrogen #12055-091). 20 000 cells per well were plated in a round-bottom 96-wellplate
and the respective antibody dilution was added to obtain a final concentration of 1 nM.
Human pan T effector cells, isolated from Buffy Coat, were added to obtain a final E:T ratio of
:1. After an overnight incubation of 18.5 h at 37°C, 5% CO2, the assay plate was centrifuged for
min at 350 x g and the supernatant was transferred into a fresh l plate. Human IFN-γ
levels in the supernatant were measured by ELISA, according to the manufacturer’s instructions
(BD OptEIA human IFN-γ ELISA Kit II from Becton Dickinson, #550612).
As ed in Figure 26, the reference IgGs show no to weak induction of IFN-γ secretion,
whereas the “2+1 IgG scFab” construct is able to activate human T cells to secrete IFN-γ.
Example 6
Re-directed T cell cytotoxicity mediated by cross-linked bispecific constructs
targeting CD3 on T cells and MCSP or EGFR on tumor cells (LDH release assay)
In a first series of experiments, bispecific constructs targeting CD3 and MCSP were analyzed for
their ial to induce T cell-mediated apoptosis in tumor target cells upon crosslinkage of the
construct via binding of the antigen binding es to their tive target antigens on cells
es 27-38).
In one experiment purified “2+1 IgG scFab” (SEQ ID NOs 5, 21, 23) and “2+1 IgG Crossfab”
(SEQ ID NOs 3, 5, 29, 33) constructs targeting human CD3 and human MCSP, and the
corresponding “(scFv)2” molecule, were compared. Briefly, huMCSP-expressing MDA-MB-435
human melanoma target cells were harvested with Cell Dissociation Buffer, washed and
resuspendend in AIM-V medium (Invitrogen # 12055-091). 30 000 cells per well were plated in
a round-bottom 96-well plate and the respective dilution of the construct was added at the
indicated tration. All constructs and corresponding l IgGs were adjusted to the same
molarity. Human pan T effector cells were added to obtain a final E:T ratio of 5:1. As a positive
control for the activation of human pan T cells, 1 µg/ml PHA-M (Sigma #L8902; mixture of
tins isolated from Phaseolus vulgaris) was used. For ization, maximal lysis of the
target cells (= 100%) was determined by tion of the target cells with a final concentration
of 1% Triton X-100. Minimal lysis (= 0%) refers to target cells co-incubated with effector cells,
but without any construct or dy. After an ght incubation of 20 h at 37°C, 5% CO2,
LDH release of apoptotic/necrotic target cells into the supernatant was measured with the LDH
detection kit (Roche Applied Science, #11 644 793 001), according to the manufacturer’s
instructions.
As depicted in Figure 27, both “2+1” constructs induce apoptosis in target cells comparable to
the “(scFv)2” molecule.
Further, purified “2+1 IgG Crossfab” (SEQ ID NOs 3, 5, 29, 33) and “2+1 IgG scFab” constructs
differing in their Fc domain, as well as the “(scFv)2” molecule, were compared. The different
mutations in the Fc domain (L234A+L235A (LALA), P329G and/or N297D, as indicated)
reduce or abolish the (NK) effector cell function d by constructs containing a ype
(wt) Fc domain. Experimental ures were as described above.
Figure 28 shows that all constructs induce apoptosis in target cells able to the “(scFv)2”
molecule.
Figure 29 shows the result of a comparison of the purified “2+1 IgG scFab” (SEQ ID NOs 5, 17,
19) and the “(scFv)2” molecule for their potential to induce T cell-mediated apoptosis in tumor
target cells. Experimental procedures were as decribed above, using huMCSP-expressing Colo-
38 human melanoma target cells at an E:T ratio of 5:1, and an overnight incubation of 18.5 h. As
depicted in the figure, the “2+1 IgG scFab” construct shows comparable cytotoxic activity to the
“(scFv)2” molecule.
Similarly, Figure 30 shows the result of a comparison of the purified “2+1 IgG scFab” construct
(SEQ ID NOs 5, 17, 19)and the “(scFv)2” molecule, using huMCSP-expressing Colo-38 human
melanoma target cells at an E:T ratio of 5:1 and an incubation time of 18 h. As depicted in the
figure, the “2+1 IgG scFab” construct shows comparable cytotoxic activity to the (scFv)2
molecule.
Figure 31 shows the result of a comparison of the purified “2+1 IgG scFab” uct (SEQ ID
NOs 5, 17, 19) and the “(scFv)2” molecule, using huMCSP-expressing MDA-MB-435 human
melanoma target cells at an E:T ratio of 5:1 and an overnight incubation of 23.5 h. As depicted in
the , the construct induces apoptosis in target cells comparably to the “(scFv)2” molecule.
The “2+1 IgG scFab” construct shows d efficacy at the highest concentrations.
Furthermore, different bispecific constructs that are monovalent for both targets, human CD3
and human MCSP, as well as the corresponding “(scFv)2” molecule were analyzed for their
potential to induce T cell-mediated apoptosis. Figure 32 shows the results for the “1+1 IgG
scFab, one-armed” (SEQ ID NOs 1, 3, 5) and “1+1 IgG scFab, one-armed inverted” (SEQ ID
NOs 7, 9, 11) constructs, using huMCSP-expressing Colo-38 human melanoma target cells at an
E:T ratio of 5:1, and an incubation time of 19 h. As depicted in the figure, both “1+1” ucts
are less active than the “(scFv)2” molecule, with the “1+1 IgG scFab, one-armed” molecule
being superior to the “1+1 IgG scFab, one-armed inverted” molecule in this assay.
Figure 33 shows the results for the “1+1 IgG scFab” construct (SEQ ID NOs 5, 21, 213), using
huMCSP-expressing Colo-38 human ma target cells at an E:T ratio of 5:1, and an
incubation time of 20 h. As ed in the figure, the “1+1 IgG scFab” construct is less
cytotoxic than the “(scFv)2” le.
In a further experiment the ed “2+1 IgG Crossfab” (SEQ ID NOs 3, 5, 29, 33), the “1+1
IgG Crossfab” (SEQ ID NOs 5, 29, 31, 33) and the “(scFv)2” molecule were analyzed for their
potential to induce T cell-mediated apoptosis in tumor target cells upon crosslinkage of the
construct via binding of both target antigens, CD3 and MCSP, on cells. huMCSP-expressing
MDA-MB-435 human melanoma cells were used as target cells, the E:T ratio was 5:1, and the
incubation time 20 h. The results are shown in Figure 34. The “2+1 IgG Crossfab” construct
induces apoptosis in target cells ably to the “(scFv)2” molecule. The comparison of the
mono- and bivalent “IgG Crossfab” formats clearly shows that the bivalent one is much more
potent.
In yet another experiment, the purified “2+1 IgG Crossfab” (SEQ ID NOs 3, 5, 29, 33) uct
was analyzed for its potential to induce T cell-mediated apoptosis in different (tumor) target
cells. Briefly, MCSP-positive Colo-38 tumor target cells, mesenchymal stem cells (derived from
bone marrow, Lonza #PT-2501 or adipose tissue, Invitrogen #R7788-115) or pericytes (from
placenta; PromoCell #C-12980), as indicated, were harvested with Cell Dissociation Buffer,
washed and resuspendend in AIM-V medium rogen #12055-091). 30 000 cells per well
were plated in a round-bottom l plate and the respective antibody dilution was added at
the ted concentrations. Human PBMC effector cells isolated from fresh blood of a healthy
donor were added to obtain a final E:T ratio of 25:1. After an incubation of 4 h at 37°C, 5% CO2,
LDH release of apoptotic/necrotic target cells into the supernatant was measured with the LDH
detection kit (Roche d Science, #11 644 793 001), according to the manufacturer’s
instructions.
As depicted in Figure 35, significant T-cell mediated cytotoxicity could be observed only with
Colo-38 cells. This result is in line with 8 cells expressing significant levels of MCSP,
whereas mesenchymal stem cells and tes s MCSP only very weakly.
The purified “2+1 IgG scFab” (SEQ ID NOs 5, 17, 19) construct and the “(scFv)2” molecule
were also compared to a glycoengineered uman MCSP IgG antibody, having a reduced
proportion of fucosylated N-glycans in its Fc domain (MCSP GlycoMab). For this experiment
huMCSP-expressing Colo-38 human melanoma target cells and human PBMC effector cells
were used, either at a fixed E:T ratio of 25:1 (Figure 36A), or at different E:T ratios from 20:1 to
1:10 e 36B). The different molecules were used at the concentrations ted in Figure
36A, or at a fixed concentration of 1667 pM (Figure 36B). Read-out was done after 21 h
incubation. As depicted in Figure 36 A and B, both bispecific constructs show a higher potency
than the MSCP GlycoMab.
In r experiment, purified “2+1 IgG Crossfab” targeting cynomolgus CD3 and human
MCSP (SEQ ID NOs 3, 5, 35, 37) was analyzed. Briefly, human MCSP-expressing MV-3 tumor
target cells were harvested with Cell iation Buffer, washed and resuspendend in DMEM
containing 2% FCS and 1% GlutaMax. 30 000 cells per well were plated in a round-bottom 96-
well plate and the respective dilution of construct or reference IgG was added at the
concentrations indicated. The bispecific construct and the different IgG ls were adjusted to
the same molarity. Cynomolgus PBMC effector cells, isolated from blood of healthy
cynomolgus, were added to obtain a final E:T ratio of 3:1. After incubation for 24 h or 43 h at
37°C, 5% CO2, LDH release of apoptotic/necrotic target cells into the supernatant was measured
with the LDH detection kit (Roche Applied Science, #11 644 793 001), according to the
manufacturer’s instructions.
As depicted in Figure 37, the bispecific construct induces concentration-dependent LDH release
from target cells. The effect is er after 43 h than after 24 h. The anti-cynoCD3 IgG (clone
FN-18) is also able to induce LDH e of target cells without being inked.
Figure 38 shows the result of a comparison of the purified “2+1 IgG Crossfab” (SEQ ID NOs 3,
, 29, 33) and the “(scFv)2“ construct, using MCSP-expressing human melanoma cell line (MV-
3) as target cells and human PBMCs as effector cells with an E:T ratio of 10:1 and an incubation
time of 26 h. As depicted in the figure, the “2+1 IgG Crossfab” construct is more potent in terms
of EC50 than the “(scFv)2“ molecule.
In a second series of experiments, bispecific constructs ing CD3 and EGFR were analyzed
for their potential to induce T cell-mediated apoptosis in tumor target cells upon crosslinkage of
the construct via binding of the antigen g moieties to their tive target antigens on
cells (Figures 39-41).
In one experiment purified “2+1 IgG scFab” (SEQ ID NOs 45, 47, 53) and “1+1 IgG scFab”
(SEQ ID NOs 47, 53, 213) constructs targeting CD3 and EGFR, and the corresponding )2”
le, were compared. Briefly, human EGFR-expressing LS-174T tumor target cells were
harvested with trypsin, washed and resuspendend in AIM-V medium (Invitrogen # 12055-091).
000 cells per well were plated in a round-bottom 96-well-plate and the tive antibody
dilution was added at the indicated concentrations. All constructs and controls were adjusted to
the same molarity. Human pan T effector cells were added to obtain a final E:T ratio of 5:1. As a
positive control for the activation of human pan T cells, 1 µg/ml PHA-M (Sigma #L8902) was
used. For ization, maximal lysis of the target cells (= 100%) was determined by
incubation of the target cells with a final concentration of 1% Triton X-100. Minimal lysis (= 0%)
refers to target cells ubated with effector cells, but without any construct or antibody. After
an overnight incubation of 18 h at 37°C, 5% CO2, LDH release of apoptotic/necrotic target cells
into the supernatant was measured with the LDH detection kit (Roche Applied Science, #11 644
793 001), according to the manufacturer’s instructions.
As depicted in Figure 39, the “2+1 IgG scFab” construct shows comparable cytotoxic activity to
the “(scFv)2” le, whereas the “1+1 IgG scFab” construct is less active.
In r experiment the purified “1+1 IgG scFab, one-armed” (SEQ ID NOs 43, 45, 47), “1+1
IgG scFab, one-armed inverted” (SEQ ID NOs 11, 49, 51), “1+1 IgG scFab” (SEQ ID NOs 47,
53, 213), and the “(scFv)2” molecule were compared. Experimental conditions were as described
above, except for the incubation time which was 21 h.
As depicted in Figure 40, the “1+1 IgG scFab” construct shows a slightly lower cytotoxic
activity than the “(scFv)2” molecule in this assay. Both “1+1 IgG scFab, one-armed (inverted)”
constructs are clearly less active than the “(scFv)2” molecule.
In yet a r experiment the purified “1+1 IgG scFab, one-armed” (SEQ ID NO 43, 45, 47)
and “1+1 IgG scFab, one-armed inverted” (SEQ ID NOs 11, 49, 51) constructs and the “(scFv)2”
molecule were ed. The incubation time in this experiment was 16 h, and the result is
depicted in Figure 41. ted with human pan T cells, both “1+1 IgG scFab, one-armed
(inverted)” ucts are less active than the “(scFv)2” molecule, but show concentrationdependent
release of LDH from target cells (Figure 41A). Upon co-cultivation of the LS-174T
tumor cells with naive T cells isolated from PBMCs, the constructs had only a basal activity –
the most active among them being the “(scFv)2” molecule (Figure 41B).
In a r experiment, purified “1+1 IgG scFab, one-armed inverted” (SEQ ID NOs 11, 51,
55), “1+1 IgG scFab” (57, 61, 213), and “2+1 IgG scFab” (57, 59, 61) targeting CD3 and
Fibroblast Activation Protein (FAP), and the corresponding “(scFv)2” molecule were analyzed
for their potential to induce T cell-mediated apoptosis in human FAP-expressing fibroblasts
GM05389 cells upon inkage of the construct via binding of both targeting moieties to their
respective target antigens on the cells. Briefly, human GM05389 target cells were harvested with
trypsin on the day before, washed and resuspendend in AIM-V medium (Invitrogen #12055-091).
000 cells per well were plated in a round-bottom 96-well plate and incubated overnight at
37°C, 5% CO2 to allow the cells to recover and adhere. The next day, the cells were centrifuged,
the supernatant was ded and fresh medium, as well as the respective dilution of the
constructs or reference IgGs was added at the indicated concentrations. All constructs and
controls were adjusted to the same molarity. Human pan T effector cells were added to obtain a
final E:T ratio of 5:1. As a positive control for the activation of human pan T cells, 5 µg/ml
PHA-M (Sigma #L8902) was used. For normalization, maximal lysis of the target cells (= 100%)
was determined by incubation of the target cells with a final concentration of 1% Triton X-100.
Minimal lysis (= 0%) refers to target cells co-incubated with effector cells, but without any
construct or dy. After an additional overnight tion of 18 h at 37°C, 5% CO2, LDH
release of tic/necrotic target cells into the atant was measured with the LDH
detection kit (Roche Applied Science, #11 644 793 001), according to the cturer’s
instructions.
As depicted in Figure 42, the “2+1 IgG scFab” construct shows comparable cytotoxic ty to
the “(scFv)2” molecule in terms of EC50 values. The “1+1 IgG scFab, one-armed inverted”
construct is less active than the other ucts tested in this assay.
In another set of experiments, the CD3/MCSP “2+1 IgG Crossfab, linked light chain” (see SEQ
ID NOs 3, 5, 29, 179) was compared to the CD3/MCSP “2+1 IgG Crossfab” (see SEQ ID NOs 3,
, 29, 33). Briefly, target cells (human Colo-38, human MV-3 or WM266-4 melanoma cells)
were ted with Cell Dissociation Buffer on the day of the assay (or with trypsin one day
before the assay was started), washed and resuspended in the riate cell culture medium
(RPMI1640, including 2% FCS and 1% Glutamax). 20 000 - 30 000 cells per well were plated in
a flat-bottom 96-well plate and the respective antibody on was added as indicated
(triplicates). PBMCs as effector cells were added to obtain a final or-to-target cell (E:T)
ratio of 10:1. All constructs and ls were adjusted to the same molarity, incubation time was
22 h. Detection of LDH release and normalization was done as described above.
Figure 49 to 52 show the result of four assays performed with MV-3 melanoma cells (Figure 49),
Colo-38 cells (Figure 50 and 51) or WM266-4 cells (Figure 52). As shown in Figure 49, the
construct with the linked light chain was less potent compared to the one without the linked light
chain in the assay with MV-3 cells as target cells. As shown in Figure 50 and 51, the construct
with the linked light chain was more potent compared to the one without the linked light chain in
the assays with high MCSP sing Colo-38 cells as target cells. Finally, as shown in Figure
52, there was no significant difference between the two constructs when high MCSP-expressing
WM266-4 cells were used as target cells.
In another experiment, two CEA-targeting “2+1 IgG Crossfab, inverted” constructs were
compared, wherein in the Crossfab fragment either the V regions (VL/VH, see SEQ ID NOs 33,
63, 65, 67) or the C regions (CL/CH1, see SEQ ID NOs 65, 67, 183, 197) were exchanged. The
assay was performed as described above, using human PBMCs as effector cells and human
CEA-expressing target cells. Target cells (MKN-45 or LS-174T tumor cells) were harvested with
trypsin-EDTA (LuBiosciences #25300-096), washed and resuspendend in RPMI1640
(Invitrogen #42404042), including 1% Glutamax (LuBiosciences #35050087) and 2% FCS. 30
000 cells per well were plated in a round-bottom l plate and the ific constructs were
added at the indicated concentrations. All constructs and controls were adjusted to the same
molarity. Human PBMC effector cells were added to obtain a final E:T ratio of 10:1, incubation
time was 28 h. EC50 values were calculated using the GraphPad Prism 5 software.
As shown in Figure 61, the construct with the CL/CH1 exchange shows slightly better activity
on both target cell lines than the uct with the VL/VH exchange. Calculated EC50 values
were 115 and 243 pM on MKN-45 cells, and 673 and 955 pM on LS-174T cells, for the
CL/CH1-exchange construct and the VL/VH-exchange construct, respectively.
Similarly, two MCSP-targeting “2+1 IgG Crossfab” constructs were compared, wherein in the
Crossfab fragment either the V regions (VL/VH, see SEQ ID NOs 33, 189, 191, 193) or the C
regions (CL/CH1, see SEQ ID NOs 183, 189, 193, 195) were exchanged. The assay was
performed as described above, using human PBMCs as effector cells and human MCSP-
expressing target cells. Target cells (WM266-4) were harvested with Cell Dissociation Buffer
(LuBiosciences #13151014), washed and resuspendend in RPMI1640 (Invitrogen #42404042),
including 1% Glutamax (LuBiosciences #35050087) and 2% FCS. 30 000 cells per well were
plated in a round-bottom l plate and the constructs were added at the ted
concentrations. All constructs and ls were adjusted to the same molarity. Human PBMC
effector cells were added to obtain a final E:T ratio of 10:1, tion time was 26 h. EC50
values were calculated using the ad Prism 5 software.
As depicted in Figure 62, the two constructs show comparable activity, the construct with the
CL/CH1 exchange having a slightly lower EC50 value (12.9 pM for the CL/CH1-exchange
construct, compared to 16.8 pM for the VL/VH-exchange construct).
Figure 63 shows the result of a similar assay, performed with human MCSP-expressing MV-3
target cells. Again, both constructs show comparable activity, the construct with the CL/CH1
exchange having a slightly lower EC50 value (approximately 11.7 pM for the CL/CH1-exchange
construct, ed to approximately 82.2 pM for the VL/VH-exchange construct). Exact EC50
values could not be calculated, since the g curves did not reach a plateau at high
concentrations of the compounds.
In a further experiment, the CD3/MCSP “2+1 IgG ab” (see SEQ ID NOs 3, 5, 29, 33) and
“1+1 IgG Crossfab” (see SEQ ID NOs 5, 29, 33, 181) constructs were compared to the
SP “1+1 CrossMab” (see SEQ ID NOs 5, 23, 183, 185). The assay was performed as
described above, using human PBMCs as or cells and WM266-4 or MV-3 target cells (E:T
ratio = 10:1) and an incubation time of 21 h.
As shown in Figure 64, the “2+1 IgG Crossfab” construct is the most potent molecule in this
assay, followed by the “1+1 IgG Crossfab” and the “1+1 CrossMab”. This ranking is even more
pronounced with MV-3 cells, expressing medium levels of MCSP, compared to high MCSP
sing WM266-4 cells. The calculated EC50 values on MV-3 cells were 9.2, 40.9 and 88.4
pM, on WM266-4 cells 33.1, 28.4 and 53.9 pM, for the “2+1 IgG Crossfab”, the “1+1 IgG
Crossfab” and the “1+1 CrossMab”, respectively.
In a further experiment, ent concentrations of the “1+1 IgG Crossfab LC fusion” construct
(SEQ ID NOs 183, 209, 211, 213) were tested, using MKN-45 or LS-174T tumor target cells and
human PBMC effector cells at an E:T ratio of 10:1 and an incubation time of 28 hours. As shown
in Figure 65, the “1+1 IgG Crossfab LC fusion“ construct induced apoptosis in MKN-45 target
cells with a calculated EC50 of 213 pM, whereas the calculated EC50 is 1.56 nM with LS-174T
cells, showing the influence of the ent tumor antigen expression levels on the potency of
the bispecific constructs within a certain period of time.
In yet another experiment, the “1+1 IgG Crossfab LC fusion” construct (SEQ ID NOs 183, 209,
211, 213) was compared to a untargeted “2+1 IgG Crossfab” molecule. MC38-huCEA tumor
cells and human PBMCs (E:T ratio = 10:1) and an incubation time of 24 hours were used. As
shown in Figure 66, the “1+1 IgG Crossfab LC fusion” construct d apoptosis of target
cells in a concentration-dependent manner, with a calculated EC50 value of approximately 3.2
nM. In st, the eted “2+1 IgG Crossfab” showed antigen-independent T cell-mediated
g of target cells only at the highest concentration.
In a final experiment, the “2+1 IgG Crossfab (V9)” (SEQ ID NOs 3, 5, 29, 33), the “2+1 IgG
Crossfab, inverted (V9)” (SEQ ID NOs 5, 23, 183, 187), the “2+1 IgG Crossfab (anti-CD3)”
(SEQ ID NOs 5, 23, 215, 217), the “2+1 IgG Crossfab, inverted (anti-CD3)” (SEQ ID NOs 5, 23,
215, 219) were compared, using human MCSP-positive MV-3 or WM266-4 tumor cells and
human PBMCs (E:T ratio = 10:1), and an incubation time of about 24 hours. As depicted in
Figure 67, the T cell-mediated killing of the “2+1 IgG Crossfab, inverted” ucts seems to be
slightly er or at least equal to the one induced by the “2+1 IgG Crossfabt” constructs for
both CD3 binders. The calculated EC50 values were as follows:
EC50 [pM] 2+1 IgG ab 2+1 IgG Crossfab 2+1 IgG Crossfab 2+1 IgG Crossfab,
(V9) inverted (V9) (anti-CD3) inverted (anti-CD3)
MV-3 10.0 4.1 11.0 3.0
WM266-4 12.4 3.7 11.3 7.1
Example 7
CD107a/b assay
Purified “2+1 IgG scFab” uct (SEQ ID NOs 5, 17, 19) and the “(scFv)2” molecule, both
targeting human MCSP and human CD3, were tested by flow cytometry for their potential to upregulate
CD107a and intracellular perforin levels in the presence or absence of human MCSP-
expressing tumor cells.
Briefly, on day one, 30 000 8 tumor target cells per well were plated in a round-bottom
96-well plate and incubated overnight at 37°C, 5% CO2 to let them adhere. Primary human pan T
cells were isolated on day 1 or day 2 from Buffy Coat, as described.
On day two, 0.15 million effector cells per well were added to obtain a final E:T ratio of 5:1.
FITC-conjugated CD107a/b antibodies, as well as the different ific constructs and controls
are added. The different bispecific molecules and dies were adjusted to same molarities to
obtain a final concentration of 9.43 nM. Following a 1 h incubation step at 37°C, 5% CO2,
monensin was added to inhibit secretion, but also to neutralize the pH within endosomes and
lysosomes. After an additional incubation time of 5 h, cells were stained at 4°C for 30 min for
surface CD8 expression. Cells were washed with staining buffer (PBS / 0.1% BSA), fixed and
permeabilized for 20 min using the BD Cytofix/Cytoperm Plus Kit with BD Golgi Stop (BD
Biosciences #554715). Cells were washed twice using 1 x BD Perm/Wash buffer, and
intracellular staining for perforin was performed at 4°C for 30 min. After a final g step
with 1 x BD Perm/Wash , cells were resuspended in PBS / 0.1% BSA and analyzed on
FACS CantoII (all antibodies were purchased from BD Biosciences or BioLegend).
Gates were set either on all CD107a/b positive, in-positive or double-positive cells, as
indicated (Figure 43). The “2+1 IgG scFab” uct was able to activate T cells and upregulate
CD107a/b and intracellular in levels only in the presence of target cells (Figure
43A), whereas the “(scFv)2” molecule shows (weak) induction of tion of T cells also in the
e of target cells (Figure 43B). The bivalent reference anti-CD3 IgG results in a lower level
of activation compared to the “(scFv)2” molecule or the other bispecific construct.
Example 8
Proliferation assay
The purified “2+1 IgG scFab” (SEQ ID NOs 5, 17, 19) and “(scFv)2” molecules, both targeting
human CD3 and human MCSP, were tested by flow cytometry for their potential to induce
proliferation of CD8+ or CD4+ T cells in the presence and absence of human MCSP-expressing
tumor cells.
Briefly, freshly isolated human pan T cells were adjusted to 1 million cells per ml in warm PBS
and stained with 1 µM CFSE at room temperature for 10 minutes. The staining volume was
doubled by addition of RPMI1640 , containing 10% FCS and 1% GlutaMax. After
incubation at room temperature for further 20 min, the cells were washed three times with prewarmed
medium to remove ing CFSE. ositive Colo-38 cells were harvested with
Cell Dissociation buffer, counted and checked for viability. Cells were adjusted to 0.2 x 106
(viable) cells per ml in AIM-V medium, 100 µl of this cell suspension were pipetted per well
into a round-bottom l plate (as indicated). 50 µl of the (diluted) bispecific constructs were
added to the cell-containing wells to obtain a final concentration of 1 nM. CFSE-stained human
pan T effector cells were adjusted to 2 x 106 e) cells per ml in AIM-V medium. 50 µl of
this cell suspension was added per well of the assay plate (see above) to obtain a final E:T ratio
of 5:1. To analyze whether the ific constructs are able to activate T cells only in the
presence of target cells, expressing the tumor antigen huMCSP, wells were included that
contained 1 nM of the respective bispecific molecules as well as PBMCs, but no target cells.
After incubation for five days at 37°C, 5% CO2, cells were centrifuged (5 min, 350 x g) and
washed twice with 150 µl/well PBS, including 0.1% BSA. Surface staining for CD8 (mouse
IgG1,κ; clone HIT8a; BD #555635), CD4 (mouse IgG1,κ; clone RPA-T4 ; BD #560649), or
CD25 (mouse IgG1,ĸ; clone M-A251; BD #555434) was performed at 4°C for 30 min, ing
to the supplier’s suggestions. Cells were washed twice with 150 µl/well PBS containing 0.1%
BSA, resuspended in 200 µl/well PBS with 0.1% BSA, and analyzed using a FACS CantoII
machine (Software FACS Diva). The relative proliferation level was determined by setting a gate
around the non-proliferating cells and using the cell number of this gate relative to the overall
measured cell number as the reference.
Figure 44 shows that all constructs induce proliferation of CD8+ T cells (A) or CD4+ T cells (B)
only in the ce of target cells, comparably to the “(scFv)2” molecule. In l, activated
CD8+ T cells proliferate more than activated CD4+ T cells in this assay.
Example 9
Cytokine release assay
The purified “2+1 IgG scFab” construct (SEQ ID NOs 5, 17, 19) and the “(scFv)2”molecule,
both targeting human MCSP and human CD3, were analyzed for their ability to induce T cell-
mediated de novo secretion of cytokines in the presence or absence of tumor target cells.
Briefly, human PBMCs were isolated from Buffy Coats and 0.3 million cells were plated per
well into a bottom 96-well plate. Colo-38 tumor target cells, expressing human MCSP,
were added to obtain a final E:T-ratio of 10:1. Bispecific ucts and IgG controls were added
at 1 nM final concentration and the cells were incubated for 24 h at 37°C, 5% CO2. The next day,
the cells were centrifuged for 5 min at 350 x g and the supernatant was transferred into a new
deep-well 96-well-plate for the subsequent is. The CBA analysis was performed according
to manufacturer’s instructions for FACS CantoII, using the Human Th1/Th2 Cytokine Kit II (BD
#551809).
Figure 45 shows levels of the different ne measured in the supernatant. In the presence of
target cells the main cytokine secreted upon T cell activation is IFN-γ. The “(scFv)2” molecule
induces a slightly higher level of IFN-γ than the “2+1 IgG scFab” construct. The same tendency
might be found for human TNF, but the overall levels of this cytokine were much lower
compared to IFN-γ. There was no significant secretion of Th2 cytokines (IL-10 and IL-4) upon
tion of T cells in the presence (or absence) of target cells. In the absence of Colo-38 target
cells, only very weak induction of TNF secretion was observed, which was highest in samples
d with the “(scFv)2” molecule.
In a second experiment, the following purified bispecific constructs targeting human MCSP and
human CD3 were analyzed: the “2+1 IgG Crossfab” construct (SEQ ID NOs 3, 5, 29, 33), the
“(scFv)2” molecule, as well as different “2+1 IgG scFab” les comprising either a wild-
type or a mutated (LALA, P329G and/or N297D, as indicated) Fc domain. Briefly, 280 µl whole
blood from a healthy donor were plated per well of a deep-well 96-well plate. 30 000 Colo-38
tumor target cells, expressing human MCSP, as well as the different bispecific constructs and
IgG controls were added at 1 nM final concentration. The cells were incubated for 24 h at 37°C,
% CO2 and then centrifuged for 5 min at 350 x g. The supernatant was transferred into a new
ell 96-well-plate for the subsequent analysis. The CBA analysis was performed according
to manufacturer’s instructions for FACS CantoII, using the combination of the following CBA
Flex Sets: human granzyme B (BD #560304), human IFN-γ Flex Set (BD #558269), human TNF
Flex Set (BD #558273), human IL-10 Flex Set (BD #558274), human IL-6 Flex Set (BD
#558276), human IL-4 Flex Set (BD #558272), human IL-2 Flex Set (BD #558270).
Figure 46 shows the levels of the ent ne measured in the supernatant. The main
ne secreted in the presence of Colo-38 tumor cells was IL-6, ed by IFN-γ. In
addition, also the levels of granzyme B strongly increased upon activation of T cells in the
presence of target cells. In general, the “(scFv)2” molecule d higher levels of ne
secretion in the presence of target cells (Figure 46, A and B). There was no significant secretion
of Th2 nes (IL-10 and IL-4) upon activation of T cells in the ce (or absence) of
target cells.
In this assay, there was a weak secretion of IFN-γ, induced by different “2+1 IgG scFab”
constructs, even in the absence of target cells (Figure 46, C and D). Under these conditions, no
significant differences could be observed between “2+1 IgG scFab” constructs with a wild-type
or a mutated Fc domain.
* * *
Although the foregoing invention has been described in some detail by way of illustration and
example for purposes of y of understanding, the descriptions and examples should not be
construed as limiting the scope of the invention. The disclosures of all patent and scientific
literature cited herein are sly incorporated in their entirety by reference.
Claims (33)
1. A T cell activating bispecific antigen binding molecule comprising a first and a second antigen g moiety, one of which is a Fab molecule capable of specific g to CD3 and the other 5 one of which is a Fab molecule capable of specific binding to a target cell antigen, and an Fc domain composed of a first and a second subunit capable of stable association; wherein the first antigen binding moiety is a crossover Fab le wherein either the le or the constant regions of the Fab light chain and the Fab heavy chain are exchanged; 10 wherein (i) the second antigen binding moiety is fused at the inus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain, or (ii) the first antigen binding moiety is fused at the C- terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen 15 binding moiety and the second n binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain; and wherein the T cell activating bispecific antigen g molecule comprises not more than one antigen binding moiety capable of ic binding to CD3.
2. The T cell activating bispecific antigen binding molecule of claim 1, wherein the Fab light 20 chain of the first n binding moiety and the Fab light chain of the second antigen binding moiety are fused to each other, optionally via a peptide linker.
3. The T cell activating bispecific antigen binding molecule of claim 1 or 2, comprising a third antigen binding moiety which is a Fab molecule capable of specific binding to a target cell antigen. 25
4. The T cell activating bispecific antigen binding molecule of claim 3, wherein the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.
5. The T cell activating bispecific antigen binding molecule of claim 3 or 4, wherein the second and the third antigen g moiety are each fused at the C-terminus of the Fab heavy chain to 30 the inus of one of the subunits of the Fc domain, and the first n binding moiety is fused at the inus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety.
6. The T cell activating bispecific antigen binding molecule of claim 3 or 4, wherein the first and the third antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the 5 N-terminus of one of the subunits of the Fc domain, and the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety.
7. The T cell activating bispecific antigen binding molecule of claim 5, wherein the second and the third n binding moiety and the Fc domain are part of an immunoglobulin molecule, 10 particularly an IgG class immunoglobulin.
8. The T cell activating ific antigen binding molecule of any one of the preceding claims, wherein the Fc domain is an IgG, specifically an IgG1 or IgG4, Fc domain.
9. The T cell activating bispecific antigen binding molecule of any one of the ing claims, wherein the Fc domain is a human Fc domain. 15
10. The T cell activating bispecific antigen binding molecule of any one of the ing claims, wherein the Fc domain ses a modification promoting the association of the first and the second subunit of the Fc domain, wherein (a) in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance 20 within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second t, and in the CH3 domain of the second subunit of the Fc domain an amino acid e is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first t is positionable; or 25 (b) at the interface of the two Fc domain subunits one or more amino acid residues is/are replaced by charged amino acid residues so that homodimer ion becomes electrostatically unfavorable but heterodimerization electrostatically favorable.
11. The T cell activating bispecific antigen binding molecule of any one of the preceding claims, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function, wherein said one or more amino acid substitution is at a position ed from the group of E233, L234, L235, N297, P331 and P329 (EU numbering).
12. The T cell activating bispecific antigen g molecule of claim 11, wherein said one or more amino acid substitution is at one or more position selected from the group of L234, L235, 5 and P329 (EU ing).
13. The T cell ting bispecific antigen binding molecule of any one of the preceding claims, wherein each subunit of the Fc domain comprises three amino acid substitutions that reduce binding to an activating Fc receptor and/or effector function wherein said amino acid substitutions are L234A, L235A and P329G (EU ing). 10
14. The T cell activating bispecific antigen binding molecule of any one of claims 11 to 13, wherein the Fc receptor is an Fcγ receptor.
15. The T cell activating bispecific antigen binding molecule of any one of claims 11 to 13, wherein the or function is antibody-dependent cell-mediated cytotoxicity (ADCC).
16. The T cell activating ific antigen binding molecule of any one of the preceding claims, 15 wherein the target cell antigen is selected from the group consisting of: Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), CD19, CD20, CD33, Carcinoembryonic n (CEA) and Fibroblast Activation n (FAP).
17. An isolated polynucleotide encoding the T cell activating bispecific antigen binding molecule of any one of claims 1 to 16. 20
18. A vector, comprising the isolated polynucleotide of claim 17.
19. The vector of claim 18, wherein the vector is an expression vector.
20. A host cell comprising the isolated polynucleotide of claim 17 or the vector of claim 18 or claim 19, wherein the host cell is not a human cell within a human.
21. A method of producing the T cell activating ific n binding molecule of any one 25 of claims 1 to 16, comprising the steps of a) culturing the host cell of claim 20 under ions suitable for the expression of the T cell activating bispecific antigen binding molecule and b) recovering the T cell activating bispecific antigen binding molecule.
22. A pharmaceutical composition comprising the T cell activating bispecific n binding molecule of any one of claims 1 to 16 and a pharmaceutically able carrier.
23. Use of the T cell activating bispecific antigen g molecule of any one of claims 1 to 16 for the manufacture of a medicament for the treatment of a disease in an individual in need 5 thereof.
24. The use of claim 23, wherein said disease is cancer.
25. An in vitro method for ng lysis of a target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of claims 1-16 in the presence of a T cell. 10
26. A T cell activating bispecific antigen binding le as claimed in any one of claims 1 to 16, substantially as herein described with reference to any example thereof.
27. An isolated polynucleotide as claimed in claim 17, substantially as herein described with reference to any example thereof.
28. A vector as claimed in claim 18 or claim 19, substantially as herein bed with reference 15 to any example thereof.
29. A host cell as claimed in claim 20, substantially as herein described with reference to any example thereof.
30. A method as claimed in claim 21, substantially as herein bed with reference to any example thereof. 20
31. A pharmaceutical composition as claimed in claim 22, ntially as herein described with reference to any example thereof.
32. Use as claimed in claim 23 or claim 24, substantially as herein described with reference to any example thereof.
33. An in vitro method as d in claim 25, substantially as herein described with reference to 25 any example thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11178370 | 2011-08-23 | ||
EP11178370.0 | 2011-08-23 | ||
EP12168192 | 2012-05-16 | ||
EP12168192.8 | 2012-05-16 | ||
NZ61820912 | 2012-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ721138A true NZ721138A (en) | 2020-02-28 |
NZ721138B2 NZ721138B2 (en) | 2020-05-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7175291B2 (en) | Bispecific T cell activation antigen binding molecule | |
US20220064296A1 (en) | Bispecific t cell activating antigen binding molecules | |
US20210070882A1 (en) | Bispecific t cell activating antigen binding molecules | |
EP3433280B1 (en) | Protease-activated t cell bispecific molecules | |
US20220275087A1 (en) | Protease-activated t cell bispecific molecules | |
EP2961773B1 (en) | Bispecific t cell activating antigen binding molecules | |
US20140242080A1 (en) | Bispecific t cell activating antigen binding molecules | |
US20130078250A1 (en) | Bispecific t cell activating antigen binding molecules | |
JP2018533928A (en) | Bispecific anti-CEAXCD3 T cell activation antigen binding molecule | |
NZ721138A (en) | Bispecific t cell activating antigen binding molecules | |
NZ721138B2 (en) | Bispecific t cell activating antigen binding molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 21 AUG 2022 BY AJ PARK Effective date: 20200703 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 AUG 2023 BY THOMSON REUTERS Effective date: 20220704 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 AUG 2024 BY ANAQUA SERVICES Effective date: 20230720 |